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Depressive and anxiety disorders as well as cardiovascular disease (CVD) 
are leading contributors to the worldwide burden of disease. Substantial 
evidence implies an association between these syndromes,1-8 but the 
mechanisms underlying this link are still unknown. Metabolic risk factors 
for CVD might connect depressive and anxiety disorders to CVD. The 
relation of depressive and anxiety disorders to metabolic risk is a relatively 
new topic of research, and only a few studies have addressed it. By means 
of this thesis we aim to expand this innovative area of research. We 
thoroughly investigate the association of depressive and anxiety disorders 
with metabolic risk factors. Moreover, the contribution of biological stress 
system alterations and lifestyle to metabolic risk in depression and anxiety 
is examined. Also, we take a broader perspective by exploring whether 
personality traits and childhood trauma are associated with adverse 
metabolic risk factors. This knowledge may help to develop and extend 
personalized prevention and treatment programs. In this introduction, we 
present background information and the general aim and outline of the 
thesis. 
 
1.1  DEPRESSIVE AND ANXIETY DISORDERS 
1.1.1  Diagnostic criteria 
A major depressive disorder (MDD) is characterized by the presence of five 
or more MDD symptoms for at least a two week period, of which minimally 
a depressed mood and/or a diminished interest or pleasure in nearly all 
activities should be manifested. Further MDD symptoms include weight 
loss or gain, insomnia or hypersomnia, psychomotor agitation or 
retardation, fatigue or loss of energy, feelings of worthlessness or guilt, 
inability to concentrate take decisions, and recurrent thoughts about 
death or suicide. A diagnosis of MDD is only applicable if symptoms cause 
significant distress or impairment in everyday functioning. 
Combinations of depressive and anxiety symptoms differ between 
individuals. For example, some depressed people report weight loss and 
severe feelings of guilt as core symptoms, while others mainly present with 
weight gain and hypersomnia. As a result of this heterogeneity of 
depressive symptoms, MDD subtypes have been formulated. MDD 
subtypes include MDD with melancholic features and MDD with atypical 
features. These subtypes are seen as particular forms of MDD and are 
observed in a subset of all patients with MDD. An MDD with melancholic 
features presents with anhedonia, worse symptoms in the morning, early 
morning awakenings, psychomotor agitation or retardation, weight loss 
and severe feelings of guilt. An MDD with atypical features is characterized 
by mood reactivity (i.e., mood brightening in response to positive events), 
weight gain, hypersomnia, leaden paralysis (i.e., heavy limbs) and 
interpersonal rejection sensitivity. A mild but chronic (> 2 years) 
depressive disorder is called dysthymia.  
  Anxiety disorders comprise situational (e.g., social phobia, and 
panic disorder with or without agoraphobia) and generalized anxiety 
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disorders (GAD), among others. Social phobia refers to a marked and 
persistent fear of certain social or performance situations in which one 
fears doing something that is embarrassing or humiliating. A panic 
disorder is characterized by recurrent unexpected panic attacks. It may be 
accompanied by agoraphobia. Agoraphobia is defined as a form of anxiety 
experienced in situations from which escape might be difficult or 
embarrassing, or in which help may not be available in case of panic. 
Typical agoraphobic situations are being outside, in a crowd or standing in 
line, and traveling by bus, train or car. GAD is an excessive anxiety and 
worry about various every day situations for at least 6 months. 
  
1.1.2  Epidemiology, burden & co-morbidity  
Depressive and anxiety disorders are very common. They both affect 
around 19 percent of the Dutch population during their lifetime, and 
respectively 4 to 10 percent during the preceding month.9 The impact of 
depressive and anxiety disorders on public health is substantial and 
increasing. According to the World Health Organisation (WHO), depressive 
disorders currently rank fourth among the leading causes of disease 
burden, and they are even estimated to rank second in the World and first 
in high-income countries by the year 2030.10 This increased disease 
burden is due to two processes. First, the risk of depression increases with 
age and the progressive ageing process will therefore raise prevalence 
rates. Simultaneously, the advancing control of physical illnesses will 
proportionally increase the burden of depression. As a consequence of 
their negative effects on individual and public health, depressive and 
anxiety disorders have a significant impact on the economy. The costs of 
such mental disorders are comparable to those of physical illnesses, 
mainly due to loss of production.11  
  Depressive and anxiety disorders often occur simultaneously. Co-
morbidity rates of over 60 percent have been reported.12
, 13 This 
interrelatedness poses the question whether they actually are distinct 
disorders. Because depressive and anxiety disorders both are highly 
prevalent and show substantial overlap, it is important to study depressive 
and anxiety disorders in concert in relation to metabolic risk. 
 
1.1.3  Depression and anxiety severity 
The severity of depressive and anxiety symptoms varies per person: some 
people show more and more severe symptoms of depression or anxiety 
than others. Since diagnoses are dichotomous classifications, a diagnosis 
of a depressive or anxiety disorder offers limited information on the 
amount of difficulties an individual person experiences. Severity scales 
both for symptoms of depression and anxiety have been developed to 
account for this variation in the severity of symptoms.133, 171 Severity scales 
assess the number of symptoms as well as give weights for each symptom. 
Some people score rather high on such a severity scale while they fall short 
of the diagnostic criteria for a depressive or anxiety disorder. Severity 
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scales recognize this group of people who is being overlooked by use of 
standard diagnostic criteria. Despite its importance, so far only some 
studies have investigated depression severity in relation to metabolic risk 
factors, and even a smaller number of studies has reported on the severity 
of anxiety. Therefore, the inclusion of severity measures for depressive and 
anxiety symptoms importantly adds to research on metabolic risk. 
 
1.1.4  Depression and anxiety dimensions 
Although variation in the general severity of symptoms among people is 
explored by severity scales, the use of severity scales is still only an 
indicative method to assess symptoms of depression or anxiety. Some 
people with severe symptoms of depression feel especially guilty, while 
others for instance mainly have lost interest in things they normally enjoy. 
Severity scales do not account for this heterogeneity in the type of 
symptoms. Moreover, as outlined earlier, depressive and anxiety disorders 
do not seem to be discrete syndromes, as they often co-exist. To tackle 
these issues of heterogeneity and co-morbidity, distinct and shared 
dimensions of depression and anxiety symptoms can be examined.14
,15 For 
this purpose the ‘tripartite model’ by Clark and Watson14 can be used. This 
model includes negative affect, positive affect and somatic arousal 
dimensions. Negative affect covers aversive emotional states such as anger 
and guilt. This dimension is associated with both depression and anxiety. 
Positive affect represents positive emotional states such as feeling active, 
excited, delighted, enthusiastic and interested. A lack of positive affect is 
associated with depressive moods. The somatic arousal dimension 
embodies symptoms of physiological hyperarousal, such as trembling, 
shaking, dizziness and sweating. Somatic arousal is thought to be 
distinctive for anxious moods, and for panic in particular.14 Every single 
person scores low, high, or somewhere in between upon all three 
dimensions. These dimensions are useful for research on depressive and 
anxiety disorders as they take account of the heterogeneity and co-
morbidity of these syndromes. Despite their additive value depression and 
anxiety dimensions have not yet been studied in relation to metabolic risk. 
 
1.2  METABOLIC RISK FACTORS FOR CVD 
Globally, CVD is the leading cause of death and an important source of 
disease burden. The WHO expects that CVD will still be the second cause 
of disease burden by the year 2030, right after depression.10 Mounting 
evidence indicates that depressive and anxiety disorders are related to an 
increased risk of CVD. Meta-analyses among patients with CVD but also in 
the general population indicate that depression increases the risk of CVD 
twofold.1-6 Anxiety is associated with an almost 40 percent increased risk 
of CVD.7
,8 Various hypotheses attempt to explain the high co-morbidity of 
depression and anxiety with CVD. One of these hypotheses suggests that 
metabolic factors may be linking mechanisms.18 Such metabolic factors as 
might be related to depressive and anxiety disorders, which also increase 
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risk of CVD, include dyslipidemia, (abdominal) obesity, hypertension and 
hyperglycemia. The metabolic syndrome is a constellation of these 
metabolic risk factors. As these metabolic risk factors collectively predict 
over half of CVD cases,16
,17 they are core targets in general CVD prevention 
and treatment.18 If related to symptoms of depression or anxiety, they 
might also be promising targets for CVD management in depressive and 
anxiety disorders. Hence it is important to thoroughly study the 
relationship of metabolic risk factors with depression and anxiety. 
 
1.2.1  Dyslipidemia 
A major metabolic risk factor for CVD is dyslipidemia. Dyslipidemia stands 
for an aggregation of serum lipid/lipoprotein abnormalities like elevated 
low-density lipoprotein (LDL) cholesterol or triglycerides, and reduced 
high-density lipoprotein (HDL) cholesterol.19 Cholesterol is an essential 
lipid in cell membranes as well as for the synthesis of steroid hormones 
and bile acids. It is produced by the liver, replenished by our diet, and 
influenced by factors such as smoking, physical activity and certain kinds 
of medication. Triglycerides are derived from dietary fats and from other 
energy sources like carbohydrates that are converted into triglycerides if 
not used immediately after consumption. LDL and HDL are lipoproteins 
that bind to lipids like cholesterol and triglycerides and thereby enable 
lipids to be transported within the water-based blood stream. LDL bound 
cholesterol and triglycerides foster plaque build-up on the artery wall and 
as a result a hardening of the arteries (i.e., atherosclerosis). Consequently, 
increased serum levels of LDL cholesterol or triglyceride adversely affect 
CVD risk. HDL removes cholesterol from the blood stream and artery walls 
and transports it back to the liver for re-use. High HDL cholesterol levels 
therefore diminish the development of atherosclerosis. 
  Findings regarding dyslipidemia in depression were not entirely 
consistent. The majority of studies reported that depression was associated 
with dyslipidemia.20-33 However, some studies found that depression 
related to favourable lipid or lipoprotein levels,34-41 while others reported 
absent associations.45-54 Relatively few studies on lipids in relation to 
anxiety have been carried out. These studies predominantly reported that 
anxiety was not associated with lipid levels at all,26,29,47 although one study 
reported an association of anxiety with unfavourable lipid values20 and 
another study40 found a favourable association.   
 
1.2.2  (Abdominal) obesity 
Another main metabolic risk factor for CVD is obesity. Two of the most 
commonly used obesity measures are waist circumference (WC) and body 
mass index (BMI). WC represents both subcutaneous (i.e., beneath the 
skin) and intra-abdominal (i.e., around the organs of the belly) fat cells in 
the abdomen. The main function of fat cells is lipid storage. Besides, intra-
abdominal fat cells are metabolically active and so induce insulin 
resistance and free fatty acid (i.e., a breakdown product of triglycerides) 
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production. Through these processes, WC could be directly associated with 
an increased CVD risk. BMI (i.e., weight (kg)/height (m)2) is an 
approximation of overall body fat.42 
  Most studies on depression and obesity have reported that 
depression was associated with a higher WC20
,23-28,43-46 or BMI,30,45,56,57 
although some studies did not objectify any association of depression with 
WC24,25,32,33,45,49 or BMI.22
,24,43,44,47 The small number of studies on anxiety 




1.2.3  Hypertension 
Hypertension (i.e., high blood pressure) points to an elevated pressure in 
the arteries. Blood pressure is subdivided into systolic and diastolic 
pressures. Systolic blood pressure is the arterial pressure during a heart 
beat. Diastolic pressure is the pressure between heart beats. When the 
systolic or diastolic blood pressure exceeds the accepted normal values, it 
is classified as hypertension. Persistent hypertension is an important risk 
factor for CVD, as it puts a continual strain on the heart and arteries.  
  Most studies on blood pressure in relation to depression did not 
find any association,22-26
, 28-30, 43-49 although two studies reported an 
association of depression with higher blood pressure,24, 30 and one found 
an association with lower blood pressure.20 Most studies on anxiety 
reported no association with blood pressure,23
, 26, 44, 46 although one study 
found that anxiety was related to a lower blood pressure.20 
 
1.2.4  Hyperglycemia 
High blood glucose levels (i.e., hyperglycemia) detrimentally affect the 
cardiovascular system as well. Glucose is a simple sugar that is derived 
from dietary carbohydrates and from bodily stored glucose. Glucose has 
various important functions in the body, among which energy supply. A 
higher than usual (fasting) glucose level is a sign of insulin resistance and 
of (pre)diabetes mellitus (DM). Normally insulin, a hormone produced by 
the pancreas, causes glucose to be stored in body cells when blood glucose 
levels increase after a meal. If body cells such as fat cells do not respond 
properly to insulin, and thus are ‘insulin resistant’, glucose builds up in 
the blood stream and therefore blood glucose levels rise. High blood 
glucose levels (i.e., hyperglycemia) cause high glucose levels inside body 
cells and consequently tissue damage, especially renal, retinal and 
neuronal but also microvascular damage. Moreover, hyperglycemia 
induces vascular inflammation.  
Most former studies reported no association of depression20
,21,23-
30,44,46,49 or anxiety20
,23,26,44,46 with glucose levels. Some studies did however 
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1.2.5  The metabolic syndrome 
A clustering of several of the abovementioned metabolic risk factors is 
referred to as the metabolic syndrome, which was originally described as 
‘Syndrome X’ by Reaven in 1988.50 These metabolic risk factors are 
interrelated and therefore tend to co-occur. For example, excess body fat 
(particularly abdominal obesity) is thought to promote the development of 
insulin resistance and therefore of high blood glucose levels. And as 
insulin not only catalyzes storage of glucose but also that of lipids out of 
the blood stream into fat cells, insulin resistant fat cells impair lipid intake 
and therefore cause dyslipidemia. High blood glucose probably also raises 
blood pressure through increased blood volume and suppression of 
vasolidation. Moreover, because the heart has to work harder to distribute 
an adequate amount of blood throughout the body, (abdominal) obesity is 
thought to increase blood pressure too. High blood pressure causes 
damage to the inside of blood vessels. This damage allows plaques (among 
others consisting of triglycerides) to build up. Obesity stimulates this 
build-up through promotion of dyslipidemia such as increased triglyceride 
levels. To be precise, adipose tissue secretes inflammatory cytokines, 
which arouse the release of lipids into the bloodstream to provide energy 
for host defense. In addition, lipids can be deployed to bind to 
inflammogens in order to block their cytotoxic effects.51 The accumulation 
of plaques on blood vessel walls narrows or even blocks them (i.e., 
atherosclerosis). The decreased circumference of the arteries forces the 
heart to work harder to be able to deliver blood to body cells, which further 
increases blood pressure. These were illustrations of the complex interplay 
between metabolic risk factors. 
 The metabolic syndrome predisposes a person to type 2 DM52 and 
CVD, and strongly predicts CVD mortality.53 Several definitions of the 
metabolic syndrome have been proposed,20,22,62-65 of which the latest 
definition is the revised one of the National Cholesterol Education 
Program—Third Adult Treatment Panel (NCEP-ATPIII).17 According to this 
definition, the metabolic syndrome is diagnosed when three or more of the 
following criteria are met: 
 
1.  Abdominal obesity: waist circumference > 102 cm in men or > 88 
cm in women 
2. Elevated triglycerides: ≥ 1.7 mmol/L (150 mg/dL), or medication for 
elevated triglycerides 
3. Reduced high-density lipoprotein (HDL) cholesterol: ≤ 1.03 mmol/L 
(40 mg/dL) in men or ≤ 1.3 mmol/L (50 mg/dL) in women, or 
medication for reduced HDL cholesterol 
4. Hypertension: blood pressure ≥ 130/85 mm Hg, or medication for 
hypertension 
5. Hyperglycemia: fasting glucose ≥ 5.6 mmol/L (100 mg/dL), or 
medication for elevated glucose 
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The metabolic syndrome is very common. It affects 6.7 percent of the 
American population aged 20-29, rising to 43.5 percent of the 60-69 old.54 
The prevalence of the metabolic syndrome in the Netherlands is estimated 
around 14 percent in adults,55 and rises to 36.5% for people aged over 
65.56 Its incidence raises, mainly through increasing obesity rates.57  
  Although metabolic risk factors included in the metabolic syndrome 
more often co-occur than chance would dictate, the value of the metabolic 
syndrome concept as such is subject of substantial debate.70,71 One of the 
issues for discussion is that metabolic syndrome risk factor combinations 
are heterogeneous: they vary considerably between individuals.17 For 
example, some people have high blood pressure, elevated glucose and a 
high waist circumference, while others have high blood pressure, high 
waist circumference and dyslipidemia. All those people meet the criteria for 
metabolic syndrome, but in different ways. A second issue is that probably 
no single underlying pathophysiological mechanism underlies the 
metabolic syndrome. Moreover, whether the whole of the metabolic 
syndrome is greater than the sum of its parts in the determination of CVD 
or DM risk is still uncertain. As a result of these doubts, it is important to 
study not only the (heterogeneous) metabolic syndrome, but also its 
separate components. However, until recently many studies focused on the 
metabolic syndrome as a whole but not on separate metabolic risk factors 
in relation to depression or anxiety. These studies yielded inconsistent 
results. Most studies found that depression increased the risk of the 
metabolic syndrome,23-32,45,46,49,50,72-74 while others did not find any 
association.33,47,48 
 In accordance with the definitions of the metabolic syndrome, 
various former studies included individual metabolic risk factors as 
dichotomous variables (for instance WC below or above 102 cm for men). 
However, these risk factors are better studied as continuous variables. 
Dichotomization of continuous variables results in a loss of information as 
individual differences in metabolic values are not being considered.    
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1.3  METABOLIC RISK IN DEPRESSIVE AND ANXIETY  
   DISORDERS 
People with depressive or anxiety disorders are at increased risk of CVD as 
compared to people without these psychiatric syndromes. As mentioned, 
people with depressive disorders have a two times higher risk of 
cardiovascular morbidity and mortality,1-6 while people with anxiety 
disorders have an increased CVD risk of almost 40 percent.7
,8 There is 
growing interest in the question whether people with a depressive or 
anxiety disorder are also prone to metabolic risk factors like the metabolic 
syndrome. As metabolic risk factors substantially contribute to the 
development of CVD, these could link depressive and anxiety disorders to 
CVD. Moreover, since metabolic risk factors are relatively easy to identify 
and treat, these could be profitable targets to improve cardiac health 
among depressed and anxious people. Thereby, improvement of metabolic 
risk factors among people with depression or anxiety could contribute to a 
reduction of general CVD prevalence. Hence, it is of interest to study 
whether depressive and anxiety disorders are related to metabolic risk 
factors. 
  The majority of former studies focused on depressive and anxiety 
disorders on the one hand and on the metabolic syndrome on the other 
hand. It is however important to additionally explore associations of 
depression and anxiety severity and dimensions with separate continuous 
metabolic risk factors, as such associations reflect more subtle individual 
differences. These associations have been less frequently addressed in 
previous research. 
 
1.3.1  Antidepressant use and metabolic risk factors  
Antidepressant medicines are used to alleviate depressive and anxiety 
disorders. The two most commonly prescribed antidepressants are tricyclic 
antidepressants (TCAs) and selective serotonin re-uptake inhibitors 
(SSRIs). There are signs that TCAs induce CVD related side effects. 
Antihistaminergic58
,59 and inflammatory60 side effects are thought to 
promote obesity and consequent dyslipidemia. TCA use is also thought to 
provoke hyperglycemia,61 and hypertension62 through agonism of the α1 
adrenergic receptor.63 To a lesser extent, SSRIs tend to induce obesity and 
thereby dyslipidemia in some patients as well. Antidepressants are a 
central part of the treatment of depressive and anxiety disorders and 
therefore commonly prescribed: in 2009, 5.8 percent of the Dutch 
population received antidepressants (i.e., 954.000 of 16.439.659 insured 
residents).64
,65 Given their side effects and their common use, 
antidepressant use among depressed and also among anxious people 
might cause them to be at higher risk of metabolic adversities and thereby 
of CVD. However, it has not yet been exhaustively studied whether 
antidepressant use relates to metabolic risk and if antidepressant use 
contributes to metabolic risk in depression and anxiety. We therefore 
intend to increase our understanding in this area. 
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1.4  CONTRIBUTORS TO METABOLIC RISK  
IN DEPRESSION AND ANXIETY  
When an increased metabolic risk among people with symptoms of 
depression or anxiety is verified, it would be valuable to study what factors 
contribute to this relationship. Thus far, such explanatory factors have not 
been extensively explored and so the nature of metabolic risk in depressive 
and anxiety disorders remains unclear. We intend to provide insight into 
these explanatory factors. Multiple factors may contribute to metabolic 
risk in depressive and anxiety disorders. In this thesis, we focus on the 
impact of biological stress systems and lifestyle.  
 
1.4.1  Biological stress systems 
 
1.4.1.1 The hypothalamic-pituitary-adrenal (HPA) axis  
The hypothalamus, pituitary and adrenals shape the HPA axis, which is 
the main neuroendocrine system involved in our response to stress. In 
reaction to stress, the paraventricular nucleus of the hypothalamus 
secretes vasopressin and corticotrophin-releasing hormone, which 
stimulate the pituitary gland to secrete adrenocorticotropic hormone 
(ACTH).  ACTH then arouses secretion of the glucocorticoid ‘stress 
hormone’ cortisol by the adrenal glands. Cortisol in turn suppresses 
hormone secretion by the hypothalamus and the pituitary gland in a 
negative feedback cycle. Cortisol enables us to react adequately to stress 
through the mobilization of stored energy by releasing stored glucose and 
cholesterol into the bloodstream.66 However, prolonged stress causes HPA 
axis exhaustion. HPA axis dysfunction is thought to underlie 
hyperglycemia, abdominal obesity and dyslipidemia,84-86 but also 
depressive and anxiety disorders.67-69 Therefore, HPA axis alteration might 
be related to increased risk of CVD among depressed and anxious people. 
Consequently, we study the possible role of the HPA axis in metabolic risk 
related to depression and anxiety.  
 
1.4.1.2 The autonomic nervous system (ANS) 
The ANS is the neural part of our stress system and consists of the 
counteracting parasympathetic and sympathetic nervous systems (PNS, 
SNS). The PNS mediates calm, vegetative activities; the SNS kicks in at 
times of stress and causes our blood pressure to rise. Consequently, 
chronic stress causes hypertension. Hypertension causes damage to the 
blood vessels, on which mobilized cholesterol aggregates,70 causing 
atherosclerosis, as explained above. SNS predominance is also a 
characteristic of obesity.71 Chronic stress during depression or anxiety is 
suggested to cause reduced PNS and increased SNS activity92,93 and 
consequently unfavorable alterations of metabolic risk factors. Given this 
possible role of the ANS in depressive and anxiety disorders as well as in 
metabolic risk, we believe it is desirable to study the role of the ANS in 
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metabolic risk among people with symptoms of depression or anxiety. This 
has not yet been investigated. 
 
1.4.1.3 Inflammation 
The immune system defends our body against infectious agents. Not only 
physical injury, but also psychological stressors activate the immune 
system and thus the release of inflammatory factors66 like C-reactive 
protein (CRP), interleukin(IL)-6 and tumor necrosis factor-alpha (TNF-α). 
Inflammation stimulates lipid release into the blood stream to fuel host 
defense and to block cytotoxic effects of inflammogens by binding to 
them.51 Adipose tissue cells release inflammatory markers themselves, and 
thereby further stimulate dyslipidemia. Depressed72 and anxious73 people 
appear to have higher levels of inflammation. Given these complex and bi-
directional associations between inflammation, metabolic risk factors and 
depressive and anxiety disorders, inflammation might well be an important 
link between the latter two entities. This was not previously examined. 
Therefore, we study the role of inflammation in the association of 
metabolic risk with depression and anxiety. 
 
1.4.2  Lifestyle 
In general, people with depression and to a lesser degree those with 
anxiety disorders more often drink higher amounts of alcohol,74 more often 
smoke, and display lower physical activity97 than those without 
psychopathology. These lifestyle tendencies lead to unfavorable alterations 
of metabolic risk factors.19
,75 They could therefore cause people with 
symptoms of depression and anxiety to have adverse levels of metabolic 
risk factors. As the role of lifestyle in metabolic risk among people with 
symptoms of depression or anxiety has not yet been studied extensively, 
we take lifestyle into account as a possible explanatory factor. 
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1.5  METABOLIC RISK IN RELATION TO  
   PERSONALITY TRAITS AND CHILDHOOD TRAUMA  
Factors other than symptoms of depression and anxiety might affect 
metabolic risk as well. It is for instance conceivable that personality and 
the experience of trauma during infancy influence levels of metabolic risk 
factors. Since personality and childhood trauma might be bi-directionally 
related, it is important to study them in tandem in relation to metabolic 
risk. 
 
1.5.1  Personality traits  
The most commonly used description of personality traits is the Big Five 
model, which classifies extraversion, openness, agreeableness, neuroticism 
and conscientiousness. Lower levels of conscientiousness99-102 and 
openness,76
,77 and higher levels of neuroticism102 are related to CVD and 
general morbidity and mortality. This might be because certain personality 
traits are associated with (unhealthy) lifestyles,78 for instance through 
seeking external stimulation and social events, vulnerability to 
depression79 and relatively poor self-discipline.80
,81 These trends affect 
metabolic risk factors and thereby risk of CVD. Until now, research on 
personality and metabolic risk has been equivocal and therefore this 
subject matter deserves further examination. 
 
1.5.2  Childhood trauma  
Childhood trauma (i.e., emotional neglect and psychological, physical or 
sexual abuse) may also detrimentally affect metabolic risk. Emotional 
neglect, and sexual or physical abuse during infancy increase risk of CVD 
in adult women.108 People who experienced trauma in infancy generally 
have a lower socio-economic status and also more often display unhealthy 
lifestyles and eating disorders in later life. They also are at increased risk 
of psychopathology82-84 and are thought to show adverse (early) adaptation 
of their biological stress systems.112-114 Such mechanisms might cause 
childhood trauma to be related to adverse levels of metabolic risk factors 
and consequently to an increased risk of CVD. Previous research indicates 
that various kinds of childhood trauma are related to (abdominal) 
obesity.85-90 Studies on metabolic risk factors other than obesity in relation 
to childhood trauma have not been reported. Consequently, the inclusion 
of a wider range of metabolic risk factors in this area of research is 
innovative.  
No previous studies have investigated both personality and 
childhood trauma in relation to metabolic risk. But since personality and 
childhood trauma are likely to be intertwined, it is enlightening to study 
them simultaneously in their associations with metabolic risk. Over 20 
percent of the variance in (traumatic) life events is due to genetic 
influences,91 and this is largely mediated by personality.92 Personality 
shapes one’s personal environment and thus protects against or facilitates 
the experience of trauma.92 Also, personality affects the appraisal of 
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potentially traumatic events.93 And vice versa, trauma affects ones 
perceptions and beliefs, and therefore shapes personality development.94 
Although the main focus of this thesis is on symptoms of 
depression and anxiety, personality and childhood trauma are additionally 
studied as possible correlates of metabolic risk. This will broaden our 
insights into characteristics that make people prone to metabolic 
adversities and consequently to CVD. 
 
1.6  THE NETHERLANDS STUDY OF DEPRESSION AND  
   ANXIETY (NESDA) 
For this thesis, we used baseline and 2-year follow-up NESDA data. 
NESDA is an ongoing longitudinal cohort study which was created to 
describe the long-term course and consequences of depressive and anxiety 
disorders. Furthermore, it integrates biological and psychosocial research 
paradigms within an epidemiological approach to examine (interactions 
between) predictors of the long-term course and consequences of these 
disorders. NESDA includes 2981 participants aged 18 to 65 years, who 
were recruited from the general population, general practices, and mental 
health organisations in the Netherlands. The NESDA sample contains 
people with a current or remitted depression and/or anxiety disorder, 
people at increased risk because of family history or subtreshold 
symptoms of depression or anxiety, and healthy controls without 
depressive or anxiety disorders in their history. Assessments comprise a 
face-to-face interview, written questionnaires and biological 
measurements. NESDA is described in detail elsewhere.95
,96  
 
1.7  GENERAL AIM OF THE THESIS 
The general aim of this thesis is to identify which characteristics of 
depression and anxiety make people prone to unfavorable metabolic risk 
factor levels. More specifically, it is the intention to discover whether 
depressive and anxiety disorders, their degree of severity or different 
dimensions are associated with adverse levels of metabolic risk factors. Up 
until now, these associations have remained unclear. Severity scales for 
depression and anxiety have not been systematically applied and their 
various dimensions have not been studied at all in this research field. 
Moreover, so far the focus has been mainly on the metabolic syndrome as 
a whole instead of on separate metabolic risk factors. Therefore, the 
relative importance of separate metabolic adversities in their association 
with symptoms of depression and anxiety will also be extensively 
discussed. And because the temporal association of depression and 
anxiety with metabolic risk is still uncertain, the association of depressive 
and anxiety symptoms with metabolic risk factors will be addressed 
longitudinally as well. The question whether antidepressant use affects 
metabolic risk factors will also be examined. In addition, the contribution 
of biological stress systems and unhealthy lifestyles to metabolic risk in 
depression and anxiety will be explored. Furthermore, the relationship of 
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personality traits and childhood trauma with metabolic risk factors will be 
studied. These objectives are shown schematically in Figure 1. 
  The knowledge that will be obtained by this thesis could be 
important for clinical practice. It will increase our understanding of what 
characteristics make people with symptoms of depression or anxiety 
vulnerable to an unfavorable metabolic profile and thus to developing CVD. 
This awareness may contribute to future guidelines for prevention and 
treatment of metabolic risk. Once characteristics that predispose people 
with depressive or anxiety disorders to increased metabolic risk have been 
established, people with these characteristics might be routinely screened 
for the presence of metabolic adversities. Subsequently, modification of 
contributors to these associations might reduce their metabolic risk.  
 
1.8  THESIS OUTLINE 
The numbers in Figure 1 refer to the thesis chapters. Chapters 2 through 
4 comprise research on cross-sectional associations of metabolic risk 
factors with symptoms of depression and anxiety. In chapter 2 we 
describe the risk of the metabolic syndrome and its components among 
people with pure MDD, pure anxiety or co-morbid MDD and anxiety, as 
compared to people without such disorders (i.e., controls). Next, we 
address the question whether severity of depression or anxiety is 
associated with the metabolic syndrome or its components. Finally, we 
examine whether antidepressant use independently increases metabolic 
syndrome (component) risk. In chapter 3, total, LDL and HDL cholesterol 
and triglycerides are compared between people with current MDD, those 
with remitted MDD, and controls. We also examine the importance of the 
severity of depression, the presence of atypical or melancholic MDD 
subtypes, co-morbid anxiety disorder or dysthymia, and suicide attempt in 
history. In chapter 4 we discuss how symptom dimensions (i.e., negative 
affect, positive affect and somatic arousal) relate to the metabolic 
syndrome and its components. 
  In chapter 5, longitudinal associations of symptoms of depression 
and anxiety with metabolic risk factors are described. We address the 
question whether baseline depression or anxiety severity predicts a change 
in metabolic values over a 2-year follow-up period, and whether changes in 
severity of depression or anxiety coincide with changes in metabolic risk 
factors.  
 Chapter 6 and 7 include studies regarding possible contributors to 
metabolic adversities among depressed and anxious people. Chapter 6 
shows general associations of the biological stress systems ANS and HPA 
axis with the metabolic syndrome. In chapter 7, we address the impact of 
biological stress system alterations and lifestyle on associations of 
metabolic risk factors with severity of depression and anxiety, and with 
antidepressant use.  
   Chapter 8 outlines whether personality or childhood trauma are 
correlates of metabolic risk factors. In chapter 9, the main results of 
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chapter 2 through 8 will be summarized and discussed within the 
framework of contemporary scientific knowledge. Furthermore, directions 
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The metabolic syndrome predisposes to cardiovascular disease and 
diabetes mellitus. There might also be an association between the 
metabolic syndrome and anxiety and depression, but its nature is unclear. 
We aimed to investigate whether diagnosis, symptom severity and 
antidepressant use are associated with the metabolic syndrome. 
 
Methods 
We addressed the odds for the metabolic syndrome and its components 
among 1217 depressed and/or anxious subjects and 629 controls, and 
their associations with symptom severity and antidepressant use. 
 
Results 
Symptom severity was positively associated with prevalence of the 
metabolic syndrome (adjusted odds ratio [OR] = 2.21 for very severe 
depression: 95% confidence interval [CI]: 1.06–4.64, p = .04), which could 
be attributed to abdominal obesity and dyslipidemia. Tricyclic 
antidepressant (TCA) use also increased odds for the metabolic syndrome 




The most severely depressed people and TCA users more often have the 
metabolic syndrome, which is driven by abdominal adiposity and 
dyslipidemia. 
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2.1  INTRODUCTION 
The metabolic syndrome is defined as a cluster of metabolic abnormalities, 
including abdominal obesity, hypertriglyceridemia, low high-density 
lipoprotein (HDL) cholesterol, hypertension and hyperglycemia. The 
metabolic syndrome thereby predisposes to cardiovascular disease (CVD) 
and diabetes mellitus.17
,97 Mapping risk factors for the metabolic syndrome 
is important given the high global risk and burden of CVD and diabetes,98 
plus the increasing prevalence of obesity and the metabolic syndrome 
worldwide.99 There is a growing interest in whether anxious or depressed 
people are at higher risk for the metabolic syndrome, since depression as 
well as anxiety show high co-morbidity with CVD.100
,101 
  In most studies investigating the link between depressive 
symptoms and the metabolic syndrome,23,24,26-29,32,46-49,73,74,132-140 a positive 
association was reported,24,26-29,32,46,48,49,73,74,132-137,139,140 while some 
described none.20
,44,45,102,103 Only few studies focused on the association 
between anxiety and the metabolic syndrome,20
,23,44,49,103-105 of which only 
two confirmed a positive association,103
,104 and others did not confirm a 
link. In studies considering the metabolic syndrome and its components, 
mainly abdominal obesity,23,24,26-29,46-48,134,138 hypertriglyceridemia 23,24,26, 
27,133,134,140,142 and a low HDL cholesterol20
,21,25,26,32,102,106,107 were found to 
be associated with depressive symptoms, while associations with 
hypertension23,24,138 or hyperglycemia24,47,73,138,140 have rarely been 
reported. In the few studies on anxiety and metabolic syndrome 
components,23,26,47,137 only an association with hypertriglyceridemia137 and 
high blood pressure20 was found. This raises the question whether anxiety 
or depression are risk factors for several individual metabolic syndrome 
components, rather than for the whole metabolic syndrome cluster. 
  It is not only important to study whether metabolic syndrome 
prevalence differs among DSM-IV diagnoses groups, but also 
simultaneously its association with symptom severity, as this latter 
approach focuses on a separate psychopathological aspect, namely 
dimensionality of disease. Vogelzangs et al.28 for example, reported an 
association of the metabolic syndrome with depression severity, while no 
association was present with the dichotomous depression classification. 
Another point of interest is whether antidepressant use influences the 
odds for having the metabolic syndrome. Previous studies have scarcely 
addressed this topic. Nevertheless, the use of TCAs is known to induce 
side effects like hypertension,62 hyperglycemia,78 and weight gain,75,76 
which may consequently promote dyslipidemia.143 To a lesser extent, the 
commonly prescribed selective serotonin re-uptake inhibitors (SSRIs) also 
tend to induce weight gain59 and thereby dyslipidemia143 in some patients, 
but they do not cause hyperglycemia.61 
 The present study is the first to analyze clinical anxiety and 
depression diagnoses, as well as symptom severity and antidepressant use, 
as potential predictors of the metabolic syndrome. We also aimed to 
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elucidate which of the individual metabolic syndrome components are 
most strongly associated with these predictors. 
 
2.2  METHODS 
Subjects 
Subjects participated in the baseline assessment of the Netherlands Study 
of Depression and Anxiety (NESDA), an 8-year longitudinal cohort study 
including 2981 persons aged 18–65 years. Subjects were recruited from 
community, primary care, and mental health care in the Netherlands. The 
baseline assessment comprised of a face-to-face interview, written 
questionnaires, and biological measurements. The study design is 
described in detail elsewhere.95 The study protocol was approved by the 
Ethical Review Board of each participating center, and all subjects signed 
informed consent at the baseline assessment. 
  For the current analyses, four study groups were constructed, i.e., 
subjects with an anxiety disorder within the past 6 months but no lifetime 
major depressive disorder (MDD) (i.e., ‘current pure anxiety’, n=276), 
subjects with an MDD within the past 6 months but no lifetime anxiety 
disorder (i.e., ‘current pure MDD’, n=272), subjects with both MDD and 
anxiety disorder within the past 6 months (i.e., ‘current anxiety and MDD’, 
n=731), and those who never had a MDD or anxiety disorder (i.e., 
‘controls’, n=652), resulting in a preliminary sample size of 1931. Then, 84 
subjects with missing values on metabolic syndrome components or on 
anxiety or depression severity (see below) were excluded, resulting in the 
current sample of 1846 subjects (i.e., n=266 current pure anxiety, n=261 
current pure MDD, n=690 current anxiety and MDD, and n=629 controls). 
 
Indicators of psychopathology 
The presence of an anxiety disorder (i.e., panic disorder with or without 
agoraphobia, social phobia or generalized anxiety disorder) or MDD within 
the past 6 months was diagnosed according to the fourth edition of the 
Diagnostic and Statistical Manual for mental disorders (DSM-IV) criteria 
using the Composite International Diagnostic Interview (CIDI).108 
  Anxiety severity was assessed by the 21-item self-report Beck 
Anxiety Inventory (BAI) ranging from 0 to 63. Beck Anxiety Inventory total 
scores were subdivided into four severity groups, i.e., normal (total score 
0–9), mild (10–18), moderate (19–29), and severe (30–63), as described 
before.109 Depression severity was assessed by the 30-item Inventory of 
Depressive Symptoms self-report (IDS-SR) ranging from 0 to 84. IDS-SR 
total scores were, as before,110 subdivided into five severity groups, i.e., low 
(total score 0–13), mild (14–25), moderate (26–38), severe (39–48), and very 
severe (49–84). 
  Antidepressant medication use within the past month, as registered 
by observation of drug containers brought in, was subdivided into selective 
serotonin re-uptake inhibitors (SSRI, ATC code N06AB), tricyclic 
antidepressants (TCA, ATC code N06AA) and other antidepressants (mainly 
METABOLIC SYNDROME, 




consisting of serotonergic and noradrenergic working antidepressants 
N06AF and N06AX). Subjects who used more than one kind of 
antidepressant (n=15) were classified according to the category with the 
strongest assumed metabolic side effects (TCAs > SSRIs > other). 
 
The metabolic syndrome 
The metabolic syndrome was defined according to the American Heart 
Association & National Heart, Lung and Blood Institute’s update of the 
National Cholesterol Education Program – Adult Treatment Panel III 
(NCEP-ATP III) definition.17 It requires the presence of three or more of the 
following criteria: i) abdominal obesity, i.e., waist circumference ≥ 102 cm 
in men and ≥ 88 cm in women; ii) hypertriglyceridemia, i.e., elevated 
triglyceride level (≥ 1.70 mmol/L) or drug treatment for elevated 
triglycerides; iii) low high-density lipoprotein (HDL) cholesterol (< 
1.03 mmol/L in men and < 1.30 mmol/L in women) or drug treatment for 
reduced HDL cholesterol; iv) hypertension, i.e., elevated blood pressure (≥ 
130/85 mmHg) or use of antihypertensive medication and v) 
hyperglycemia, i.e., elevated fasting glucose level (≥ 5.6 mmol/L) or use of 
antidiabetic medication. 
  Waist circumference was measured with a measuring tape at the 
central point between the lowest front rib and the highest front point of the 
pelvis, upon light clothing. Triglyceride, HDL cholesterol and glucose levels 
were determined using routine standardized laboratory methods after a 
mean of 11:16 h (SD = 1:50 h) overnight fast. Systolic and diastolic blood 
pressure were measured twice during supine rest on the right arm by the 
OMRON M4 IntelliSense (HEM-752A; Omron Healthcare, Inc., 
Bannockburn, IL, USA), and were averaged over the two measurements. 
ATC coded111 use of HDL increasing or triglyceride lowering (ATC codes 
C10AB, C10AD, C10BA01), antihypertensive (ATC codes C02, C03, C07, 
C08, C09) or antidiabetic medication (ATC code A10) within the past 
month was registered by observation of drug containers brought in.  
  In line with previous research,137,148 the number of metabolic 




Sociodemographic variables included age, sex (male/female) and years of 
education. Oral contraceptive use (no/yes) was identified through self-
report. Clinic site (five sites) was added as a covariate as well. We also 
included lifestyle characteristics previously associated with anxiety, 
depression and the metabolic syndrome: smoking status 
(never/former/current) and alcohol use (<1/1–2/>2 drinks per day) were 
assessed by standardized questionnaires; physical activity was assessed 
using the International Physical Activity Questionnaire,112 and expressed 
in 1000 metabolic equivalent of task (MET)-minutes in the past week. MET 
reflects the ratio of the associated metabolic rate for specific activities 
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divided by the resting metabolic rate, multiplied by the minutes performed 
activity. Prevalent medicated CVD or diabetes mellitus were assessed by 
standardized questionnaires. 
 
Statistical analyses  
Characteristics of DSM-IV diagnosis groups were compared by Kruskal–
Wallis test (Monte Carlo method with 95% confidence intervals) for (non-
normally distributed) quantitative variables, and by χ2 statistics for 
categorical variables. To evaluate which group differences accounted for 
significant overall p values, post hoc tests were done by Mann–Whitney U-
tests with Bonferroni correction. Mann–Whitney U-tests were performed 
only between controls and the three psychopathology groups (and not 
between all groups) to reduce the type I error rate. Multivariate logistic 
regression analyses were conducted to assess the association between 
DSM-IV diagnosis (controls [i.e., reference group]/current pure 
anxiety/current pure MDD/current anxiety and MDD), anxiety (BAI) or 
depression severity (IDS-SR) group or antidepressant use group (none [i.e., 
reference group]/SSRI/TCA/other; all independent variables) and the 
presence of the metabolic syndrome (absent [i.e., reference group]/present; 
dependent variable). We adjusted for basic covariates (i.e., age, sex, years 
of education, clinic site and oral contraceptive use) in model 1, and 
additionally for lifestyle-related covariates (i.e., smoking status, alcohol 
use, and physical activity) in model 2. Since sex differences in the 
association between anxiety, depression and the metabolic syndrome have 
been observed before,21
, 43, 105 sex × DSM-IV diagnosis/anxiety 
severity/depression severity interaction terms were examined in model 2. 
Furthermore, CVD / diabetes × DSM-IV diagnosis / anxiety severity / 
depression severity interaction terms were tested within model 2. 
Differences in the mean number of prevalent metabolic components per 
DSM-IV diagnosis group, anxiety or depression severity group, and per 
antidepressant use group were assessed by χ2 statistics (using linear-by-
linear tests for anxiety and depression severity). In multivariate logistic 
regression analyses, the associations were assessed between DSM-IV 
diagnosis, anxiety or depression severity or antidepressant use group 
(independent variables) and the presence of each single component of the 
metabolic syndrome (absent [i.e., reference group]/present; dependent 
variables). In analyses on symptom severity or antidepressant use, only 
those subjects with psychopathology were included. Statistical significance 
was inferred at p < 0.05. All statistical analyses were undertaken with 
SPSS 16.0 (IBM company, Chicago, Illinois, USA). 
 
2.3  RESULTS 
Table 1 shows the characteristics of the DSM-IV diagnosis groups. The 








Table 1. Characteristics according to DSM-IV diagnosis in 1846 subjects 




Current anxiety and 
MDD 
p * 
n 629 266 261 690  
Age  43.0   (27.0-55.0) 42.0    (29.8-53.0) 41.0  (30.0-51.0) 42.0   (31.0-51.0) .58 
Sex (% men) 38.3 38.0 39.1 30.6 .009 
Years of education 12.0a  (10.0-15.0) 
11.0b   (10.0-15.0) 11.0b (10.0-
15.0) 
11.0b  (9.0-15.0) <.001 
Oral contraceptive use (%) 18.9 16.2 20.7 19.7 .55 
Smoking status (%)     <.001 
      Never 36.7 25.6 26.8 27.0  
      Former  36.2 31.6 31.0 26.1  
      Current  27.0 42.9 42.1 47.0  
Alcohol use (%)     .009 
      <1 glasses/day 57.6 60.9 65.9 67.5  
      1-2 glasses/day 23.7 23.7 18.8 17.2  
      > 2 glasses/day 18.8 15.4 15.3 15.2  
Physical activity (in 1000 MET-minutes last 
week) 
3.2a    (1.6-4.9) 
2.8a       (1.4-4.8) 
2.9a    (1.2-4.6) 2.7b     (1.2-4.8) .02 
Antidepressant use (%)      
      Selective serotonin re-uptake inhibitors 0.6 14.7 24.9 32.9 <.001 
      Tricyclic antidepressants 0.2 2.6 3.1 4.9 <.001 
      Other antidepressants 0.2 4.5 9.6 12.3 <.001 
Anxiety severity (BAI; %)     <.001 
      Normal 87.9 32.3 46.0 15.9  
      Mild 10.5 35.3 32.6 29.1  
      Moderate 1.4 24.4 17.6 32.6  
      Severe 0.2 7.9 3.8 22.3  
Depression severity (IDS-SR; %)     <.001 
      None 80.3 21.8 9.6 4.2  
      Mild 16.4 43.6 30.3 17.8  
      Moderate 2.9 26.7 40.2 40.6  
      Severe 0.5 6.4 15.7 24.8  







Table 1. Continued 




Current anxiety and 
MDD 
p* 
n 629 266 261 690  
Metabolic syndrome (%) 19.4 22.2 21.8 22.5 .56 
      Abdominal obesity (≥ 88/102 cm, %) 28.6 29.3 32.6 36.7 .01 
      Hypertriglyceridemia (≥ 1.7 mmol/L, %) 18.6 21.8 21.5 21.3 .68 
      Low HDL-cholesterol (< 1.03/1.3 mmol/L, %) 11.1 14.3 15.7 15.9 .18 
      Triglyceride lowering or HDL cholesterol    
      increasing medication use (%) 
0.3 
0.4 
0.4 0.1 .88 
      Hypertension (≥ 130/85 mmHg, %) 61.9 57.5 54.8 57.0 .15 
      Antihypertensive medication use, %) 14.5 15.8 11.9 14.1 .63 
      Hyperglycemia (≥ 5.6 mmol/L, %) 21.3 23.4 21.5 21.3 .90 
      Antidiabetic medication use (%) 3.7 2.6 3.1 3.6 .85 
Abbreviations: BAI, Beck Anxiety Inventory; HDL, high-density lipoprotein; DSM-IV, Diagnostic and Statistical Manual of mental 
disorders – fourth edition; IDS-SR, Inventory of Depressive Symptoms self-report; MDD, major depressive disorder; MET, metabolic 
equivalent of task. 
Medians (interquartile ranges) or percentages are given, when appropriate. 
*: p by Kruskal-Wallis test for quantitative variables or χ² statistics for categorical variables. 
abc: Superscript letters that differ from the superscript letter of the control group indicate that the post hoc p values of those groups differ 









Control subjects had more years of education, tended to use more alcohol 
and to smoke less than the anxiety or MDD groups. The prevalence of 
abdominal obesity tended to be higher among depressed or anxious 
subjects. There were no statistically significant differences in the 
prevalence of the metabolic syndrome or its components between diagnosis 
groups. 
As shown in Table 2, no statistically significant associations 
between diagnosis group and the metabolic syndrome were found. 
Although the moderate and severe anxiety groups were associated with the 
presence of the metabolic syndrome in unadjusted analyses, no 
statistically significant associations were found in models 1 and 2. The 
odds for presence of the metabolic syndrome increased with increasing 
levels of depression severity, which was statistically significant for very 
severe depression as compared to the reference group (OR = 2.21, 95% CI: 
1.06–4.64, p = .04 in model 2). Additional adjustment for antidepressant 
use did not alter these results (OR = 2.18, 95% CI: 1.04–4.60, p = .04). 
Prevalence of the metabolic syndrome was also significantly increased in 
TCA users as compared to the group not using antidepressants (OR = 2.30, 
95% CI: 1.21–4.36, p = .01 in model 2), which was not affected by 
additional adjustment for depression severity (OR = 2.18, 95% CI: 1.15–
4.15, p = .02). In Table 2, repeated analyses of model 2 including 
sex × DSM-IV diagnosis/anxiety severity/depression severity interaction 
terms, showed no statistically significant interaction (all p > 0.6). This 
suggests that associations do not significantly differ for men or women. 
CVD/diabetes × DSM-IV diagnosis/anxiety severity/depression severity 
interaction terms were also non-significant (all p > 0.20), suggesting 
similar associations among subjects with or without CVD or diabetes. 
Figure 1 shows that the mean number of metabolic syndrome components 
did not differ between DSM-IV diagnosis groups. The number of metabolic 
syndrome components increased over increased severity of both anxiety 
(p < 0.001) and depression (p < 0.001). Moreover, antidepressant use, and 
TCA use in particular, was associated with a higher mean number of 
metabolic syndrome components. 
Table 3 shows the odds for the presence of each single metabolic 
syndrome component across DSM-IV diagnoses, anxiety or depression 
severity and antidepressant use groups in model 2. The unadjusted higher 
odds for having abdominal obesity in co-morbid current MDD and anxiety 
(OR = 1.44, 95% CI: 1.15–1.82, p = .002), as compared to controls, was no 
longer statistically significant in model 2. Nevertheless, the odds for 
abdominal obesity increased with increasing severity of anxiety symptoms. 
However, its association with low HDL cholesterol in model 1 (OR = 1.88, 
95% CI: 1.14–3.10, p = .01) was reduced in model 2. In model 1, very 
severe depression was associated with abdominal obesity (OR = 2.37, 95% 
CI: 1.27–4.41, p = .007) and hypertriglyceridemia (OR = 2.11, 95% CI: 
1.05–4.24, p = .04), but only the association with abdominal obesity 
 
 
Table 2. The associations between DSM-IV diagnosis, severity, antidepressant use and the presence of the metabolic syndrome 
  Crude Model 1 Model 2 
 n OR 95% CI p OR 95% CI p OR 95% CI p 
DSM-IV diagnosis           
    Controls*  629 1.00   1.00   1.00   
    Current pure anxiety  266 1.18 0.83-1.68 .34 1.10 0.75-1.60 .64 1.04 0.71-1.54 .83 
    Current pure MDD  261 1.16 0.82-1.65 .41 1.19 0.81-1.75 .37 1.12 0.76-1.66 .57 
    Current anxiety and 
MDD  
690 1.20 0.92-1.57 .17 
1.14 
0.85-1.53 
.39 1.08 0.80-1.46 .62 
Anxiety severity (BAI)°           
    Normal* 316 1.00   1.00   1.00   
    Mild 380 1.21 0.82-1.77 .34 1.11 0.73-1.67 .63 1.09 0.72-1.66 .68 
    Moderate  336 1.68 1.15-2.46 .007 1.38 0.92-2.07 .12 1.37 0.90-2.07 .14 
    Severe  185 1.81 1.17-2.79 .008 1.46 0.91-2.33 .12 1.38 0.85-2.23 .19 
Depression severity 
(IDS-SR)° 
          
    None* 112 1.00   1.00   1.00   
    Mild  318 1.51 0.83-2.74 .17 1.21 0.64-2.29 .55 1.24 0.65-2.35 .52 
    Moderate  456 1.44 0.81-2.56 .22 1.11 0.60-2.06 .74 1.09 0.58-2.04 .79 
    Severe  229 2.48 1.36-4.53 .003 1.65 0.87-3.14 .13 1.51 0.78-2.91 .22 
    Very severe  102 3.27 1.68-6.38 <.001 2.55 1.24-5.25 .01 2.21 1.06-4.64 .04 
Antidepressant use°           
    None* 730 1.00   1.00   1.00   
    SSRI  328 1.35 0.99-1.84 .06 1.30 0.93-1.82 .13 1.22 0.87-1.72 .25 
    TCA  49 3.35 1.85-6.05 <.001 2.56 1.36-4.82 .004 2.30 1.21-4.36 .01 
    Other  110 1.21 0.75-1.96 .44 0.97 0.59-1.61 .92 0.97 0.58-1.63 .91 
Abbreviations: BAI, Beck Anxiety Inventory; CI, confidence interval; DSM-IV, Diagnostic and Statistical Manual of mental disorders– fourth 
edition; IDS-SR, Inventory of Depressive Symptoms self-report; MDD, major depressive disorder; OR, odds ratio by multivariate logistic 
regression analysis; SSRI, selective serotonin re-uptake inhibitor; TCA, tricyclic antidepressant. 
Model 1: adjusted for age, sex, years of education, clinic site and oral contraceptive use. 
Model 2: additionally adjusted for smoking status, alcohol use and physical activity. 
*: Reference group to the subsequent groups. 







Table 3. The association between DSM-IV diagnosis, severity, antidepressant use and the presence of individual metabolic syndrome 
components 
  Abdominal obesity Hypertriglyceridemia Low HDL cholesterol  
 n OR 95% CI p OR 95% CI p OR 95% CI p 
Model 2           
DSM-IV diagnosis           
    Controls*  629 1.00   1.00   1.00   
    Current pure anxiety   266 0.96 0.68-1.35 .80 1.10 0.76-1.61 .61 1.06 0.68-1.64 .81 
    Current pure MDD  261 1.23 0.88-1.72 .22 1.07 0.73-1.57 .72 1.12 0.73-1.72 .61 
    Current MDD and anxiety  690 1.28 0.99-1.66 .06 1.08 0.80-1.45 .62 1.00 0.71-1.40 .98 
Anxiety severity (BAI)°           
    Normal* 316 1.00   1.00   1.00   
    Mild  380 1.16 0.82-1.66 .41 1.07 0.71-1.61 .75 1.12 0.70-1.79 .64 
    Moderate 336 1.40 0.97-2.00 .07 1.43 0.96-2.14 .08 1.47 0.92-2.33 .11 
    Severe  185 1.74 1.14-2.65 .01 1.33 0.83-2.13 .24 1.57 0.94-2.64 .09 
Depression severity (IDS-SR)°           
    Low* 112 1.00   1.00   1.00   
    Mild  318 0.92 0.54-1.57 .76 1.06 0.57-1.94 .86 1.26 0.62-2.53 .52 
    Moderate  456 0.96 0.57-1.60 .87 1.09 0.61-1.97 .77 0.99 0.50-1.97 .98 
    Severe  229 1.52 0.88-2.63 .13 1.37 0.73-2.57 .32 1.34 0.65-2.75 .43 
    Very severe  102 2.30 1.22-4.34 .01 1.72 0.85-3.52 .14 1.20 0.53-2.67 .67 
Antidepressant use°           
    None* 730 1.00   1.00   1.00   
    SSRI  328 1.12 0.83-1.51 .45 1.27 0.91-1.78 .17 1.06 0.74-1.53 .75 
    TCA  49 1.88 1.00-3.54 .05 2.57 1.36-4.84 .004 1.40 0.68-2.89 .36 
    Other  110 1.27 0.81-1.97 .30 1.27 0.78-2.08 .33 0.85 0.46-1.57 .60 
Abbreviations: BAI, Beck Anxiety Inventory; CI, confidence interval; DSM-IV, Diagnostic and Statistical Manual of mental disorders – fourth 
edition; HDL, high-density lipoprotein; IDS-SR, Inventory of Depressive Symptoms self-report; MDD, major depressive disorder; OR, odds ratio 
by multivariate logistic regression analysis; SSRI, selective serotonin re-uptake inhibitor; TCA, tricyclic antidepressant. 
Model 2: adjusted for age, sex, years of education, clinic site, oral contraceptive use, smoking status, alcohol use and physical activity. 
*: Reference group to the subsequent groups. 








Table 3. Continued 
  Hypertension Hyperglycemia 
 n OR 95% CI p OR 95% CI p 
Model 2        
DSM-IV diagnosis        
    Controls*  629 1.00   1.00   
    Current pure anxiety   266 0.97 0.69-1.36 .86 1.09 0.74-1.59 .68 
    Current pure MDD  261 0.75 0.54-1.05 .10 1.12 0.76-1.66 .57 
    Current MDD and anxiety  690 0.90 0.69-1.17 .43 1.09 0.81-1.47 .58 
Anxiety severity (BAI)°        
    Normal* 316 1.00   1.00   
    Mild  380 0.97 0.69-1.37 .87 0.87 0.58-1.30 .49 
    Moderate 336 1.06 0.74-1.51 .77 1.04 0.69-1.55 .86 
    Severe  185 1.41 0.91-2.18 .12 1.09 0.67-1.76 .73 
Depression severity (IDS-SR)°        
    Low* 112 1.00   1.00   
    Mild  318 1.00 0.61-1.66 1.00 0.91 0.50-1.66 .76 
    Moderate  456 0.90 0.55-1.46 .66 0.96 0.54-1.71 .89 
    Severe  229 0.86 0.50-1.47 .57 0.99 0.53-1.84 .97 
    Very severe  102 0.94 0.50-1.77 .84 1.65 0.80-3.37 .17 
Antidepressant use°        
    None* 730 1.00   1.00   
    SSRI  328 0.96 0.71-1.30 .78 1.01 0.71-1.42 .98 
    TCA  49 2.29 1.07-4.91 .03 1.38 0.70-2.71 .35 
    Other  110 1.35 0.83-2.21 .23 0.69 0.40-1.18 .18 
Abbreviations: BAI, Beck Anxiety Inventory; CI, confidence interval; IDS-SR, Inventory of Depressive Symptoms self-report; MDD, major 
depressive disorder; OR, odds ratio by multivariate logistic regression analysis; SSRI, selective serotonin re-uptake inhibitor; TCA, tricyclic 
antidepressant. 
Model 2: adjusted for age, sex, years of education, clinic site, oral contraceptive use, smoking status, alcohol use and physical activity. 
*: Reference group to the subsequent groups. 










persisted in model 2. These results were not significantly altered by 
additional adjustment for antidepressant use (data not shown). TCA users 
demonstrated higher odds for having abdominal obesity, 
hypertriglyceridemia and hypertension, as compared to non-users of 
antidepressants. Additional adjustment for depression severity did not 
















































































































































Figure 1. Dots indicate mean number of metabolic syndrome (MetSyn) components; bars 
indicate 95% confidence intervals. Analyses on DSM-IV diagnosis are based on the complete 
sample (n=1846). Analyses on anxiety severity group, depression severity group or 
antidepressant use are based on the sample excluding controls (n=1217). p by χ² statistics. χ² 
linear-by-linear test was applied for anxiety and depression severity. 
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2.4  DISCUSSION 
In this large cohort study, the prevalence of the metabolic syndrome was 
uniformly not increased in subjects with either MDD or an anxiety 
disorder, as compared to controls. However, subjects with more severe 
depressive symptoms did have increased metabolic syndrome odds, which 
were mainly driven by increased abdominal adiposity, lower HDL 
cholesterol levels and hypertriglyceridemia. TCA users were also at 
increased odds for the metabolic syndrome, which was not only 
determined by the increased prevalence of abdominal obesity and 
hypertriglyceridemia, but also that of hypertension. 
  The finding that metabolic syndrome prevalence was increased in 
subjects with severe psychopathology, but not among diagnosis groups, 
indicates that symptom severity is more differentiating than diagnostic 
DSM-IV categories. The high co-morbidity between depression and 
anxiety113
,114 supports this indication. This implies that the use of 
dimensional instruments is a more sensitive approach, and therefore may 
be more helpful in the understanding of the complex relationship between 
psychopathology and the metabolic syndrome. This is supported by a 
study by Vogelzangs et al.,25 in which they did not find an association 
between the metabolic syndrome and a dichotomous depression standard, 
but did report an association with a severity scale. 
  Abdominal adiposity, hypertriglyceridemia and low HDL cholesterol 
were the components that were increased in subjects with 
psychopathology. Previous studies also found these three components,23,24, 
26-29,35,46-48,133,134,138,140,142 but rarely hypertension20
,21,102 or hyperglycemia, 
24,47,73,138,140 to be more prevalent in subjects with anxiety or depression. 
This suggests that abdominal adiposity and dyslipidemia largely account 
for the increased metabolic syndrome odds in anxiety and depression, 
which is in line with a factor analytical study that demonstrated that lipids 
and abdominal adiposity form a distinct cluster within the metabolic 
syndrome.115 These findings add to the general debate on whether the 
whole metabolic syndrome is more than the sum of its parts, and 
consequently on its usefulness as an unambiguous cluster in research and 
clinical practice,116 at least in affective disorders.  
  Several possible explanations exist for the increased odds for 
abdominal obesity and dyslipidemia in subjects with more severe 
psychopathology. First, this might be a reflection of unfavorable lifestyle 
habits that are associated with anxiety and depression.117 However, the 
lifestyle factors smoking, alcohol use and physical activity that were 
adjusted for in the present study, could only partly explain the 
associations. Unfortunately, we were unable to take dietary factors into 
account, while depression is associated with poor diets rich in 
carbohydrates and saturated fat.118 A second -common causal- pathway 
might be the upregulation of the hypothalamic-pituitary-adrenal (HPA) 
axis. HPA axis perturbations may lead to psychopathology67
,119 and to 
visceral adipose tissue accumulation, which subsequently, through 
METABOLIC SYNDROME, 




inflammatory factor secretion by adipose tissue, might induce 
dyslipidemia.120 Depression-related inflammation,155,156 which might be 
enhanced by reduced levels of anti-inflammatory factors such as 
adiponectin in depression,121 could also aggravate metabolic alterations in 
psychopathology. Finally, hyperactivity of the autonomic nervous 
system,122 or another third factor, might underlie the metabolic 
dysregulation in severe psychopathology. 
  Tricyclic antidepressant users demonstrated a distinct metabolic 
pattern, likely induced by TCA side effects. Next to the antihistaminergic 
effects that induce weight gain75,76 and subsequently dyslipidemia,143 TCA 
use is also associated with hypertension62 through peripheral α1 
adrenergic receptor agonism.63 As metabolic syndrome disturbances in 
TCA users and that in subjects with severe psychopathology overlap, these 
findings may be linked: TCA users are, at least before starting medication, 
more severely depressed than current SSRI users. However, TCA use 
remained an independent predictor of metabolic syndrome alterations after 
adjustment for depression severity. 
  The first limitation of our study is the cross-sectional design, which 
does not allow us to make causal inferences on whether psychopathology 
precedes metabolic alterations or vice versa. Second, the number of TCA 
users was relatively small, which could have led to some imprecision of 
effect estimates of the actual associations between TCA use and metabolic 
syndrome alterations. Strengths of our study are the large, 
psychopathology-based sample, the assessment of both DSM-IV diagnoses 
and disease severity scores, and the possibility to reliably illuminate the 
role of antidepressant use and individual metabolic syndrome components. 
  In conclusion, prevalence of the metabolic syndrome was not 
generally increased in large groups of subjects with anxiety and depressive 
disorders. However, the most severely depressed persons and TCA users 
had increased odds for the metabolic syndrome, which was driven by the 
abdominal adiposity and dyslipidemia components. To prevent CVD and 
diabetes mellitus, we recommend to screen for these metabolic syndrome 
components, especially in severely depressed patients, or when considering 
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Several studies have suggested an association between lipids or 
lipoproteins and depression, but findings are contradictory. However, 
previous studies did not always take into consideration potentially 




We compared levels of serum total, low-density lipoprotein (LDL), and high-
density lipoprotein (HDL) cholesterol and triglyceride between 761 subjects 
with current major depressive disorder (MDD) (Composite International 
Diagnostic Interview, based on the DSM-IV), 1071 subjects with remitted 
MDD, and 629 controls, aged 18 to 65 years. Subjects participated in the 
baseline assessment of the Netherlands Study of Depression and Anxiety, 
which lasted from September 2004 to February 2007. We studied the 
impact of adjustment for sociodemographics, lifestyle-related covariates, 
and antidepressant use, and examined the association between specific 
psychopathological characteristics and lipid/lipoprotein levels. 
 
Results 
HDL cholesterol level was lower (p = .007) and triglyceride level was higher 
(p = .001) in current MDD versus remitted MDD and controls. After 
adjustment for level of education, body mass index (BMI), smoking status, 
and alcohol use, dissimilarities lost statistical significance. Depression 
severity, co-morbid dysthymia, and melancholic and atypical features were 
all associated with lipids/lipoproteins, but most associations attenuated 
after adjustment for covariates, especially BMI. The association between 
melancholic features and lower HDL cholesterol (p = .038), and between 
atypical depression and higher total and LDL cholesterol (p = .004 and p = 
.002, respectively) persisted after full adjustment. 
 
Conclusions 
Adverse lipoprotein patterns were found in patients with MDD. The fact 
that these associations diminished after adjustment for lifestyle-related 
factors, especially BMI, suggests that the unfavorable lipid/lipoprotein 
pattern among depressed subjects is mainly secondary to lifestyle-related 
factors. However, melancholic features were independently associated with 
lower HDL cholesterol, and atypical depression was independently 
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3.1  INTRODUCTION 
Serum lipids and lipoproteins are argued to be associated with depression, 
but findings regarding this link have been inconsistent. Most studies have 
found lower total cholesterol in subjects with depressive  symptoms versus 
controls.34-40 Other studies have reported higher total cholesterol34 or 
found no differences.51-54Levels of low-density lipoprotein (LDL) cholesterol, 
high-density lipoprotein (HDL) cholesterol, and triglyceride were assessed 
in relation to depression or depressive complaints as well,32
,35,36,39,40,123,124 
but less extensively. Again, contradictory results were obtained.  
  Several possible explanations exist for these mixed findings. First, 
study designs differed widely. For example, various depression assessment 
scales were used, and the universal gold standard to identify clinical 
depression, the Diagnostic and Statistical Manual of mental disorders 
(DSM), was infrequently applied.31
,35,36,123,124 Furthermore, some samples 
were small,36 contained a small proportion of depressed subjects,31 covered 
a restricted age range, such as elderly37,42,43,51,53 or adolescents,37 or 
included either men31
,34,38-40 or women.37 This reduces comparability of 
studies and generalizability of results to clinical practice.  
  Second, the inconsistencies in previous research might be due to 
the fact that major depressive disorder (MDD) is often approached as a 
homogeneous disorder. Therefore, its range of psychopathological 
characteristics has been ignored. Depressed subjects differ concerning 
depression severity, and often display co-morbid anxiety disorders or 
dysthymia. Also, suicidality regularly accompanies depression, which 
might also be associated with lipid/lipoprotein deviations.41 Furthermore, 
some depressed subjects exhibit atypical or melancholic features, which 
may be more strongly associated with lipid/lipoprotein alterations. 
A third explanation for the contradictory results is the potential 
mediation of lifestyle in the association between depression and 
lipids/lipoproteins. In previous studies, body mass index,37
,38,40,123,124 
smoking behavior,40 and alcohol use38
,40 were seldom taken into account, 
whereas depressed subjects on average have a higher body mass index,125 
are more likely to smoke,126
,127 and use either less128 or more alcohol74 
compared to non-depressed subjects. Moreover, obesity,129 smoking,75 and 
alcohol use130 modify lipid/lipoprotein metabolism, and are important 
anchor points in the management of an unhealthy lipid profile.97 Another 
possible confounder might be antidepressant use, as some are known to 
induce antihistaminergic side effects: for example, weight gain.58
,131  
To our knowledge, this is the largest sample in which the 
association between lipids/lipoproteins and DSM-diagnosed MDD is 
studied. Our sample includes men and women over a broad age range. We 
distinguish between controls, those with a remitted MDD, and those with a 
current MDD, since residual symptoms in persons with a remitted 
depression are commonly found,132 and, therefore, we expect the 
associations in our study to be graded over the control, remitted 
depression, and current depression groups. By investigating the role of 
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psychopathological characteristics, lifestyle, and antidepressant use, we 
aim to elucidate aspects that mainly influence the association between 
lipids/lipoproteins and depression. 
 
3.2  METHODS 
Subjects 
Subjects participated in the baseline assessment of the Netherlands Study 
of Depression and Anxiety (NESDA), which lasted from September 2004 to 
February 2007 and included 2981 persons aged 18 to 65 years. Subjects 
were recruited from community, primary care, and mental health care in 5 
Dutch regions (Amsterdam, Emmen, Groningen, Heerenveen, Leiden). The 
baseline assessment comprised a face-to-face interview, written 
questionnaires, and biologic measurements. The detailed study design is 
described elsewhere.95 The study protocol was approved by the Ethical 
Review Board of each participating center, and all subjects signed 
informed consent at baseline assessment.  
For the current analyses, 3 groups were included, i.e., subjects 
with an MDD diagnosis in the past month (i.e., “current MDD,” n=802), 
subjects with an MDD diagnosis before the last month (i.e., “remitted 
MDD,” n=1123), and those who never had a depressive or anxiety disorder 
(i.e., “controls,” n=652), resulting in a preliminary sample size of 2577. 
Excluding cases with one or more missing values on total, HDL, or LDL 
cholesterol, triglyceride, or depression severity (see below) resulted in a 
sample of 2461 subjects (i.e., 761 with current MDD, 1071 with remitted 
MDD, and 629 controls). 
 
Major depressive disorder 
Major depressive disorder (MDD) was diagnosed according to the 
Diagnostic and Statistical Manual for mental disorders, fourth edition 




For subjects with current MDD, various psychopathological characteristics 
were assessed. Depression severity was assessed by the 30-item Inventory 
of Depressive Symptoms self-report (IDS-SR),133 ranging from 0 to 84. 
Atypical depression was coded as “absent/present,” as done before,134 
based on the following IDS-SR items: a score of 0, 1, or 2 on item 8 for 
mood reactivity as well as two or more of the following: a score of 3 on item 
28 for leaden paralysis; a score of 2 or 3 on item 12 or item 14 for weight 
gain; a score of 2 or 3 on item 4 for hypersomnia; a score of 3 on item 27 
for interpersonal sensitivity. Similarly, the presence of melancholic 
features was coded as “absent/present,” with the following criteria: a score 
of 2 or 3 on item 19 for capacity for pleasure, or 3 on item 8 for mood 
responsiveness, and three or more of the following: a score of 2 or 3 on 
item 10 for quality of mood; a score of 0 on item 9a for morning mood, a 
LIPIDS & DEPRESSION 49 
 
  
score of 3 on item 3 for early awakening; a score of 2 or 3 on item 23 or 24 
for psychomotor changes; a score of 2 or 3 on item 11 or 13 for anorexia; a 
score of 2 or 3 on item 16 for feelings of guilt. The presence of co-morbid 
current (past month) anxiety disorder (social phobia, agoraphobia with or 
without panic disorder, or generalized anxiety disorder) and co-morbid 
current dysthymia was identified by the CIDI. Suicide attempt in history 
(absent/present) was determined by a single question.135 
 
Lipids/lipoproteins 
Blood samples were taken around 8:47 AM (SD=0.20 min), after a mean 11 
h 15 minutes (SD=111 min) overnight fasting period. The samples were 
transported to a laboratory within one hour. Levels of total, LDL, and HDL 
serum cholesterol as well as triglyceride were determined according to 
routine laboratory methods in all 5 participating laboratories. All methods 
were standardized through periodical external quality assessments by the 
Dutch Foundation for Quality Assessment in Clinical Laboratories. The 
maximum intra-assay variation coefficients of the methods were 0.8% for 
total cholesterol, 0.8% for LDL cholesterol, 1.0% for HDL cholesterol, and 
1.5% for triglycerides. The maximum inter-assay variation coefficients were 
1.7% for total cholesterol, 1.2% for LDL cholesterol, 1.3% for HDL 
cholesterol, and 1.8% for triglycerides. 
 
Covariates 
Sociodemographic variables (age, sex, level of education), smoking status 
(never/former/current), alcohol use (mean of 0/1–2/>2 glasses per day), 
presence of cardiovascular disease (CVD) or diabetes, and use of oral 
anticonceptives were assessed by standardized questionnaires. Level of 
education was classified as basic (i.e., elementary education or less), 
intermediate (i.e., lower or intermediate vocational education), or high (i.e., 
higher vocational, college, or university education). CVD was defined as the 
self-reported cardiac infarct, angina pectoris, heart failure, heart rhythm 
disorders, or cardiac surgery. Diabetes diagnosis was identified through 
self-report and/or the present use of antidiabetics. Use of antidiabetics, 
lipid-lowering medication (ATC code111 C10) and antidepressants (tricyclic 
antidepressant [TCA]/selective serotonin re-uptake inhibitor [SSRI]/other) 
in the past month was registered by observation of drug containers 
brought in. Antidepressants were subdivided into SSRI (ATC code N06AB), 
TCA (ATC code N06AA), and other antidepressants (monoamine oxidase 
inhibitors N06AG, nonselective N06AF, and antidepressants classified as 
N06AX). Height and weight were measured to calculate body mass index 
(BMI). Because a nonlinear association between depressive symptoms and 
BMI is conceivable, BMI was divided into 4 categories (< 18.5, 18.5–24.99, 
25–29.99, and ≥ 30 kg/m2).136 
 




Differences between study groups were analyzed by analysis of variance 
(ANOVA) for quantitative variables, or χ2 linear-by-linear test for 
categorical variables. Lipid and lipoprotein data were naturally log 
transformed because of their positively skewed distribution, and geometric 
mean values are presented. Potential nonlinear (i.e., curved) associations 
between depression and lipids/lipoproteins were explored by plotting mean 
IDS-SR total score and the prevalence of diagnoses (current MDD, lifetime 
MDD, controls) by lipid/lipoprotein quintiles. Correlations between overall 
lipid/lipoprotein levels were calculated by Pearson’s correlation coefficient. 
Geometric mean values (and 95% confidence intervals [CIs]) were 
calculated by analysis of covariance (ANCOVA), to compare 
lipid/lipoprotein levels (dependent variables) between study groups (factor 
variable), adjusting for basic sociodemographic and health covariates (i.e., 
age, sex, level of education, use of lipid-lowering medication, use of oral 
anticonceptives (yes/no), CVD, and diabetes) in model 1, adjusting for 
additional lifestyle-related covariates (i.e., basic covariates and smoking 
status, alcohol use, and BMI categories) in model 2, and additionally 
adjusting for use of antidepressants in model 3. Cohen’s d (the difference 
in group geometric means, divided by their pooled standard deviation) was 
calculated as a measure of effect size. Linear regression analyses were 
used to assess associations between IDS-SR total score and other 
psychopathological characteristics (as separate independent variables) and 
lipid/lipoprotein levels (as continuous dependent variables) after basic 
(model 1) and additional (model 2 and model 3) adjustment in subjects 
with current MDD. In additional analyses, we excluded subjects using 
lipid-lowering medication and subjects with CVD or diabetes, and we 
additionally adjusted for laboratory site. Statistical significance was 
inferred at p <.05. All statistical analyses were undertaken with SPSS 14.0 
(SPSS Inc., Chicago, Illinois, USA). 
 
3.3  RESULTS 
Table 1 shows the characteristics of the study groups. The mean age of the 
sample was 41.9 years (SD = 12.9) and 33.1% were male. Subjects with 
current or remitted depression were less educated than controls but did 
not differ statistically in age, sex, or diabetes and CVD prevalence. 
Subjects with a current MDD had a higher BMI, and tended to use less 
alcohol than the other two groups. Subjects with a remitted MDD 
demonstrated a higher depression severity score (IDS-SR) as compared to 
controls but a lower score than subjects with a current MDD.  
  Because the plotted distribution pattern of mean IDS-SR total score 
and of depression diagnoses across quintiles of lipid/lipoprotein levels did 
not indicate curved associations (data not shown), all subsequent analyses 
were based on linear models. Correlations between lipid/lipoprotein levels 
ranged from –.14 (for LDL and HDL cholesterol) through .88 (for total and 
LDL cholesterol). Table 2 presents lipid/lipoprotein levels across study  




Table 1. Characteristics according to study group for 2461 subjects 
Characteristics Current MDD Remitted MDD Controls p* 




42.4   (41.6-
43.1) 
41.2    (40.1-
42.4) 
.18 
Sex (% men) 33.6 29.5 38.6 .08 
Level of education (%)    <.001 
       Basic 10.1 5.2 3.5  
       Intermediate 64.9 56.6 52.8  
       High 25.0 38.2 43.7  
Body Mass Index (%)    <.001 
       < 18.5  3.0 1.8 2.2  
       18.5 – 24.99  43.6 52.0 54.4  
       25.0 – 29.99  30.9 30.8 29.9  
       ≥ 30.0 22.5 15.4 13.5  
Smoking status (%)    .97 
       Never 27.1 23.7 36.4  
       Former  27.7 35.6 36.2  
       Current  45.2 40.7 27.3  
Alcohol use (%)    .012 
       <1 glasses/day 66.5 61.3 57.9  
       1-2 glasses/day 16.8 23.8 23.7  
       >2 glasses/day 16.7 14.9 18.4  
Use of oral anticonceptives 
(%) 
17.6 17.6 18.9 .54 
Antidepressant medication 
use (%) 
    
       Selective serotonin  
       re-uptake inhibitors 
30.6 19.8 0.6 <.001 
       Tricyclic antidepressants  3.9 3.5 0.2 <.001 
       Other antidepressants 10.8 6.3 0.2 <.001 
Diabetes (%) 8.5 6.9 6.2 .09 
Cardiovascular disease (%) 6.2 6.2 5.6 .65 
Use of lipid lowering 
medication (%) 
8.5 6.5 6.0 .06 





8.6c    (8.0-9.2) <.001 
Melancholic features (%)  17.3 1.5 0.0 <.001 
Atypical features (%) 27.2 6.8 1.4 <.001 
Co-morbid anxiety disorder 
(%) 
62.9 33.1 0.0 <.001 
Co-morbid dysthymia (%) 28.5 2.3 0.0 <.001 
History of suicide attempt 
(%) 
23.1 12.0 1.4 <.001 
Abbreviations: IDS-SR, Inventory of Depressive Symptoms self-report; MDD, major depressive 
disorder. 
Means (95% confidence intervals) or percentages are given, when appropriate. 
*: overall p by analysis of variance for quantitative variables or χ² linear-by-linear test for 
categorical variables. 
abc: Superscript letters which are dissimilar between groups indicate that the post hoc p values 





Table 2. Serum lipid and lipoprotein levels (mg/dL) in controls and subjects with a remitted or current  
              major depressive disorder. 
 Current MDD Remitted MDD Controls p 
                           n 761 1071 629  
 Mean 95% CI Mean 95% CI Mean 95%CI  
Total cholesterol         
       Crude 193.3 190.5-196.1 193.7 191.3-196.1 191.4 188.4-194.5 .51 
       Model 1 193.8 191.3-196.4 193.0 190.9-195.1 191.9 189.2-194.7 .61 
       Model 2 193.3 190.9-195.9 192.9 190.8-195.0 192.6 189.9-195.4 .93 
       Model 3 192.2 189.7-194.7 192.7 190.6-194.8 194.4 191.5-197.3 .53 
LDL cholesterol         
       Crude 119.7 117.0-122.3 117.2 114.9-119.5 115.6 112.9-118.4 .12 
       Model 1 119.6 117.2-122.1 117.0 115.0-119.0 116.0 113.4-118.6 .11 
       Model 2 118.9 116.5-121.3 117.0 115.0-119.0 116.9 114.3-119.5 .42 
       Model 3 117.9 115.6-120.4 116.8 114.8-118.7 118.4 115.7-121.2 .57 
HDL cholesterol         
       Crude 59.2a 58.0-60.3 61.4b 60.4-62.4 61.4b 60.1-62.7 .007 
       Model 1 59.8 58.8-60.9 60.7 59.8-61.6 61.7 60.5-62.9 .08 
       Model 2 60.7 59.7-61.7 60.7 59.8-61.5 60.7 59.7-61.8 .99 
       Model 3 60.6 59.6-61.6 60.7 59.8-61.5 60.8 59.7-62.0 .97 
Triglycerides         
       Crude 104.8a 101.1-108.5 97.1b 94.1-100.1 95.7b 91.9-99.7 .001 
       Model 1 103.3a 99.9-106.9 97.9b 95.2-100.7 95.8b 92.3-99.4 .008 
       Model 2 101.0 97.8-104.3 98.3 95.7-100.9 97.9 94.6-101.4 .34 
       Model 3 100.1 96.9-103.4 98.1 95.5-100.7 99.3 95.7-102.9 .62 
Abbreviations: CI, confidence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MDD, major depressive disorder. 
Geometric means are presented, based on estimated marginal means, calculated by analysis of covariance (ANCOVA). 
Model 1: adjusted for age, sex, level of education, use of lipid lowering medication, use of oral anticonceptives, CVD and diabetes.  
Model 2: additionally adjusted for smoking status, alcohol use and BMI categories. 
Model 3: additionally adjusted for antidepressant use. 
ab: Superscript letters which are dissimilar between groups indicate that in post hoc analyses groups differ significantly (p<0.05 after Bonferroni 
correction).  
To convert total, LDL or HDL cholesterol values from mg/dL to mmol/L, divide by 38.7. To convert  
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groups. In crude analyses, total and LDL cholesterol levels did not differ 
significantly between groups. Lower HDL cholesterol level was found in the 
current MDD versus the remitted MDD and control groups (post hoc p 
values after Bonferroni correction were .01 and .03, respectively), with a 
small effect size for current MDD versus controls (d = –0.137). 
Furthermore, higher triglyceride levels in the current MDD group versus 
the remitted MDD and control groups were found (post hoc p values after 
Bonferroni correction were .005 and .003, respectively), with a small effect 
size for current MDD versus controls (d = 0.178). Subjects with remitted 
MDD and controls did not differ significantly with regard to HDL 
cholesterol or triglyceride levels. Adjustment for covariates in model 1 
reduced HDL cholesterol differences between groups to statistically non-
significant. Both education level and BMI as the only covariate already 
reduced these differences to statistically non-significant. Differences in 
triglyceride levels between study groups in crude analyses (p = .001) and in 
model 1 (p = .008) were not found after additional adjustment in model 2 (p 
= .34). BMI largely explained the differences in triglyceride levels between 
groups. Additional adjustment for antidepressant use in model 3 did not 
change associations importantly.  
Associations between psychopathological characteristics (i.e., 
independent variables) and lipids/lipoproteins (i.e., continuous dependent 
variables) were assessed in currently depressed subjects (see Table 3). 
Crude associations are not shown because associations did not change 
importantly after adjustment for covariates in model 1. In model 1, 
statistically significant, positive associations were found between IDS-SR 
total score and total cholesterol (β = .073, p = .025), LDL cholesterol (β = 
.082, p = .015), and triglyceride levels (β = .102, p = .003), and an inverse 
association was seen with HDL cholesterol (β = –.118, p = .001). However, 
associations were no longer statistically significant after additional 
adjustment in model 2. Again, BMI as the only covariate already resulted 
in statistically non-significant associations. The presence of atypical 
depression (n=207; 27.,2% of the currently depressed) was associated with 
higher levels of total and LDL cholesterol as well as triglycerides and lower 
HDL cholesterol levels. The associations between atypical features and 
total (β = .096, p = .004) and LDL cholesterol (β = .102, p = .002) remained 
statistically significant after full adjustment in model 3. Corresponding 
effect sizes for current MDD with versus without atypical features were 
small to modest (d = 0.234 and d = 0.253, respectively). Associations 
between melancholic features (n=131; 17.2% of the currently depressed) 
and triglycerides and inverse HDL cholesterol found in model 1, were 
somewhat attenuated in model 2 and model 3. The association between 
melancholic features and HDL cholesterol remained statistically significant 
(β = –.066, p = .038), with a small to modest effect size for current MDD 
with versus without melancholic features (d = –0.203). Other 
psychopathological characteristics (co-morbidity of dysthymia or anxiety or  
 
 
Table 3. Associations between lipids/lipoproteins and psychopathological characteristics  
              in 761 subjects with a current major depressive disorder 
Psychopathological characteristics  Total cholesterol LDL cholesterol HDL cholesterol Triglycerides 
                                                                    n* β p β p β p β p 
Model 1          
     Depression severity    
     (IDS-SR) 
  .073 .025  .082 .015 -.118 .001  .102 .003 
     Atypical features  207  .110 .001  .122 <.001 -.075 .031  .067 .05  
     Melancholic features  131  .047 .15  .052 .13 -.092 .008  .074 .03 
     Co-morbid anxiety  
     disorder   
479  .006 .84 -.018 .60 -.008 .82  .002 .99 
     Co-morbid dysthymia  217  .019 .55  .006 .86 -.062 .07  .083 .014 
     Suicide attempt in history  176  .053 .11  .039 .24  .014 .69  .027 .44 
Model 2          
     Depression severity  
     (IDS-SR) 
  .063 .06  .056 .10 -.034 .28  .045 .17 
     Atypical features  207  .107 .001  .116 .001 -.038 .24  .031 .34 
     Melancholic features  131  .048 .14  .051 .13 -.069 .029  .060 .07 
     Co-morbid anxiety  
     disorder   
479 -.002 .95 -.028 .40  .017 .58  -.020 .54 
     Co-morbid dysthymia  217  .014 .66  .002 .94 -.035 .27  .057 .08 
     Suicide attempt in history  176  .050 .13  .033 .33  .040 .21  .007 .84 
Model 3          
     Depression severity  
     (IDS-SR) 
  .047 .16  .036 .29 -.031 .34  .036 .29 
     Atypical features  207  .096 .004  .102 .002 -.035 .28  .023 .48 
     Melancholic features  131  .035 .29  .034 .31 -.066 .038  .050 .13 
     Co-morbid anxiety  
     disorder   
479 -.007 .83 -.034 .30  .019 .54 -.023 .47 
     Co-morbid dysthymia  217 .007 .83 -.007 .84 -.033 .30  .053 .10 
     Suicide attempt in history  176 .045 .17  .027 .41  .040 .20  .004 .90 
β coefficients indicate the standardised beta by linear regression analyses 
Abbreviations: HDL, high-density lipoprotein; IDS-SR, Inventory of Depressive Symptoms self-report; LDL, low-density lipoprotein. 
*: n refers to the number of the 761 currently depressed subjects with the concerning psychopathology characteristic. 
Model 1: adjusted for age, sex, use of lipid lowering medication, use of oral anticonceptives, education level, CVD and diabetes.  
Model 2: additionally adjusted for smoking status, alcohol use and BMI categories. 














































































































































































































































































































































Figure 1. In the upper 4 graphs adjusted geometric mean lipid/lipoprotein levels in controls and current MDD without or with atypical features 
are presented. In the lower 4 graphs adjusted geometric mean lipid/lipoprotein levels in controls and current MDD without or with melancholic 
features are presented.  
Bars indicate geometric means, basically adjusted for age, sex (male / female), use of lipid lowering medication (yes / no), use of oral 
anticonceptives (yes / no), education level (basic / intermediate / high), CVD (yes / no) and diabetes (yes / no) in analysis of covariance 
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suicide attempt in history) were not associated with lipid/lipoprotein levels 
after additional adjustment (model 2 and model 3).  
  Figure 1 shows that geometric mean total and LDL cholesterol 
levels were higher and HDL cholesterol and triglyceride levels were lower in 
MDD with atypical features versus MDD without atypical features or 
controls. Also, geometric mean LDL cholesterol and triglyceride levels were 
higher and HDL cholesterol levels were lower in MDD with melancholic 
features, compared to MDD without melancholic features or controls. 
Additional analyses that excluded subjects using lipid-lowering medication 
or those suffering from CVD or diabetes and analyses that were 
additionally adjusted for laboratory site showed largely similar results 
(data not shown). 
 
3.4  DISCUSSION 
This large-scale study showed that currently depressed subjects had 
significantly lower mean HDL cholesterol and higher triglyceride levels 
compared to subjects with a remitted depression and healthy controls. No 
differences were found for total and LDL cholesterol levels. Although 
control subjects and those with remitted and current depression displayed 
a graded increase in depression severity scores, we did not find graded 
differences in lipid levels among study groups. Among currently depressed 
subjects, lipids/lipoproteins were especially unfavorable among those with 
high depression severity and atypical and melancholic features. 
Differences in lipids/lipoproteins between study groups and most 
associations with psychopathology characteristics attenuated after 
adjustment for smoking status, alcohol use and, especially, BMI. Yet, 
atypical features remained associated with higher levels of total and LDL 
cholesterol, and melancholic features remained associated with lower HDL 
cholesterol levels, even after additional adjustment for antidepressant use.  
  Equality of total cholesterol among study groups is in line with 
some previous studies,47
,123,124,137 but contradicts others.31
,34-40 However, 
we found high levels of total cholesterol in atypical depression only, and 
insufficient attention for depression heterogeneity in previous research 
possibly accounts for these discrepant results. Also, variability in study 
design might have contributed to these varying results. Our finding of 
lower HDL cholesterol levels in depression is in line with previous 
findings.32
,36 However, one study124 found higher instead of lower HDL 
cholesterol levels and lower instead of higher triglyceride levels in major 
depressed subjects compared to controls. The fact that their depressed 
participants visited a general health screening unit, and consequently 
might have been preoccupied with health, might explain these findings. 
Furthermore, their sample size was small (n=107), and participants were of 
Taiwanese origin, which might account for cultural and other differences 
(e.g., in genetic background and diet) compared to our study. In line with 
our findings, depression severity has previously been associated with 
higher total cholesterol level.33  
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  Only few studies investigating lipids/lipoproteins in depression 
adjusted analyses for factors like smoking,40 alcohol use,38
,40 and 
BMI.37
,38,40,123,124 One study123 that adjusted for BMI found no differences in 
lipids/lipoproteins between depressed and non-depressed elderly. 
Likewise, an association between low total cholesterol level and more 
severe depressive complaints was attenuated after adjustment for lifestyle-
related factors.137 Combined with the attenuation in our study of 
associations between lipids/lipoproteins and depression after adjustment 
for smoking, alcohol use, and BMI, these findings suggest that this 
association is not direct, but rather secondary to health-related factors. 
Depressed persons have less healthy eating habits,126 are more likely to be 
obese,125 more often smoke,47
,127 and use either less128 or more alcohol74 
compared to non-depressed persons. In the present study, these 
tendencies were also found regarding obesity and decreased alcohol use. 
As a consequence, obesity,129 smoking,75 and alcohol use130 might have 
affected lipid/lipoprotein metabolism. The hypothesis of an indirect 
relationship between depression and lipids/lipoproteins is supported by 
statin trials in which no effect138
,139 or even a protective effect140 of total 
cholesterol reduction on depression or suicide risk has been found. Our 
finding of a lower BMI and current smoking status in subjects with a 
remitted depression compared to subjects with a current depression and 
the remitted subjects’ lipid profiles being comparable to controls also 
supports this hypothesis. Alternatively, increased BMI might partly be the 
result of an adverse lipoprotein pattern in depression through an as yet 
unknown mechanism. Still, other (biologic) mechanisms may be involved, 
for example, hypothalamic-pituitary-adrenal axis dysregulation,141 or a 
low-grade inflammatory process as observed in depression may result in 
altered lipid metabolism (possibly through an increase in lipid peroxidation 
through oxidative stress).142 Otherwise, obesity might lead to depression 
through increased bodily pain or psychosocial factors, such as a negative 
self-body image.143 Another possible confounder in the association between 
depression and lipids/lipoproteins is the use of antidepressants. Despite 
its known antihistaminergic side effects, such as weight gain, especially of 
the tricyclic class,58
,131 use of antidepressants was not taken into account 
in previous studies. However, the use of antidepressants did not explain 
the associations between depression and lipids/lipoproteins in the present 
study.  
  The fact that study groups displayed a graded increase in 
depression severity score yet we did not find graded differences in lipid 
levels among study groups, suggests that alterations in lipid levels are 
dependent on a current depressive state rather than on a history of lifetime 
depression. This is in line with a study by Olusi and Fido,35 in which lipid 
levels tended to normalize after clinical recovery from MDD.   
Persistent dyslipidemia in atypical depression could be explained 
by two of its diagnostic criteria that might increase total and LDL 
cholesterol levels:144 an increased appetite and/or weight, and leaden 
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paralysis, which might reduce physical activity. The continual association 
between melancholic features and lower HDL cholesterol level might be 
explained by the metabolic syndrome,141 which comprises reduced HDL 
cholesterol97 and is thought to be associated with depression23 through 
shared underlying biologic pathways, such as hypercortisolism.25  
  Finally, although previous research suggests that both CVD and 
diabetes more often occur in depressed subjects as compared to 
controls,145
,146 we did not find a significant difference in CVD or diabetes 
prevalence between controls and subjects with a current or remitted 
depression. This may reflect the rather young age of our sample in which 
these somatic conditions are not yet highly prevalent.  
  Our study has some limitations. Because of our cross-sectional 
analyses, no causal inferences can be made. Furthermore, nutritional 
data, which were not available, could have helped to study underlying 
mechanisms of our results. A strength of our study is the large sample 
size, which provides enough subjects with depression to reliably 
differentiate the association between lipids/lipoproteins and several 
psychopathological characteristics. Importantly, depression was diagnosed 
according to the gold standard, DSM-IV, and important potential 
confounders were taken into account.  
In conclusion, we found that current depression was associated 
with an unfavorable lipid and lipoprotein profile, especially in patients with 
melancholic and atypical features but that this association is to a large 
extent due to underlying lifestyle-related factors, especially obesity. 
Unfavorable lipid/lipoprotein patterns are associated with an increased 
CVD morbidity and mortality risk97 and could therefore contribute to the 
increased CVD risk among the depressed.147 Consequently, it could be 
advisable for care providers to promote a healthy lifestyle, especially 











Symptom dimensions of depression and anxiety and the 
metabolic syndrome 
 
Floriana S. Luppino 
Arianne K.B. van Reedt Dortland 
Klaas J. Wardenaar 
Paul F. Bouvy 
Erik J. Giltay 
Frans G. Zitman 
Brenda W.J.H. Penninx 
 















It was our objective to investigate the associations of depression and 
anxiety symptoms with the metabolic syndrome using a dimensional 
approach. The association between depression and anxiety on the one 
hand, and the metabolic syndrome as a cluster or its individual 
components on the other hand, is equivocal. The categorical nature of the 
Diagnostic and Statistical Manual of mental disorders might partly explain 
the inconsistent findings.  
 
Methods  
In 2433 Netherlands Study of Depression and Anxiety participants (mean 
age, 42.3 years; 33.1% male), three symptoms dimensions -lack of positive 
affect (depression specific); negative affect (aspecific); and somatic arousal 
(anxiety specific)- were assessed by a shortened adaptation of the Mood 
and Anxiety Symptom Questionnaire (MASQ). The association between 
symptom dimensions and metabolic syndrome components (i.e., waist 
circumference, triglycerides, high-density lipoprotein cholesterol, glucose, 
and mean blood pressure) was analyzed, using linear regression analysis.  
 
Results 
The occurrence rate of the metabolic syndrome was 20.1% (n=490). 
Somatic arousal, but not positive affect and negative affect, was strongly 
associated with four out of five metabolic syndrome components, especially 
waist circumference, triglycerides, and blood pressure (β = 0.046, p <.01; β 
= 0.077, p <.001; and β = 0.069, p <.001, respectively), and with the total 
number of metabolic syndrome components (β = 0.098, p <.001).  
 
Conclusions 
Our results demonstrate a strong association of most of the metabolic 
syndrome components with the somatic arousal dimension, but not with 

















4.1  INTRODUCTION 
Mood and anxiety disorders are related to an increased risk of 
cardiovascular morbidity and mortality.147,1 The metabolic syndrome is a 
cluster of cardiovascular risk factors (i.e., elevated waist circumference, 
triglycerides, blood pressure, and fasting glucose, and reduced high-
density lipoprotein [HDL]) cholesterol)17 and is thought to partly mediate 
this relationship.148 The association between depression and anxiety and 
the metabolic syndrome has been extensively investigated. Most studies149 
focused on the association between depression and the cluster of the 
metabolic syndrome and its individual components. Other studies,23
,103 
however less numerous, investigated the association between anxiety and 
both the metabolic syndrome cluster and its individual components. In 
addition, in a recent publication,150 we examined whether disorder status 
and symptom severity were associated with the metabolic syndrome. No 
significant difference was found between subjects with and without 
psychopathology (both depression and/or anxiety). Only the subgroups of 
the most severely depressed or anxious subjects had increased occurrence 
rates of the metabolic syndrome, an association predominantly driven by 
abdominal obesity and dyslipidemia. Despite these observations, the 
question remains whether a complete mood disorder diagnosis or rather 
only specific symptom dimensions are related to the metabolic syndrome 
and whether the dichotomous metabolic syndrome diagnosis or only some 
of its components are related to psychopathology dimensions.  
 There are three major reasons that could explain why this question 
has so far remained unanswered. First, the studies have been conducted 
in widely differing samples, which limits the possibilities to formulate a 
broadly generalizable model. For instance, there have been differences in 
the settings (e.g., clinical population or the general population),151 age of 
the subjects (an elderly population or young adult patients),48
,152 and the 
assessment of psychopathology (questionnaires versus clinical 
diagnoses).49
,153 Second, the categorical diagnostic approach (using the 
Diagnostic and Statistical Manual of mental disorders, fourth edition 
[DSM-IV]) for depressive and anxiety disorders, lumping together disparate 
symptom clusters, may have limited the power to detect subtle 
associations.154 Patients with the same diagnosis can be very different in 
terms of their symptom profiles, whereas other individuals with important 
mental health problems fail to meet the diagnostic criteria due to symptom 
heterogeneity. Third, like the DSM-IV diagnosis, the metabolic syndrome 
concept is also heterogeneous, and is the subject of substantial 
debate.116
,155 Because at least three of five components are needed to fulfil 
the criteria of the metabolic syndrome, there are numerous combinations 
of components possible that all lead to the same metabolic syndrome 
diagnosis. Studies156 have shown that sometimes only specific components 
of the metabolic syndrome are associated with depression, which casts 
doubt over the usability of the total metabolic syndrome concept in 
psychopathology research. It is possible that, in the large variety of 
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depression/anxiety symptoms, some are “specifically” associated with a 
distinct metabolic syndrome component (e.g., energy loss, often leading to 
decreased physical activity, might lead to elevated waist circumference 
[WC]). Based on the criticized definition of the metabolic syndrome and the 
possible specific associations between diagnostic and metabolic syndrome 
symptoms, it would thus be informative to investigate the association 
between specific depression/anxiety symptoms, on the one hand, and the 
metabolic syndrome, both defined as a cluster of symptoms and as 
individual components, on the other hand.  
 So far, research on the association between depression and anxiety 
and the metabolic syndrome has mainly focused on categorical and 
heterogeneous assessments of affective disorders symptomatology or 
anxiety and depression severity scales.157
,158 In addition, diagnoses show 
overlapping criteria and co morbidity rates are high.159
,160 To overcome 
these problems, diagnoses should be more homogeneous and not 
dichotomous. A feasible alternative for categorical diagnoses is the use of a 
dimensional approach. Within a dimensional approach, a patient is 
described in terms of coexisting different symptom domains or dimensions, 
and not in terms of presence or absence of psychopathology. Each 
dimension provides specific information on the level of a specific symptom 
domain, running from absent or healthy to severe. Importantly, 
dimensions are continuous by principle. Along a continuous scale, 
changes from one level to another are subtle, whereas in a dichotomous 
scale, changes are rough and restricted (e.g., depressed versus non-
depressed). This makes continuous variables more sensible for detection of 
(small) differentiating factors,  thus increasing statistical power.162  
 A well-known dimensional model is the tripartite model for 
depression and anxiety, which distinguishes three symptom dimensions.14 
The broad “negative affect” dimension describes general symptoms of 
psychological distress (e.g., lack of concentration or pessimism) that are 
seen both in depression and anxiety and could account for their high co-
morbidity. The (lack of) “positive affect” dimension (also called anhedonic 
depression), covers anhedonic symptoms, which are mainly specific to 
depression. The “somatic arousal” dimension covers symptoms of 
hyperarousal (e.g., palpitations, shortness of breath, and dizziness), which 
are specific for anxiety, especially panic disorder. The dimensional model 
was not developed for detection of DSM-IV diagnoses, but rather to provide 
a descriptive alternative for the presence or absence of psychopathological 
symptoms in a subject. The tripartite model was developed to circumvent 
the lack of diagnostic specificity due to the high levels of co morbidity 
observed in depression and anxiety, one of the major problems of the 
DSM-IV “golden standard.” Typifying patients in terms of their negative 
affect, positive affect, and somatic arousal scores has two advantages: first, 
co morbidity is circumvented; and second, based on the profile of the 
scores, patients can be described in more specific terms of 
symptomatology. Several studies163
,164 have shown these specific 
METABOLIC SYNDROME 




dimensions to be specifically increased in depression (positive affect) and 
anxiety (mainly panic disorder, somatic arousal) and that negative affect 
was more indicative for overall severity across patients.  
 The aim of the present study was to investigate the relationship 
between the symptom dimensions of depression and anxiety of the 
tripartite model, and the metabolic syndrome and its individual 
components within the Netherlands Study of Depression and Anxiety 
(NESDA), as a dimensional approach makes it possible to look more 
specifically into these associations. 
 
4.2  METHODS 
Subjects 
Subjects selected for these analyses were baseline participants of NESDA, 
a cohort study among 2981 individuals aged 18 years through 65 years. 
Respondents were recruited in the community, in primary care, and in 
specialized mental healthcare settings from September 2004 through 
February 2007, throughout The Netherlands. All subjects completed a 
medical examination, a face-to-face interview, and self-report 
questionnaires. A detailed description of NESDA is reported elsewhere.95 
The study protocol was approved by the Ethical Review Board of each 
participating centre and all subjects signed an informed consent.  
 In the same study sample, tricyclic antidepressant (TCA) users were 
found to have a significantly increased prevalence of the metabolic 
syndrome.150 This association was not found for users of other types of 
antidepressants, such as selective serotonin re-uptake inhibitors.150 
Therefore, the relatively small group of TCA users (n=80) was excluded 
from our analyses, so that the results would not be affected by the 
potential confounding influence of TCAs. Subjects with missing metabolic 
syndrome or Mood and Anxiety Symptom Questionnaire (MASQ) values 
(n=468) were excluded as well, resulting in a sample of 2433 (81.6%) 
subjects. An important number of the included subjects comprised healthy 
controls or remitted patients (n=1449), whereas other subjects had a 
current diagnosis of pure depression (n=222), pure anxiety (n=226), or co 
morbid disorder (n=536). No inpatients were included. The included 
subjects did not differ from the excluded group in sex distribution, 
presence of cardiovascular disease (CVD), and physical activity. Included 
subjects were older (42.3 years versus 40.0 years, p <.001), were more 
educated (12.3 versus 11.3 years, p <.001), were less often smokers (35.8% 
current smokers versus 50.9%, p <.001), and consumed more alcohol 
(16.4% consumed >2 glasses/day versus 15.3%, p <.001) compared with 
the excluded subjects. 
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MASQ dimensions  
The three dimensions of the tripartite model were measured with the 30-
item adaptation (MASQ-D30) of the MASQ.164
, 165 The MASQ-D30 was 
previously validated and showed reliability and validity within the NESDA 
study.15
, 163, 166 The MASQ-D30 consists of three ten-item scales, 
representing negative affect, positive affect and somatic arousal (see Table 
1). On each item, participants were asked to rate how much in the past 
week they have experienced “feelings, sensations, problems and 
experiences that people sometimes have” on a 5 point scale, 1 being “not at 
all” and 5 being “extremely.” Higher scores indicate more severe symptom 
levels for that specific dimension. 
 
Table 1. Individual symptoms incorporated in the three dimensions of the MASQ-D30 
Negative Affect Positive Affect Somatic Arousal 
Felt confused Felt successful Startled easily 
Felt worthless Felt really happy Felt nauseous 
Felt irritable Felt optimistic Felt dizzy or light-headed 
Felt hopeless Felt like I was having a lot of fun Was trembling or shaking 
Blamed myself for a lot of 
things 
Felt like I accomplished a lot Had pain in my chest 
Felt dissatisfied with 
everything 
Felt like I had a lot to look 
forward to 
Had hot or cold spells 
Felt pessimistic about the 
future 
Felt really talkative Was short of breath 
Felt inferior to others Felt really ‘up’ or lively Muscles were tense or sore 
Had trouble making 
decisions 
Felt like I had a lot of energy Heart was racing or 
pounding 
Worried a lot about things  Felt really good about myself Had trouble swallowing 
 
The metabolic syndrome 
The metabolic syndrome and its components, when expressed as 
dichotomous variables (i.e., elevated WC, triglycerides, blood pressure, and 
fasting glucose, and reduced HDL cholesterol), were exactly defined 
according to the revised criteria of the National Cholesterol Education 
Program-Adult Treatment Panel III.17 WC was measured with a measuring 
tape at the central point between the lowest rib and the highest point of 
the iliac crest, on light clothing. Triglycerides, HDL cholesterol, and 
glucose levels were determined by standardized routine laboratory assays, 
and diastolic and systolic blood pressures were measured during supine 
rest (OMRON M4 IntelliSense Digital Blood Pressure Monitor, HEM-752A, 
Omron Healthcare, Inc., Bannockburn, Illinois). Use of triglyceride or HDL 
cholesterol-influencing medication and use of antihypertensive or glucose 
reducing drug were registered. In addition, we used continuous variables 
for the metabolic syndrome components (which is preferable when aiming 
for more statistical power).162 In these analyses, we “adjusted” the values 
for those subjects, using a metabolic syndrome component influencing 
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medication. This was done following the methods described in several 
previous publications.167
,168 For the use of fibrates, 0.10 mmol/L (3.8 
mg/dL) was subtracted from HDL cholesterol, and 0.67 mmol/L (60 
mg/dL) was added to the triglycerides. For the use of nicotinic acid, 0.15 
mmol/L (5.8 mg/dL) was subtracted from HDL cholesterol, and 0.19 
mmol/L (17 mg/dL) was added to the triglycerides. For the use of 
antidiabetic medication and a glucose level of < 7 mmol/L (126 mg/dL), a 
value of 7 mmol/L (126 mg/dL) was given to glucose, as was done 
previously.25 Mean blood pressure (MBP) was expressed as the arithmetic 
mean of systolic and diastolic blood pressures, which were both measured 
twice during supine rest on the right arm (OMRON M4 IntelliSense Digital 
Blood Pressure Monitor, HEM-752A, Omron Healthcare, Inc.) and averaged 
over the two measurements. For persons using antihypertensive 
medication, 10 mm Hg was added to systolic blood pressure, and 5 mm Hg 
was added to diastolic blood pressure, in line with earlier studies.25 These 





Information on depression and anxiety severity was collected during the 
baseline measurement of the NESDA study,95 using the Beck Anxiety 
Inventory (BAI)171 and the Inventory of Depressive Symptoms self-report 
(IDS-SR),110 in which the most severe groups were defined as “severe 
anxiety symptoms” with a score of ≥ 29 on the BAI and “very severe 
depressive symptoms” with a score of ≥ 49 on the IDS-SR. Previous NESDA 
research150 indicated that the prevalence rates of the metabolic syndrome 
were increased in those with severe anxiety symptoms (n=185) in crude 
models and independently increased in those with very severe depressive 
symptoms (n=102) after fully adjusted models. Because information on the 
BAI and IDS-SR scores was available for our sample, we decided to 
investigate whether the previous found associations in the same cohort 
between the highest scores of the BAI and IDS-SR severity scales and 
metabolic derangements would be driven by symptom dimensions. 
 
Covariates 
Covariates were grouped into two types of variables: sociodemographic and 
lifestyle variables. Sociodemographic variables included age, sex, and years 
of education. Lifestyle characteristics included smoking status 
(never/former/current), alcohol use (<1/1–2/>2 drinks per day), both 
assessed by standardized questionnaires, and physical activity, which was 
assessed by the International Physical Activity Questionnaire112 and 
expressed in 1000 metabolic equivalent of task (MET)-minutes in the past 
week. MET reflects the ratio of the associated metabolic rate for specific 
activities divided by the resting metabolic rate multiplied by the minutes 
performed activity. CVD was considered to be present when participants 
self-reported a diagnosis of coronary heart disease, cardiac arrhythmia, 
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angina, heart failure, or myocardial infarction, confirmed with the use of 
cardiovascular medication. Medication use of any kind within the past 
month was registered by observation of drug containers brought in and 




Sample characteristics were summarized, using means and standard 
deviations (SD) for quantitative variables and by percentages for 
categorical variables. Multivariate linear regression analyses were 
conducted to assess the association between each MASQ-D30 dimensions 
(i.e., positive affect, negative affect and somatic arousal) and the individual 
continuous metabolic syndrome components and the total number of 
metabolic syndrome components. Analyses for each dimension were 
performed separately. To normalize residuals, non-normally distributed 
dependent variables were naturally log-transformed. After running crude 
models, we adjusted for basic covariates (i.e., age, sex, and years of 
education) in model 1, and for additional lifestyle-related covariates (i.e., 
smoking status, alcohol use, and physical activity) in model 2. Because sex 
differences in the association between anxiety, depression, and the 
metabolic syndrome have previously been observed,21
, 156 appropriate 
interaction terms with sex were explored. To evaluate the influence of 
prevalent CVD, participants diagnosed with CVD were excluded in a 
sensitivity analysis.  
 To evaluate whether the earlier described association between 
severity of depressive and anxious symptoms and metabolic syndrome 
abnormalities were driven by symptom dimensions, additional regression 
analyses were performed. We analyzed the association of BAI and IDS-SR 
severity categories with the individual metabolic syndrome components 
and the total number of components by performing linear regression 
analyses, adjusting for models 1 and 2 covariates, and additionally 
adjusting for those symptom dimensions that demonstrated to be 
associated significantly with the metabolic syndrome components in the 
main analyses.  
 Multivariate logistic regression analyses were performed to assess 
the association between the SDs of continuous scores of the three 
symptom dimensions and the metabolic syndrome diagnosis. All 
assumptions for linearity were tested and fulfilled. All tests were two-tailed 
with p <.05 denoting statistically significance. Statistical analyses were 
done with SPSS 16.0 (IBM Company, Chicago, Illinois, USA). 
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4.3  RESULTS 
Sample characteristics are shown in Table 2. The mean age was 42.3 years 
(SD 13.1), 33.1% were men, and mean number of years of education was 
12.3 years (SD 3.3). The criteria for the metabolic syndrome were fulfilled 
by 20.1% (n=490). The reported means and SDs for each dimension are 
calculated from the continuous values of all subjects included (n=2433) for 
that dimension. 
 
Table 2. Sample characteristics in 2433 subjects 
General characteristics   
Age  42.3    (13.1) 
Sex (% men) 33.1  
Years of education  12.3    (3.3) 
Cardiovascular disease 5.8 
Smoking status (%)  
     Never 29.3 
     Former 34.9 
     Current 35.8 
Alcohol use (%)  
     < 1 glasses/day 61.0 
     1-2 glasses/day 22.4 
     > 2 glasses/day 16.4 
Physical activity (1000 MET minutes)  3.7      (3.06) 
Metabolic syndrome components  
Waist circumference (cm)  88.7    (13.8) 
HDL cholesterol (mmol/L)  1.6      (0.4) 
Triglycerides (mmol/L)  1.3      (0.8) 
Glucose (mmol/L)  5.2      (0.9) 
Systolic blood pressure (mmHg)  136.2  (19.7) 
Diastolic blood pressure (mmHg)  81.5   (11.1) 
Mean blood pressure (mmHg) 108.9 (14.7) 
Number of metabolic syndrome components  1.45   (1.3) 
Metabolic syndrome (%) 20.1 
MASQ symptom dimensions   
     Positive affect 33.4   (9.7) 
     Negative affect 20.0   (8.6) 
     Somatic arousal 15.7   (6.1) 
Means and standard deviations are given for age, years of education, physical activity, 
number of metabolic syndrome components and the three symptom dimensions. Percentages 
are given for sex, smoking status, alcohol use, and presence of metabolic syndrome.  
Abbreviations: HDL, high-density lipoprotein; MASQ, Mood and Anxiety Symptom 
Questionnaire; MET, metabolic equivalent of task. 
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Outcomes of the linear regression analyses between MASQ-D30 
dimensions and metabolic syndrome components are shown in Table 3. 
Positive affect showed a significant association with every metabolic 
syndrome component in the crude model. Adjustments in model 1 led to a 
decrease of the β with >10% and to non-significant associations with WC, 
fasting glucose levels, and MBP. Analyses with the separate covariates of 
model 1 showed age to be the most important confounder. Associations of 
positive affect with triglycerides and HDL cholesterol became statistically 
non-significant after adjustment for lifestyle factors (model 2). No 
significant associations were found for negative affect with any of the 
metabolic syndrome components, in the unadjusted and fully adjusted 
models. On the contrary, in the crude unadjusted model, somatic arousal 
showed a significant association with all metabolic syndrome components 
except for fasting glucose. The associations for somatic arousal remained 
significant in both adjusted models with regard to WC (WCcrude: β = 0.061, 
p = .003; WCmodel 2: β = 0.046, p = .01), triglycerides (Trigcrude: β = 0.077, p 
<.001; Trigmodel 2: β = 0.046, p = .02) and MBP (MBPcrude: β = 0.069, p 
<.001; MBPmodel 2: β = 0.068, p <.001). The significant crude association of 
somatic arousal with HDL cholesterol weakened after adjustment in model 
1, and further in model 2 to a non-significant level. Also, the association of 
somatic arousal with the number of metabolic syndrome components (Nr.) 
remained highly statistically significant throughout all models (Nr.crude: β = 
0.098, p <.001; Nr.model 2: β = 0.062, p <.001).  
The graded, positive association between somatic arousal and the 
number of metabolic syndrome components, and between somatic arousal 
and quartiles of the individual fully adjusted metabolic syndrome 
components are shown in Figure 1. In sensitivity analyses in which 141 
subjects with CVD were excluded, results did not change (data not shown). 
None of the interaction terms between dimensions with sex were 
statistically significant, which suggests that associations were largely 
similar for men and women.  
 To evaluate whether another measure for somatic symptoms would 
give comparable results, we repeated the linear regression model analyses 
with the validated BAI somatic subscale.171 These analyses confirmed an 
association for the somatic BAI subscale and a much less consistent 
association for the nonsomatic BAI subscale. The associations with the BAI 
somatic scale score remained significant in the fully adjusted models for 
the number of metabolic syndrome components (Nr. metabolic syndrome: 
β = 0.072, p <.001), and all metabolic syndrome components, except for 
HDL cholesterol, which showed a trend toward significance with a β = -
0.033, p = .08 (WC: β = 0.056, p <.001; Trig: β = 0.083, p <.001; Gluc: β = 
0.038, p = .04; MBP: β = 0.046, p = .01). There was a strong 
intercorrelation between the somatic symptom dimension of the MASQ and 
the subscale of the BAI (rsBAI = 0.73, p <.001). We did not analyze 
associations with subscales of the IDS-SR because earlier work by 




Table 3. Linear regression for associations between MASQ dimensions and metabolic syndrome components in 2433 subjects 
 Waist circumference Triglycerides HDL cholesterol Glucose Blood pressure Number of metabolic 
syndrome components 
 β p β p β p β p β p β p 
Negative affect             
       Crude  .070 .001 .097 <.001 -.063 .002 .079 <.001  .076 <.001 .107 <.001 
       Model 1 -.001 .94 .044 .02 -.039 .04 .027 .15  .008 .64 .036 .05 
       Model 2 -.009 .60 .021 .29 -.012 .52 .026 .17  .009 .63 .019 .29 
Positive affect             
       Crude -.002 .93 .031 .12 -.036 .08 .008 .68 -.028 .17 .018 .37 
       Model 1  .016 .34 .042 .03 -.017 .36 .036 .05 -.001 .94 .033 .07 
       Model 2  .011 .51 .022 .25  .001 .08 .037 .05 -.002 .90 .020 .27 
Somatic arousal             
       Crude  .061 .003 .077 <.001 -.056 .01 .025 .22  .069 <.001 .098 <.001 
       Model 1  .050 .01 .064 .001 -.045 .02 .023 .21  .062 <.001 .074 <.001 
       Model 2  .046 .01 .046 .02 -.018 .32 .023 .22  .068 <.001 .062 .001 
β, standardized beta by linear regression analyses.  
Abbreviations: HDL, high-density lipoprotein; MASQ, Mood and Anxiety Symptom Questionnaire.  
Model 1: adjusted for age, sex and years of education. 
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clear somatic subscale (in factor analyses, the rather restricted somatic 
items were attributed to all three subscales). So, no valid somatic IDS-SR 
subscale exists. Therefore, it is not appropriate to use a subscale in a 
comparative analysis. To explore whether results would also be consistent 
for the nonsomatic symptom subscale, we also conducted linear regression 
analyses with the nonsomatic BAI subscale (BAI subjective scale score). We 
expected that associations for the subjective BAI subscale would be similar 
to those for the positive affect and negative affect dimensions of the MASQ-
30, which was confirmed. None of the associations with the BAI subjective 
scale score were statistically significant in the fully adjusted models, with 
exception of the number of metabolic syndrome components (β = 0.041, p 
= .02).  
 Regression analyses performed to investigate whether previously 
found positive associations between metabolic syndrome abnormalities 
and symptom severity were driven by symptom dimensions, in particular 
the somatic arousal dimension, showed the following: Initial significant 
outcomes (in which the number of metabolic syndrome components was 
the dependent variable and BAI and IDS-SR severity categories were the 
independent variables) lost statistical significance after adjustment with 
the somatic arousal dimension. This means that the earlier described 
associations between the high severe groups according to the BAI and IDS-
SR with the metabolic syndrome were largely attributable to a high somatic 
arousal score. 
  Logistic regression analyses of the symptom dimensions with the 
metabolic syndrome showed a small but significant crude relationship 
between positive affect and the metabolic syndrome. Negative affect was 
not significantly associated with the metabolic syndrome. The initial 
significant crude relationship between somatic arousal and the metabolic 
syndrome remained statistically significant throughout multivariable 
adjustment (odds ratio per SD increase, 1.15; 95% confidence interval, 
1.04 –1.28; p = .008, see Table 4). Analyses in which the associations of 
BAI or IDS severity categories with the metabolic syndrome were adjusted 
for somatic arousal, showed that the severity category indicator lost 
statistical significance after adjustment.  
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Table 4. Logistic regression for the association between standard deviations (SDs) of  
              continuous scores on MASQ dimensions and the odds of metabolic syndrome  
              in 2433 subjects 
 OR  95% CI p 
Positive Affect 
       Crude  1.16 1.05-1.28 .004 
       Model 1 1.02 0.92-1.14 .67 
       Model 2 0.99 0.88-1.10 .99 
Negative Affect 
       Crude  1.01 0.92-1.12 .78 
       Model 1 1.01 0.99-1.02 .28 
       Model 2 1.04 0.93-1.16 .51 
Somatic Arousal 
       Crude  1.19 1.08-1.31 <.001 
       Model 1 1.18 1.06-1.30 .002 
       Model 2 1.15 1.04-1.28 .008 
Abbreviations: OR, odds ratio per SD increase by logistic regression analysis; CI, 
confidence interval; MASQ, Mood and Anxiety Symptom Questionnaire. 
Model 1: adjusted for age, sex, years of education.  
Model 2: additionally adjusted for lifestyle factors: smoking status, alcohol use and 
physical activity.  
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Figure 1. Adjusted (geometric) means across quartiles of somatic arousal on the MASQ-D30, 
for the individual metabolic syndrome components and the total number of metabolic 
syndrome components. Data are adjusted for age, sex, educational level, alcohol use, smoking 
status and physical activity. Error bars indicate 95% confidence intervals of the mean, and 
regression lines are shown. nquartile 1=744; nquartile 2=436; nquartile 3=652; nquartile 4=601.   
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4.4  DISCUSSION 
The main finding of this study is that only the somatic arousal symptom 
dimension is strongly and independently associated with most of the 
metabolic syndrome components (especially waist circumference [WC], 
triglycerides, and mean blood pressure [MBP]) and shows a graded 
association with the number of metabolic syndrome components. Using a 
dimensional approach, somatic arousal was thus associated with an 
increased metabolic risk. No independent associations of the metabolic 
syndrome with negative affect and positive affect were observed. These 
results are supported by our finding that the somatic scale of the BAI is 
associated with the metabolic syndrome components, whereas the non-
somatic scales are not.  
  Approaching depression and anxiety dimensionally, the aspecific 
negative affect dimension and the depression specific positive affect 
dimension did not show any association with the metabolic syndrome. We 
only found a strong and consistent relationship between the somatic 
arousal dimension and multiple metabolic syndrome components. This is 
in line with previous research on symptom dimensions of especially 
depression in relation to somatic outcomes, in which the somatic/affective 
sub-dimension, rather than other important dimensions (e.g., 
cognitive/affective and appetitive), was most strongly associated with 
cardiovascular risk and outcome.173
,174 It seems we are looking at a specific 
sub-dimension: the “somatic depression/anxiety” sub-dimension. On the 
one hand, this subtype could be reflective of underlying dysregulated 
homeostasis mechanisms due to anxious or depressed mood states, such 
as inflammation,72 impaired hypothalamus-pituitary-adrenal axis 
function,68
,175 or a higher sympathetic and lower parasympathetic 
autonomic tone.176 Elevated levels of inflammatory markers could induce a 
depressive episode;177 altered lipid patterns caused by high levels of 
cortisol141
,148 could lead to other lipid-related symptoms (overweight, 
abdominal obesity, and hypertriglyceridemia);161,178 and activation of the 
sympathetic nervous system leads to increased blood pressure179 and thus 
to hypertension.148
,180 This network of pathways can thus result in an 
increased metabolic or cardiovascular risk and cardiovascular disease. On 
the other hand, the reverse mechanism could be active: Ongoing metabolic 
dysregulations could be causing (especially somatic arousal) symptoms of 
depression and anxiety.22
,181-184 Regardless of the underlying mechanisms 
and the direction of causality, the dose-response gradient between the 
number of metabolic syndrome components and levels of somatic arousal 
indicates that when more somatic arousal symptoms are present, more 
metabolic syndrome abnormalities are present. Apart from biological 
mechanisms, other processes may be involved during a depressive episode 
as a consequence of anhedonia, such as altered lifestyle patterns (poor diet 
and decreased physical activity),185
,186 which might induce metabolic 
changes and cardiovascular risk factors.  
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Previous research based on NESDA data150 showed that the prevalence 
rates of the metabolic syndrome were increased in those with the highest 
levels of anxiety or depressive symptoms based on the BAI and the IDS-SR. 
After adjustment for the MASQ somatic arousal dimension, the earlier 
described associations lost statistical significance. These results indicate 
that the earlier described association between the metabolic syndrome and 
the most severe depression and anxiety symptom scales can be explained 
by the fact that these persons had high scores on the somatic arousal 
dimension.  
 In terms of metabolic risk evaluation and detection, a dimensional 
approach has more differentiating capacities compared with the widely 
used diagnostic DSM-IV categories. The somatic symptom dimension could 
therefore be the key feature in the association between depression/anxiety 
and somatic outcomes.  
 Using a dimensional approach, the level of a symptom dimension 
varies differentially between diagnostic groups (e.g., singular depression, 
singular anxiety, or co-morbid state). At the same time, all symptom 
dimensions can be present at a significant level within every diagnostic 
group. This means that the clinical presentation of a subject is dependent 
on the symptom dimension(s) with the highest scores. Our results 
demonstrate that the somatic arousal dimension is associated with several 
metabolic syndrome components. The fact that somatic arousal levels are 
not equally high for every depressed and/or anxious subject might explain 
the inconsistent findings in literature on the association with the metabolic 
syndrome.  
 Our study has several strengths. This is, to our knowledge, the first 
study describing the relationship of depression and anxiety dimensions in 
relation to the metabolic syndrome. We not only approached the metabolic 
syndrome and its components as continua, in line with the idea that 
metabolic syndrome components have a natural continuous 
distribution,187 but also distinguished depression and anxiety symptom 
dimensions.187 Because we chose this approach, we were able to show a 
dose-response gradient with somatic arousal levels. Furthermore, the 
results are based on a large sample, making results reliable. Finally, in the 
analyses, we adjusted for a substantial number of covariates, minimizing 
the chance that the findings can be explained by confounding.  
 This study presents some limitations. First, the tripartite model is a 
rather simple dimensional model. Probably, there are more relevant 
subdimensions present.188 Second, the sample includes both healthy 
controls and subjects with (remitted) psychopathology, who were recruited 
from the community as well as mental healthcare settings. As inpatients 
were excluded, our results cannot be generalized to this group. Third, the 
concept of the metabolic syndrome has been criticized,116
,155 and our 
findings support the idea that it may be worthwhile to study (the number 
of) individual metabolic components in addition to a dichotomous 
metabolic syndrome variable. Finally, due to the cross-sectional design, 
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our results cannot be used to make any causal inferences. Prospective 
studies, especially across more heterogeneous populations, would help to 
understand the direction of the potential causal relationship.  
 In this sample, in which previously the association between a 
categorical diagnosis on the one hand and the metabolic syndrome 
components on the other hand, was found only for the most severe 
depressive symptoms,150 we demonstrate a strong association between the 
somatic arousal symptom dimension and the metabolic syndrome and its 
individual components, especially WC, triglycerides, and blood pressure, 
and the number of metabolic syndrome components. Not every depressed 
subject is at increased metabolic risk. But our findings suggest that those 
with an elevated somatic arousal level are. Those with elevated non-
somatic dimensions scores (i.e., positive affect and negative affect) did not 
show an increased metabolic risk. This indicates the additional value of a 
dimensional approach in terms of metabolic risk evaluation. In addition, 
we found that the association between depression severity (BAI severity 
categories) and the metabolic syndrome is, in part, driven by the somatic 
arousal dimension. Although our results need to be replicated, the 
discriminating ability of a dimensional approach could facilitate the 
identification of those with a higher metabolic risk within a clinical 
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Previous research indicates that patients with severe symptoms of 
depression or anxiety are prone towards the development of dyslipidemia 




Among 2126 Netherlands Study of Depression and Anxiety (NESDA) 
participants, we studied whether severity of depressive (Inventory of 
Depressive Symptoms) or anxiety (Beck Anxiety Inventory) symptoms at 
baseline was associated with changes in lipids (i.e., total, high or low-
density [HDL or LDL] cholesterol and triglycerides) or waist circumference 
(WC) during a 2-year follow-up period. We also examined whether changes 
in severity of symptoms were associated with changes in lipid or WC levels 
over these 2 years. Analyses were adjusted for age, sex, education and 
tobacco consumption in multivariate linear regression analyses. 
 
Results 
Baseline symptoms of depression or anxiety predicted a decrease in HDL 
cholesterol (adjusted β = -.062, p = .003 and β = -.050, p = .02, 
respectively) and an increase in WC (adjusted β = .060, p = .01 and β = 
.053, p = .02, respectively) over 2 years. Reduction of symptoms of 
depression or anxiety over time did not coincide with an amelioration of 
lipid or WC values.  
 
Conclusions 
People with initially severe symptoms of depression or anxiety showed a 
subsequent decrease in HDL cholesterol levels and an increase in 
abdominal obesity over time, independent of a potential reduction in 
symptom severity in this time period. Therefore, those people are at 
elongated and increasing risk of dyslipidemia and obesity, predisposing 
them to cardiovascular disease. 
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5.1  INTRODUCTION 
Patients with depression and anxiety are prone to the cardiovascular 
disease (CVD) risk factors dyslipidemia (i.e., increased total cholesterol, 
low-density lipoprotein [LDL] cholesterol and triglyceride levels and lower 
high-density lipoprotein [HDL] cholesterol) and abdominal obesity (i.e., 
increased waist circumference [WC]).23-26
,43,45,106,107 Associations of 
depression or anxiety with the other classic cardiovascular risk factors 
hyperglycemia and hypertension are less consistent and strong: most 
studies on hyperglycemia20,21,23-30,44,46 or hypertension22-26,28-30,43-46,47-49 did 
not find significant associations, while only some did (See for 
hyperglycemia:22,43,45  and for hypertension:21,27,44. Previously we also 
reported an increased prevalence of dyslipidemia and obesity and not of 
hyperglycemia and hypertension in patients with depression or anxiety. 
These prominent associations of depression and anxiety with dyslipidemia 
and abdominal obesity may contribute to the generally increased risk of 
CVD in patients with depressive100 and anxiety disorders.189 Therefore, we 
aimed to further explore the associations of depression and anxiety with 
dyslipidemia and obesity.   
 Most previous studies on dyslipidemia and obesity in depression 
and anxiety had cross-sectional designs. To further disentangle these 
relationships, it is important to also study associations over time. This 
may reveal whether or not depression or anxiety are associated with 
sustained dyslipidemia and obesity, and whether changes in depression or 
anxiety status over time go together with changes in lipid or obesity levels.
 Most existing longitudinal studies focused on depression 
diagnoses,35,41,190 while scales for severity of symptoms are likely to detect 
the more subtle differences and changes in depressive or anxiety state. 
Because of their continuous nature,312,313 severity scales allow more 
precise (longitudinal) associations of depression or anxiety with lipid or 
obesity values than associations based on dichotomous diagnoses. In line 
with this thought, it was found in several cross-sectional analyses that the 
severity of symptoms is more strongly related to lipid levels and abdominal 
obesity than diagnostic categories.25,117,150 
  Despite the importance, only a few longitudinal studies explored 
associations of depression severity with lipids and/or obesity,28,191,192 and 
no studies reported on severity of anxiety. Concerning severity of 
depression, Pulkki-Raback et al.28 found that baseline severity of 
depression predicted WC but not HDL cholesterol or triglyceride levels 9 
years later. Vogelzangs et al.192 reported that among 2088 elderly, baseline 
depression severity did not predict changes in WC over 5 years. 
Deisenhammer et al.191 found that change in depression severity score over 
a 4 week period was not accompanied by changes in total, LDL and HDL 
cholesterol or in triglycerides among 50 patients with MDD.  
  Given the limited research so far, longitudinally studying severity of 
depression and anxiety in relation to dyslipidemia and abdominal obesity 
importantly adds to this research field. Furthermore, depression and 
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anxiety are highly co-morbid, with co-morbidity rates of over 60 
percent.12,13 Therefore, it is valuable to examine how depression and 
anxiety independently relate to dyslipidemia and abdominal obesity. 
    The present study examined within the Netherlands Study of 
Depression and Anxiety (NESDA) whether depressive or anxiety symptoms 
at baseline predicted an increase in abdominal obesity or dyslipidemia over 
a 2-year follow-up period. We also intended to study whether 2-year 
changes of depressive or anxiety symptoms over time coincided with 2-year 
changes in lipid and abdominal obesity values. Because severity of 
depressive and anxiety symptoms have been found to be related to 
dyslipidemia and obesity, we expected that symptoms of depression and 
anxiety predicted an aggravation of dyslipidemia and abdominal obesity, 
and we also hypothesized that changes in severity of depression or anxiety 
went together with lipid and abdominal obesity changes. Finally, as 
relatively more studies found depression to be related to dyslipidemia20-30 
(versus45-49 finding no association) or abdominal obesity20,23-28,43-46 
(versus49 finding no association) than anxiety (20found anxiety to be related 
to dyslipidemia while26,29,47 found no association, and none23,26,29,47 found 
anxiety to be related to abdominal obesity), we expected that depression 
severity dominates anxiety severity in relation to dyslipidemia and 
abdominal obesity. 
 
5.2  METHODS 
Subjects 
Subjects participated in the baseline (data collection from September 2004 
to February 2007) and 2-year follow-up (data collection from September 
2006 to February 2009) assessment of the Netherlands Study of 
Depression and Anxiety (NESDA), a cohort study including 2981 persons 
aged 18 to 65 years. Subjects were recruited from community (n=564, 
18.9%), primary care (n=1610, 54%, of which 373, 12.5% subjects had 
never had a depressive or anxiety disorder), and mental health care 
settings (n=807, 27.1%) in the Netherlands. Subjects with personal or 
family history of depression and anxiety as well as healthy controls that 
never had experienced any depressive or anxiety disorder were recruited in 
order to reflect a range of settings and stages of psychopathology. See for 
further details:95. The baseline and 2-year follow-up assessment both 
comprised a face-to-face interview, written questionnaires and biological 
measurements, as described in detail elsewhere.95
,96 According to the 
Composite Interview Diagnostic Instrument (CIDI, version 2.1), at baseline 
2329 subjects had a lifetime depressive or anxiety disorder (i.e., social 
phobia, panic disorder with or without agoraphobia or generalized anxiety 
disorder) of which 1701 during the 6 months prior to the baseline 
interview, and 652 subjects had never had a depressive or anxiety 
disorder.95 The response rate at 2-year follow-up was 87.1%.193 The study 
protocol was approved by the Ethical Review Board of each participating 
centre, and all subjects signed informed consent. 
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Subjects who did not attend the 2-year follow-up assessment (n=385) or 
who otherwise lacked data on severity of depression or anxiety or on lipid 
or WC measures either at baseline or at the 2-year follow-up assessment 
(n=470) were excluded from analyses. This resulted in the current sample 
of 2126 subjects, aged 18-65 years at baseline. Subjects who were 
excluded due to missing data were younger (mean age 40.1 [SD 12.9] 
versus 42.6 [SD 13.1], p <.001), more often female (69.9 versus 65.0%, p = 
.01) and had less years of education (mean 11.7 [SD 3.3] versus 12.4 [SD 
3.3], p <.001) than those without missing data. Also, excluded subjects 
more often had an MDD (43.5 versus 34.9%, p <.001) or an anxiety 
disorder (50.5 versus 41.1%, p <.001) in the 6 months preceding the 
baseline assessment. 
 
Severity of depression and anxiety 
Because we previously found no cross-sectional associations of obesity and 
lipid measures with MDD or anxiety disorder diagnoses but only with 
severity scales for depression and anxiety, we now examine longitudinal 
associations of severity of depression and anxiety with lipids and 
abdominal obesity. Depression severity was assessed by the 30-item 
Inventory of Depressive Symptoms self-report (IDS-SR) ranging from 0 to 
84.133 Anxiety severity was assessed by the 21-item self-report Beck 
Anxiety Inventory (BAI) ranging from 0 to 63.171  
  Cronbach´s alphas were .90 at baseline and .89 at 2-year follow-up 
for the IDS-SR. Cronbach´s alphas were .92 at both time points for the 
BAI. Those values are considered acceptable.287 Test-retest reliability 
correlation coefficients were .72 for the IDS-SR and .69 for the BAI, which 
mark a high to moderate test-retest reliability. 
Lipid and abdominal obesity measures 
HDL cholesterol, LDL cholesterol, triglycerides and WC were previously 
found to be cross-sectionally associated with severity of depressive and 
anxiety symptoms in NESDA.117
,150 Total, HDL and LDL cholesterol as well 
as triglyceride levels were determined using routine standardised 
laboratory methods. To account for medication use, HDL cholesterol, LDL 
cholesterol and triglyceride values were adjusted according to changes 
observed in clinical trials, as previously performed.25 Medication use within 
the past month was registered by observation of drug containers brought 
in, and ATC coded.111 For persons using fibrates, 0.10 mmol/L was 
subtracted from HDL cholesterol, and 0.67 mmol/L was added to 
triglycerides.167
,168 For persons using nicotid acid, 0.15 mmol/L was 
subtracted from HDL cholesterol, and 0.19 mmol/L was added to 
triglycerides. For persons using LDL-lowering medication, 0.74 mmol/L 
was added to LDL cholesterol.194 A sensitivity analysis including the 
original lipid values, and lipid affecting medication use as a covariate,  
yielded largely similar results to the original findings reported in this 
paper. WC was measured with a measuring tape at the central point 
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between the lowest front rib and the highest front point of the pelvis, upon 
light clothing.  
 
Covariates 
Sociodemographic variables included age, sex and years of education at 
baseline. Since tobacco use likely is a confounder, number of tobacco (i.e., 
cigarette, cigar or pipe) consumptions a day - as assessed through 
standardised questionnaires - was taken into account. 
  Exercise was not taken into account as a covariate as in a recently 
published article340 we reported that exercise did not play a significant role 
in the associations of dyslipidemia or obesity with depression or anxiety. 
For certainty, we did additional analyses including physical activity as a 
covariate, and indeed physical activity did not affect associations 
significantly (data not shown). 
Statistical analyses 
Baseline, 2-year follow-up and 2-year change characteristics of the sample 
were expressed in percentages for categorical variables, and in means (95% 
confidence intervals, CIs) for continuous variables. Paired-sample T tests 
were performed to explore whether mean 2-year changes were statistically 
significant; McNemar’s test was used for paired dichotomous variables. 2-
year changes in lipid or obesity, and in severity of depression or anxiety 
were computed as follow-up values minus baseline values. Linear 
regression analyses were conducted 1) to confirm associations of baseline 
severity of depression and anxiety with baseline lipid and obesity values 
that we previously reported,117
,150 and to further examine 2) whether 
baseline severity of depression or anxiety predicted 2-year changes in lipid 
or WC values (while adjusting for baseline lipid or WC values), 3) and if 2-
year change in severity of depression or anxiety was accompanied by 2-
year changes in lipid or WC levels (while adjusting for baseline depression 
or anxiety severity and the concerning lipid or WC values). All analyses 
were then adjusted for age, sex, years of education and tobacco 
consumption. Because of the co-morbidity of depression and anxiety, 
analyses on depression severity were additionally adjusted for anxiety 
severity scores and vice versa in order to understand how depression and 
anxiety collaborate in relation to dyslipidemia and obesity.341 Since sex 
differences in the association between anxiety, depression and 
cardiovascular risk factors have been observed before,21,43,105 
sex × depression severity / anxiety severity interaction terms were 
examined in adjusted models. To ensure that associations were not due to 
CVD, all 118 subjects with prevalent medicated CVD (i.e., stroke, 
myocardial infarction, angina pectoris or coronary heart disease, as 
assessed by standardized questionnaires and observation of drug 
containers brought in) at baseline were excluded in a sensitivity analysis. 
Previously, we found subjects who used tricyclic antidepressants (TCAs) 
but not those on other kinds of antidepressants to be prone to 
dyslipidemia and obesity.150 Therefore, an additional sensitivity analysis 
LONGITUDINAL RELATIONSHIPS 85 
 
  
was performed by excluding subjects who used TCAs at baseline (n=10), at 
2-year follow-up (n=13) or at both time points (n=42). TCA use within the 
past month was registered by observation of drug containers brought in 
and ATC coded.111 All statistical analyses were done with SPSS 18.0 (IBM 
company, Chicago, Illinois, USA). 
 
5.3  RESULTS 
Sample characteristics at baseline and 2-year follow-up as well as changes 
between these time points are presented in Table 1. Mean age at baseline 
was 42.6 years (95% confidence interval [CI] 42.0-43.2), and 35.1% were 
male. The mean depression severity score significantly diminished over 
time, as did the mean anxiety severity score. HDL cholesterol levels 
decreased during 2 years of follow-up. Triglyceride levels and WC 
significantly increased over time. Associations of baseline severity of 
depression and anxiety with baseline lipid and obesity values (data not 
shown) were similar to the results we reported earlier.117,150 At baseline, 
severity of depression was associated with higher triglycerides and WC 
(adjusted β = .061, p = .003 and β = .093, p <.001, respectively); baseline 
severity of anxiety was associated with lower HDL cholesterol (adjusted β = 
-.048, p = .02) and higher triglyceride and WC levels (adjusted β = .066, p = 
.002 and β = .077, p <.001, respectively).  
 
 
Table 2 shows crude and adjusted associations of severity of baseline 
depression and anxiety with 2-year changes in lipid and obesity values. 
Baseline severity of depression was associated with a significant increase 
in WC over 2 years (basically adjusted β = 0.60, p = .01, respectively) and a 
decline in HDL cholesterol (basically adjusted β = -.062, p = .003). Baseline 
severity of anxiety was also associated with a significant increase in WC 
(adjusted β = .053, p = .02) and a decline in HDL cholesterol over 2 years 
(adjusted β = -.050, p = .02) and an. The associations of more severe 
symptoms of anxiety at baseline with increasing waist circumference (β = 
Table 1. Baseline, 2 year follow-up and 2 year change characteristics of 2126 subjects  
Characteristics Baseline 2 year follow-up p* 2 year changes 
Age (years, at baseline) 42.6  (42.0-43.2)    
Sex (% men) 35.1    
Years of education 12.4  (12.2-12.5)    
Tobacco consumptions a day 4.6    (4.3-5.0) 4.1    (3.8-4.5) <.001 -0.5   (-0.7- -0.3) 
Depression severity  (IDS-SR) 20.5  (19.9-21.1) 16.0  (15.4-16.5) <.001 -4.5   (-5.0- -4.1) 
Anxiety severity (BAI) 11.3  (10.9-11.8) 8.8    (8.4-9.1) <.001 -2.6   (-2.9- -2.3) 
Waist circumference (cm) 89.0  (88.5-89.7) 89.8  (89.2-90.4) <.001  0.7   (0.5-1.0) 
Total cholesterol (mmol/L) 5.2    (5.1-5.2) 5.1    (5.1-5.2) .051 -0.03 (-0.1-0.0) 
LDL cholesterol (mmol/L) 3.2    (3.2-3.3) 3.2    (3.2-3.3) .14  0.02 (-0.01-0.05) 
HDL cholesterol (mmol/L) 1.6    (1.6-1.7) 1.6    (1.5-1.6) <.001 -0.10 (-0.11- -0.9) 
Triglycerides (mmol/L) 1.3    (1.25-1.32) 1.3    (1.3-1.4) .003  0.05 (0.02-0.08) 
Lipid affecting medication use (%) 7.3 8.1 .054  0.8 
Abbreviations: BAI, Beck Anxiety Inventory; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; IDS-SR, Inventory of Depressive Symptoms self-report. 
Means (95% confidence intervals) or percentages are given, when appropriate. 
*: p by paired-sample t test for means, and McNemar’s test statistics for lipid medication use. 
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.053 to .017, i.e., Δ -67.9%) and with lowering of HDL cholesterol levels (β 
= -.050 to -.002, i.e., Δ -95.0%) were significantly explained by co-morbid 
symptoms of depression. Associations of depression severity with 
increasing waist circumference (β .060 to .047, i.e., Δ -21.7%) and with 
lowering of HDL cholesterol levels (β -.062 to -.061, i.e., Δ -1.6%) were less 
substantially explained by co-morbid symptoms of anxiety. There was no 
considerable multicollinearity in these models (variance inflation factors 
were all 2.5). Adjustment for tobacco use did not affect the associations. 
No associations were found of baseline depression or anxiety severity with 
changes in total or LDL cholesterol or in triglyceride levels.  
 Table 3 shows crude and adjusted associations of 2-year change in 
severity of depressive and anxiety symptoms with 2-year changes in lipids 
and WC. Changes in depression or anxiety severity were not accompanied 
by significant changes in lipid or WC values. Adjustment for tobacco 
consumption did not affect these findings. 
  Repeated analyses including sex × depression severity / anxiety 
severity interaction terms showed no statistically significant interaction 
(p ranged from .11 to .99). This suggests that associations do not 
significantly differ for men or women. Sensitivity analyses in which 118 
subjects with CVD or 65 subjects who were using TCAs at either time point 












Table 2. Associations of baseline depression and anxiety severity with 2 year changes in lipid and obesity values 
 2 year changes in lipid and obesity values 
 Total cholesterol LDL cholesterol HDL cholesterol Triglycerides  Waist circumference  
Baseline depression severity (IDS-SR) β p β p β p β p β p 
     Crude -.003 .90 -.004 .85 -.046 .04 -.001 .95  .026 .23 
     Adjusteda -.003 .87  .001 .95 -.062 .003 -.008 .71  .060 .01 
      
Baseline anxiety severity (BAI) β p β p β p β p β p 
     Crude  .013 .54  .006 .77 -.022 .31  .012 .57  .026 .24 
     Adjusteda  .006 .79  .008 .69 -.050 .02  .024 .29  .053 .02 
Abbreviations: BAI, Beck Anxiety Inventory; HDL, high-density lipoprotein; LDL, low-density lipoprotein; IDS-SR, Inventory of Depressive 
Symptoms self-report.  
β coefficients indicate the standardised beta by linear regression analysis. Statistically significant (p<.05) associations are marked bold. 
All analyses are adjusted for the concerning baseline lipid or obesity values. 
a: Adjusted for age, sex, years of education, and baseline as well as 2 year change in tobacco consumption.  
Table 3. Associations of 2 year change in depression and anxiety severity with 2 year changes in lipid and obesity values 
 2 year changes in lipid and obesity values 
 Total cholesterol LDL cholesterol HDL cholesterol Triglycerides  Waist circumference  
2 year changes in depression severity (IDS-SR) β p β p β p β p β p 
     Crude  .014 .53  .013 .56  .049 .03  .004 .87  .008 .73 
     Adjusteda  .017 .46  .008 .73  .045 .06 -.002 .95  .025 .32 
      
2 year changes in anxiety severity (BAI) β p β p β p β p β p 
     Crude  .012 .60  .017 .42  .032 .14 -.023 .30 -.016 .47 
     Adjusteda  .008 .71  .018 .46  .032 .18 -.026 .30  .003 .90 
Abbreviations: BAI, Beck Anxiety Inventory; HDL, high-density lipoprotein; LDL, low-density lipoprotein; IDS-SR, Inventory of Depressive 
Symptoms self-report.  
β coefficients indicate the standardised beta by linear regression analysis. Statistically significant (p<.05) associations are marked bold. 
All analyses are adjusted for the concerning baseline depression or anxiety severity and lipid or obesity values. 
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5.4  DISCUSSION 
Earlier we reported that more severe symptoms of depression and also of 
anxiety made people prone to dyslipidemia and abdominal obesity.117
, 150 In 
this longitudinal follow-up study, we observed that people who had more 
severe symptoms of depression or anxiety at baseline displayed a further 
decline in HDL cholesterol levels and an increase in abdominal obesity over 
the subsequent 2 years. These associations were driven by depression 
severity: anxiety severity seemed to be related to increasing dyslipidemia 
and abdominal obesity mainly through its close relationship with 
depression.341 Finally, a reduction of symptoms of depression or anxiety 
over this time period did not go together with amelioration of lipid or 
abdominal obesity values.  
  So far no comparable studies concerning symptoms of anxiety have 
been reported. Moreover, we were to our knowledge the first to study the 
relative contribution of depression and anxiety to the development of 
dyslipidemia and abdominal obesity. Our results showed that anxiety 
severity rather is a proxy risk factor for depression severity in aggravating 
dyslipidemia and abdominal obesity.341  
  Our finding that baseline severity of depression predicted 
progressive abdominal obesity over the subsequent 2 years corresponds to 
another study that reported that baseline severity of depression predicted 
an increased abdominal obesity value after 9 years.28 Our finding is also in 
line with a meta-analysis which revealed that baseline depression was 
associated with an increased odds ratio for developing overall obesity over 
time (47). Yet another study found no predictive relationship over 5 
years.192 Our finding that symptoms of depression predicted a decline in 
HDL cholesterol levels was not replicated over 9 years.28 Conversely, our 
result that a reduction of depressive symptoms did not coincide with 
changes in HDL cholesterol was largely comparable to an earlier study over 
a period of 1 month in which a reduction in depression score did not 
coincide with changes in HDL cholesterol.191 Our findings are also in line 
with the observation that patients with severe depressive symptoms after 
myocardial infarction who were successfully treated for their depression 
showed no improvement in their high risk of cardiac mortality.75  
  The fact that a reduction in severity of depression or anxiety did not 
go together with changes in HDL cholesterol or abdominal obesity, 
indicates that reductions of depressive or anxiety symptoms do not 
manifest themselves as improved dyslipidemia or obesity, at least over a 
rather short term of 2 years. This finding, together with the observed 
worsening of dyslipidemia and abdominal obesity independent of an 
improved mental state, indicates that probably multiple relatively stable 
etiological factors connect a liability to depression and anxiety to lower 
HDL cholesterol and to abdominal obesity. Among these possible 
mechanisms are lifestyle, biological, and genetic factors. A first possible 
lifestyle mechanism is smoking. Smoking lowers HDL cholesterol,19,75 and 
people with depressive or anxiety disorders smoke more regularly.118 
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Moreover, they often have difficulty with smoking cessation after mood 
improvement, possibly due to antidepressant effects of nicotine.145,197 
Sustained smoking could thus have lead to decreased HDL cholesterol 
levels in people with initially more severe symptoms of depression or 
anxiety. Smoking did however not explain our results. A second underlying 
lifestyle factor could be that people who are vulnerable to depression or 
anxiety, independent of their current mental state, continue to eat more 
carbohydrates and (saturated) fat.118 Persistent unhealthy dietary habits 
may have led to increases in dyslipidemia and abdominal obesity. A 
biological mechanism may be low-grade inflammation. People with 
depressive200,72,199 or anxiety disorders73 display higher levels of 
inflammation than controls. At the same time, inflammation causes a 
reduction in HDL lipoproteins51 and also induces obesity through leptin 
resistance.201,202 As baseline symptoms of depression predict augmentation 
of inflammation203 and inflammation may not decline after recovery from 
depression,204 chronic inflammation in people who are vulnerable to 
depression or anxiety might cause progressive dyslipidemia and abdominal 
obesity. This may be independent of an improved mood. Lastly, it is 
possible that symptoms of depression and anxiety share genetic and 
complex biological etiological substrates with HDL cholesterol and 
abdominal obesity. For instance, gene-environment interactions may have 
activated the hypothalamic-pituitary-adrenal axis, which subsequently has 
led to depression as well as to aggravation of obesity.205 Mechanistic 
factors may however normalize in the longer term. Our previous 
observation that HDL cholesterol values in people with a remitted 
depression during lifetime were similar to those of controls117 supports this 
premise.  
  In addition, it is noteworthy that depressive and anxiety symptoms 
declined significantly over the 2-year follow-up period. Due to our 
recruitment method, a large proportion of our subjects had prevalent 
depressive or anxiety disorders at baseline. Although residual symptoms of 
depression and anxiety are common, it is estimated that over half of 
patients with depression show clinical recovery after two years,342 and also 
anxiety disorders seem to decline over time.343,344 This common decline in 
symptoms of depression and anxiety may have explained the significant 
decrease of depression and anxiety symptoms in our general sample. 
Moreover, part of the improvement may be ascribed to regression to the 
mean effects. 
 A first important limitation of our study is that changes in 
depression and anxiety severity and in lipid and obesity values over time 
showed relatively low variability. This might be caused by the high 
proportion of subjects from mental health care, who are more likely to have 
longstanding disorders9 which may have caused a slower improvement in 
symptoms of depression and anxiety in the general group. This may have 
limited the power to detect longitudinal associations. Second, the 2-year 
time interval between assessments might have been too short to establish 
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a degree of relieve in depression or anxiety symptoms that was able to 
account for considerable lipid or obesity changes. A major strength of our 
study is the prospective design, through which we were able to extensively 
explore the longitudinal associations of depression and anxiety severity 
with lipid and obesity patterns. Strength of our recruitment procedures 
was that because we oversampled subjects in different stages of 
psychopathology, we could analyse the impact of current and prolonged 
symptomatology of depression and anxiety with relatively high precision. 
Another main strength is the assessment of the severity of depression and 
anxiety using validated scales as well as the assessment of lipid and 
obesity values at both time points in a large cohort. Furthermore, severity 
of anxiety symptoms had not yet been prospectively studied in relation to 
metabolic risk factors. Exploration of this association adds importantly to 
the existing longitudinal literature, as symptoms of anxiety have been 
found to be almost as strong markers for dyslipidemia and abdominal 
obesity as symptoms of depression. 
  In conclusion, we found that people with more severe symptoms of 
depression or anxiety showed a decrease in HDL cholesterol levels and an 
increase in abdominal obesity over the subsequent 2 years, independent of 
a reduction in symptoms of depression or anxiety. These findings could be 
of clinical importance. As low HDL cholesterol as well as abdominal obesity 
are important risk factors for CVD,17 those people are at elongated and 
increasing risk of CVD. It is important for clinicians to be aware of an 
increased CVD risk in patients with depressive and anxiety disorders, that 
does not seem to fade after remission of symptoms. These patients should 
therefore be continuously evaluated for the presence of metabolic risk 
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Stress is suggested to lead to metabolic dysregulations as clustered in the 
metabolic syndrome, but the underlying biological mechanisms are not yet 
well understood. We examined the relationship between two main stress 
systems, the autonomic nervous system and the hypothalamic-pituitary-
adrenal (HPA) axis, with the metabolic syndrome and its components.  
 
Methods 
The design was baseline data (years 2004–2007) of a prospective cohort: 
the Netherlands Study of Depression and Anxiety (NESDA). The study 
comprised general community, primary care, and specialized mental 
health care. This study included 1883 participants aged 18–65 years. 
Autonomic nervous system measures included heart rate, respiratory 
sinus arrhythmia (RSA; high RSA reflecting high parasympathetic activity), 
and preejection period (PEP; high PEP reflecting low sympathetic activity). 
HPA axis measures included the cortisol awakening response, evening 
cortisol, and a 0.5 mg dexamethasone suppression test as measured in 
saliva. Metabolic syndrome was based on the updated Adult Treatment 
Panel III criteria and included high waist circumference, serum 
triglycerides, blood pressure, serum glucose, and low high-density 
lipoprotein cholesterol.  
 
Results 
RSA and PEP were both independently negatively associated with the 
presence of the metabolic syndrome, the number of metabolic 
dysregulations as well as all individual components except high-density 
lipoprotein cholesterol (all p < 0.02). Heart rate was positively related to the 
metabolic syndrome, the number of metabolic dysregulations, and all 
individual components (all p < 0.001). HPA axis measures were not related 
to metabolic syndrome or its components.  
 
Conclusion 
Our findings suggest that increased sympathetic and decreased 
parasympathetic nervous system activity is associated with metabolic 
syndrome, whereas HPA axis activity is not. 
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6.1  INTRODUCTION 
It has often been hypothesized that stress leads to metabolic 
dysregulations.206-208 In response to stress, two main stress systems, the 
autonomic nervous system (ANS) and the hypothalamic-pituitary-adrenal 
(HPA) axis, are both centrally activated.207
,208 Persistent (over)activation of 
these stress systems could lead to metabolic alterations, such as high 
blood pressure, serum triglycerides, serum glucose, waist circumference, 
and low high-density lipoprotein (HDL) cholesterol.208-210 The metabolic 
syndrome consists of a cluster of these metabolic abnormalities and 
predisposes to cardiovascular disease (CVD)211
,212 and diabetes.213 Whether 
both stress systems are associated with the metabolic syndrome has only 
partially been examined.122
,209,210 
  Some studies have shown evidence for a role of ANS dysfunction in 
the metabolic syndrome. For sympathetic nervous system (SNS) activity, 
measured by, for example, muscle sympathetic nerve activity, elevated 
levels were found in subjects with the metabolic syndrome.214
,215 However, 
Grassi et al.215 showed that different measures of SNS activity show 
divergent associations with the metabolic syndrome; therefore, evidence for 
the relationship between purely sympathetic activity and the metabolic 
syndrome remains ambiguous and cannot be considered conclusive. More 
evidence is present for a negative relationship between parasympathetic 
nervous system (PNS) activity and the metabolic syndrome,216-218 although 
inconsistencies have been found. For example, PNS activity (as reflected by 
the high frequency spectra of heart rate variability) was unassociated217
,219 
as well as negatively associated with having the metabolic syndrome.216
,218 
Studies have also shown inconsistent results for the association of PNS 
activity with various metabolic dysregulations.216-218 In addition, some 
studies were limited by rather short periods of physiological recordings or 
no consideration of cardiovascular disease and cardiac medication.216-218  
  Cortisol measured in saliva is considered a reliable and noninvasive 
indicator of HPA axis activity.220 Although there are several studies that 
examined the association between salivary cortisol and the metabolic 
syndrome or its components, the relationship is still not elucidated. 
Results are inconsistent concerning the direction of the relationship as 




,226 associations have 
been reported between salivary morning cortisol or cortisol awakening 
response and components of the metabolic syndrome. Studies specifically 
examining evening cortisol and metabolic syndrome components are 
scarce, mostly reporting no association.221
,224 Results regarding cortisol 
suppression after dexamethasone ingestion showed less suppression after 
dexamethasone to be associated with hypertension224 and all other 
metabolic syndrome components,223 whereas Putignano et al.222 reported 
no association with obesity. However, previous studies were rather small, 
measured morning cortisol by only one salivary sample, or did not adjust 
for important covariates such as sleep duration and awakening time.  
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Therefore, we examined the association between metabolic syndrome and 
its components with multiple extensive measures of both ANS and HPA 
axis activity in a large cohort study considering important covariates to 
explore to what extent both stress systems are involved in metabolic 
abnormalities.  
 
6.2  METHODS 
Subjects 
Data are from The Netherlands Study of Depression and Anxiety (NESDA), 
a large longitudinal cohort study among 2981 adults (18–65 years), 95.2% 
of North European ancestry (see Ref.95). Respondents were recruited from 
the community, in primary care through a screening procedure conducted 
among 65 general practitioners, and in specialized mental health care 
when newly enrolled at one of the 17 participating mental health 
organization locations. The research protocol was approved by the ethical 
committee of participating universities and all respondents provided 
written informed consent. 
  Of the total sample, we excluded 80 persons using tricyclic 
antidepressants because of their effect on the ANS,227 HPA axis,68 and 
metabolic syndrome.105 Of the 2901 remaining participants, we excluded 
27 pregnant or breast-feeding women and 158 participants on 
corticosteroids because of their effects on the HPA axis, leaving a sample of 
2716 respondents. Of 109 participants, no ANS data were available, 
another 695 did not return (sufficient) saliva samples for HPA axis activity 
assessment, and of 29 persons data on metabolic abnormalities were 
missing. Therefore, the present study sample consisted of 1883 
participants. 
Participants in the present study sample (n=1883) did not differ 
from the excluded participants (n=833) in presence of the metabolic 
syndrome (21.1 vs. 23.4%, p = .17) or CVD (5.8 vs. 7.1%, p = .18) but were 
less often female (64.9 vs. 68.9%, p = .02), older (43.0 vs. 39.9 years, p < 
0.001), and more educated (12.4 vs. 11.7 years, p < 0.001).  
 
The metabolic syndrome 
The metabolic syndrome was defined according to the American Heart 
Association and National Heart, Lung, and Blood Institute’s update of the 
U.S. National Cholesterol Education Program-Adult Treatment Panel III 
(NCEP-ATP III) criteria.17 The NCEP-ATP III guidelines define the metabolic 
syndrome as a presence of three or more of the following criteria: i) waist 
circumference 102 cm or greater in men and 88 cm or greater in women, ii) 
triglycerides 1.7 mmol/L or greater (150 mg/dL) or medication for 
hypertriglyceridemia, iii) HDL cholesterol less than 1.03 mmol/L (40 
mg/dL) in men and less than 1.30 mmol/L (50 mg/dL) in women or 
medication for reduced HDL cholesterol, iv) systolic blood pressure (SBP) 
130 mmHg or greater and/or diastolic blood pressure 85 mmHg or greater 
or antihypertensive medication, and v) fasting plasma glucose 5.6 mmol/L 
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or greater (100 mg/dL) or antidiabetic medication. The number of 
metabolic syndrome components was used as an indicator of severity of 
metabolic abnormalities.105  
 
Metabolic syndrome components 
In addition to the metabolic syndrome, associations with continuous levels 
of individual metabolic components were examined to investigate 
consistency across components. Waist circumference was measured with a 
measuring tape at the central point between the lowest front rib and the 
highest front point of the pelvis on light clothing. Triglycerides, HDL 
cholesterol, and glucose were determined using routine standardized 
laboratory methods. To incorporate medication use into the continuous 
variable, for persons using antidiabetic medication when glucose level was 
less than 7.0 mmol/L (126 mg/dL), a value of 7.0 mmol/L (126 mg/dL) 
was assigned.17 Similarly, for persons using fibrates, 0.10 mmol/L (3.8 
mg/dL) was subtracted from HDL cholesterol and 0.67 mmol/L (60 mg/dL) 
was added to triglycerides.17 For persons using nicotinic acid, 0.15 
mmol/L (5.8 mg/dL) was subtracted from HDL cholesterol and 0.19 
mmol/L (17 mg/dL) added to triglycerides, based on mean changes after 
medication treatment.17 SBP and diastolic blood pressure were measured 
twice during supine rest on the right arm with the Omron M4-I, HEM 
752A, and were averaged over the two measurements. For persons using 
antihypertensive medication, 10 mm Hg was added to the SBP.62  
 
ANS 
During the visit to the research centers, The Netherlands Study of 
Depression and Anxiety subjects were wearing the Vrije Universiteit 
ambulatory monitoring system. The Vrije Universiteit ambulatory 
monitoring system is a light-weight, unobtrusive device that records the 
electrocardiogram (ECG) and changes in thorax impedance (dZ) from six 
surface electrodes placed at the chest and on the back of the subjects.228
, 
229 The interbeat interval time series was extracted from the ECG signal to 
obtain heart rate, an indicator of combined SNS and PNS activity. To 
separately index the cardiac effects of both ANS branches, pre-ejection 
period (PEP; high PEP reflects low SNS activity) and respiratory sinus 
arrhythmia (RSA; high RSA reflects high PNS activity) were extracted from 
the combined dZ and ECG signals. 
  The PEP reflects noradrenergic inotropic drive to the left ventricle 
and was obtained from the dZ/dt signal, ensemble averaged across 1-min 
periods time locked to the R-wave of the ECG. The PEP was defined as the 
interval from the B point (upstroke) to the X point (incisura) of the dZ/dt 
signal, as described in detail elsewhere.229 The RSA reflects cardiac 
parasympathetic activity and was obtained by combining the interbeat 
interval time series with the filtered (0.1–0.4 Hz) dZ signal, which 
corresponds to the respiration signal. RSA was obtained by subtracting the 
shortest interbeat interval (IBI) during heart rate acceleration in the 
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inspiratory phase from the longest IBI during deceleration in the expiratory 
phase for all breaths, as described in detail elsewhere.228 Automated 
scoring of IBI, RSA, and PEP was checked by visual inspection, and valid 
data were averaged over 90.2 ± 23 min time to create a single PEP, RSA, 
and heart rate value.  
  To additionally investigate whether patterns of sympathetic and 
parasympathetic co-activation or parallel activation/inhibition were related 
to the metabolic syndrome, two measures of autonomic balance were 
acquired following the approach of Berntson et al.230. Cardiac autonomic 
balance (CAB) was calculated as the difference between normalized values 
of RSA and PEP [formula = zRSA − (−zPEP) (because increased sympathetic 
control is associated with shortened PEP values, PEP was multiplied by 
−1)] such that low values reflect parallel high sympathetic and low vagal 
cardiac control (unfavorable cardiac pattern) and high values reflect low 
sympathetic and high vagal cardiac control (favorable cardiac pattern). 
Cardiac autonomic regulation (CoAR) was calculated as the sum of the 
normalized values of RSA and PEP [formula = zRSA + (−zPEP)] and low 
values represent co-inhibition (low SNS and low PNS activity) and high 




As described in more detail elsewhere,231 respondents were instructed to 
collect saliva samples at home on a regular (working) day, which has 
shown a reliable and minimally intrusive method to assess the active, 
unbound form of cortisol.220 The median time between the interview and 
saliva sampling was 9.0 d (25th to 75th percentile: 4–22). Saliva samples 
were obtained using Salivettes (Sarstedt, Germany) at seven time points. 
The cortisol awakening response includes four sampling points; at 
awakening (T1) and 30 (T2), 45 (T3), and 60 (T4) min later. Two evening 
values were collected at 2200 h (T5) and 2300 h (T6). Dexamethasone 
suppression was measured by cortisol sampling the next morning at 
awakening (T7) after ingestion of 0.5 mg dexamethasone directly after the 
saliva sample at 2300 h (T6). Samples were stored in refrigerators and 
returned by mail. After receipt, Salivettes were centrifuged at 2000 g for 10 
min, aliquoted, and stored at −80 C. Cortisol analysis was performed by 
competitive electrochemiluminescence immunoassay (E170; Roche, Basel, 
Switzerland), as described in Van Aken et al.232 The functional detection 
limit was 2.0 nmol/L and the intra- and inter-assay variability coefficients 
in the measuring range were less than 10%. Data cleaning excluded values 
greater than 2 SD above the mean (i.e., above 59.6–123.6 nmol/L for T1–
T4, 40.9 nmol/L for T5, 59.8 nmol/L for T6, and 35.6 nmol/L for T7). 
One-hour awakening cortisol. The area under the curve with respect to the 
increase (AUCi) and ground (AUCg) were calculated using the formulas 
described by Pruessner et al.233 The AUCg is an estimate of the total 
cortisol secretion over the first hour after awakening, and the AUCi is a 
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measure of the dynamic of the cortisol awakening response, more related 
to the sensitivity of the system, emphasizing changes over time.234 For area 
under the curve calculations, all four morning samples were required 
(n=1584). 
  Evening cortisol. Because the correlation between the two evening 
values was high (r = 0.52, p < 0.001), the mean of the two values was used 
for analyses to reflect evening cortisol (n=1871).  
  Dexamethasone suppression test. A total of 1712 of the 1781 
subjects with cortisol sample T1 and T7 (96.1%) had taken the 0.5 mg 
dexamethasone after 2300 h on the first sampling day. We used a cortisol 
suppression ratio calculated by cortisol value at awakening on the first day 
(T1) divided by cortisol value at awakening the next day (T7) after ingestion 
of 0.5 mg dexamethasone the evening before.  
 
Covariates 
Sociodemographic factors included sex, age, and years of attained 
education. Use of oral contraceptives (yes/no) and menopause (yes/no) 
were identified by self-report. Smoking status was categorized into never 
smoked, former smoker, and current smoker. Daily alcohol use was 
categorized into no, mild to moderate (maximal 2 U/d), and heavy (>2 
U/d). Physical activity was assessed by the International Physical Activity 
Questionnaire235 and expressed in 1000 metabolic equivalent of task (MET-
)minutes in the past week. Cardiovascular disease (including coronary 
disease, cardiac arrhythmia, angina, heart failure, and myocardial 
infarction) was ascertained by self-report. Furthermore, it was determined 
whether subjects were using heart medication by copying the names of 
medicines from the containers brought in by the subjects. Using the World 
Health Organization’s anatomical therapeutic chemical (ATC) classification, 
medication was classified. Use both of beta-blockers (ATC code C07, used 
daily or more than 50% of the time) and other heart medication (ATC codes 
C01 [cardiac therapy], C02 [antihypertensives], C03 [diuretics], C04 
[peripheral vasodilators], C05 [vasoprotectives], C08 [calcium channel 
blockers], or C09 [renin and angiotensin agents]) was ascertained. 
Additionally, for analyses with cortisol measures, sampling factors that 
have been shown to influence cortisol measures by Vreeburg et al.231 were 
included. Respondents reported time of awakening and working status on 
the sampling day. Season was categorized into dark months (October 
through February) and months with more daylight (March through 
September). Average sleep duration during the last week was assessed 
using the Insomnia Rating Scale236 and dichotomized into sleeping more or 
less than 6 hours a night.  
 
Statistical analyses 
Baseline characteristics were compared across metabolic syndrome status 
using χ2 and ANOVA statistics. Partial correlation coefficients (adjusting for 
age, sex, and education) between ANS and cortisol measures were 
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calculated to examine the inter-correlations between both stress systems. 
Multiple logistic regression analyses were conducted with ANS measures 
(i.e., heart rate, RSA, or PEP) and salivary cortisol measures (i.e., AUCg, 
AUCi, evening cortisol, or cortisol suppression ratio) as independent 
variables and metabolic syndrome as the dependent variable. Multiple 
linear regression, adjusted for all covariates, was used to analyze the 
association of ANS and salivary cortisol measures with either the number 
of metabolic syndrome components (0–5) or continuous individual 
metabolic syndrome components as dependent variables. All metabolic 
syndrome components were normally distributed, except for triglycerides 
and glucose levels, which were log transformed before analyses. If linear 
regression with the number of metabolic syndrome components yielded 
significant results; fully corrected analysis of covariance analyses were 
performed to compare the mean ANS and HPA axis values of persons with 
increasing number of metabolic syndrome components (i.e., 0, 1, 2, 3, 4, 
and 5) and investigate linearity. p ≤ 0.05 was regarded as statistically 
significant. All analyses were conducted using SPSS 15.0 (SPSS Inc., 
Chicago, Illinois, USA).  
 
6.3  RESULTS 
In our sample, 21.2% met the criteria for the metabolic syndrome; 25.1% 
met none of the criteria, 31.3% one, 22.4% two, 12.9% three, 6.4% four, 
and 1.9% all five criteria. Sample characteristics are presented in Table 1. 
Persons with the metabolic syndrome were more likely to be male, older, 
and less educated, a nondrinker or heavy drinker, a former smoker, using 
heart medication, or having prevalent CVD and were less likely to be using 
oral contraceptives than persons without the metabolic syndrome. Persons 
with the metabolic syndrome showed on average a lower RSA, CAB, and 
CoAR, higher heart rate, and shorter PEP, whereas no differences were 
seen in cortisol measures, except for a trend toward less suppression after 
dexamethasone. 
  Table 2 shows the results of the partial correlations between HPA 
axis measures and ANS measures adjusted for age, sex, and education. In 
contrast to an expected inter-correlatedness because of shared central 
activation of both stress systems, ANS measures did not significantly 
correlate with HPA axis measures (all p > 0.11). 
  After full adjustment, RSA, heart rate, and PEP were significantly 
related to the metabolic syndrome as well as the number of metabolic 
abnormalities (see Table 3 and Figure 1). The odds for the metabolic 
syndrome increased when RSA and PEP decreased, indicating that 
decreased parasympathetic and increased sympathetic activity are 
associated with increased likelihood of metabolic syndrome. Lower RSA  
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Table 1. Sample characteristics 
   Metabolic syndrome   
 
No Yes  
n 
1484 399 pa 
Sociodemographics       
  Age, mean (SD), y 41.1 (13.0) 50.4 (10.1) <.001 
  % Female 68.5 51.6 <.001 
 Education, mean (SD), y 12.7 (3.2) 11.3 (3.3) <.001 
Health factors       
 Physical activity, mean (SD), 1000 MET 
 min/week 
3.7 (3.0) 3.6 (3.0) .36 
 % Smoking       
   Non-smoker 32.0 22.6 
<.001    Former smoker 35.2 45.1 
   Current smoker 32.8 32.3 
 % Alcohol use       
   Non drinker 14.4 19.5 
.003    Mild/moderate drinker 69.9 61.2 
   Heavy drinker 15.7 19.3 
 % Use beta-blockers 4.3 22.1 <.001 
 % Use other heart medication 5.7 30.3 <.001 
 % Use of oral contraceptives 19.5 6.8 <.001 
   % Post-menopausal women 18.7 26.6 .001 
 % Cardiovascular disease 5.7 11.5 <.001 
 Time of awakening, mean (SD), h:min  7:31 (1:16) 7:19 (1:06) .006 
 % Working on day of sampling 63.4 56.4 .01 
 % Sampling in month with more day light 58.6 57.9 .79 
 %  6 hours of sleep 24.7 32.3 .002 
Autonomic measures       
 RSA, mean (SD), ms 46.1 (24.5) 32.2 (19.8) <.001 
 HR, mean (SD), beats/min 71.1 (9.3) 72.0 (10.5) .06 
 PEP, mean (SD), ms 122.9 (16.2) 119.8 (21.9) .005 
 CAB, mean (SD) 0.158 (1.33) -0.593 (1.57) <.001 
 CoAR, mean (SD) 0.053 (1.33) -0.323 (1.42) <.001 
HPA-axis measures       
 AUCg,mean (SD), nmol/l/h 19.0 (7.1) 19.6 (6.9) .18 
 AUCi, mean (SD), nmol/l/h 2.4 (6.2) 2.1 (6.6) .48 
 Mean evening level, mean (SD), nmol/l 5.4 (3.5) 5.6 (3.0) .31 
 Cortisol suppression ratiob, mean (SD) 2.9 (1.7) 2.7 (1.6) .10 
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Table 1. Continued    
Continuous measures of metabolic syndrome       
 Waist circumference, mean (SD), cm 85.0 (11.2) 103.3 (11.8) <.001 
 Systolic BP, mean (SD), mmHg 133.0 (17.8) 151.8 (19.4) <.001 
 Glucose, mean (SD), mmol/lc 4.9 (1.1) 5.9 (1.2) <.001 
 HDL cholesterol, mean (SD), mmol/l 1.7 (0.4) 1.3 (0.4) <.001 
 Triglycerides, mean (SD), mmol/lc 1.0 (1.5) 1.8 (1.6) <.001 
 No. of metabolic components, mean (SD), no. 1.0 (0.8) 3.5 (0.7) <.001 
Abbreviations: SD, standard deviation; MET, metabolic equivalent of task; RSA, respiratory 
sinus arrhythmia; HR, heart rate; PEP, pre-ejection period; AUCg/i, area under the curve with 
respect to the ground/increase; BP, blood pressure; HDL, high-density lipoprotein.  
a: based on χ² and analysis of variance for dichotomous or categorical and continuous 
measures respectively.   
b: cortisol suppression ratio = cortisol T1/ cortisol T7 after 0.5 mg dexamethasone 
c: glucose and triglyceride levels are back-transformed 
 
 












RSA, ms -.031 -.027 -.016 -.010 
HR, beats/min  .040  .038  .020  .039 
PEP, ms  .037  .006  .046 -.038 
CAB  .020 -.002  .043 -.037 
CoAR -.039 -.013 -.030  .041 
Abbreviations: RSA, respiratory sinus arrhythmia; HR, heart rate; PEP, pre-ejection period; 
AUCg/i, area under the curve with respect to the ground/increase. 
a: adjusted for age, sex and education. 
 
 
and PEP were also associated with the number of metabolic syndrome 
components present (see Table 3 and Figure 1). A higher heart rate was 
associated with increased odds for the metabolic syndrome and an 
increase in number of metabolic syndrome components. None of the HPA 
axis measures was associated with the metabolic syndrome or with the 
number of its components (see Table 3). 
  Table 4 shows the associations of ANS and HPA axis measures with 
the different continuous metabolic syndrome components. Again, salivary 
cortisol measures were not significantly related to the continuous 
metabolic syndrome components. However, RSA (increased PNS activity) 
and PEP (decreased sympathetic activity) were negatively associated with 
waist circumference (β = −0.078, p = .005 and β = −0.143, p <.001, 
respectively), triglycerides (β = −0.092, p = .002 and β = −0.081, p = .001, 
respectively), and SBP (β = −0.111, p <.001 and β = −0.115, p <.001, 
respectively). RSA was also negatively associated with glucose (β = −0.066, 
p = .02). Heart rate was positively associated with waist circumference (β = 
METABOLIC ABNORMALITIES, 




0.111, p < 0.001), triglycerides (β = 0.186, p < 0.001), SBP (β = 0.150, p < 
0.001), and glucose (β = 0.140, p <.001) and negatively associated with 
HDL cholesterol (β = −0.062, p = .01). 
 
Table 3. Adjusteda associations between the stress systems and metabolic syndrome and  
              number of metabolic syndrome components. 
 
Metabolic syndrome Number of metabolic    
syndrome components 
 OR (95% CI)  p β  p 
Autonomic nervous system     
     RSA, per 10 ms i 0.81 (0.74-0.90) <.001 -.110 <.001 
     HR, per 10 bpm i 1.72 (1.46-2.02) <.001  .220 <.001 
     PEP, per 10 ms i 0.87 (0.80-0.94) <.001 -.132 <.001 
     CAB, per 1 unit i 0.75 (0.67-0.84) <.001 -.163 <.001 
     CoAR, per 1 unit i 1.06 (0.94-1.20)   .31  .045   .12 
HPA axis     
     AUCg, per 10 nmol/l/h i 1.07 (0.88-1.29)   .50  .008   .72 
     AUCi, per 10 nmol/l/h i 1.05 (0.85-1.30)   .65 -.003   .87 
     Evening cortisol, per 10 nmol/l i 0.84 (0.57-1.23)   .36 -.012   .56 
     Cortisol suppression ratio, per 1 unit i 1.05 (0.87-1.26)   .64  .004   .87 
Abbreviations: OR, odds ratio; CI, confidence interval; β, standardized beta; i, increase; RSA, 
respiratory sinus arrhythmia; HR, heart rate; PEP, pre-ejection period; CAB, cardiac 
autonomic balance; CoAR, cardiac autonomic regulation; HPA, hypothalamic-pituitary-
adrenal; AUCg/i, area under the curve with respect to the ground/increase. 
a: based on logistic and linear regression analyses adjusted for age, sex, education, oral 
contraceptive use, menopause, cardiovascular disease, physical activity, smoking, alcohol 
use, use of beta-blockers and other heart medication. For HPA axis, analyses were 
additionally adjusted for working, awakening time, season and sleep. 
 
When we performed a multivariable analysis in which PEP and RSA were 
entered together, the odds ratios (ORs) and βs remained largely similar to 
the separate univariable analyses [e.g., for the metabolic syndrome, RSA 
OR = 0.83 (95% CI: 0.75–0.92) and PEP OR = 0.88 (95% CI: 0.82–0.95), p’s 
< 0.001], suggesting that both branches are independently associated with 
the metabolic syndrome and its components. To further investigate 
whether associations for sympathetic (PEP) and parasympathetic activity 
(RSA) with metabolic syndrome components were independent from each 
other, additional analyses were performed with the CAB and CoAR (see 
Table 3). Results showed that the CAB, reflecting reciprocal SNS activation 
and PNS inhibition, significantly decreased the odds of metabolic 
syndrome [per 1 U increase in CAB OR = 0.75 (95% CI: 0.67–0.84)]. 
Moreover, higher CAB was negatively associated with the number of 
metabolic dysregulations and all individual components of the metabolic 
syndrome (except for HDL cholesterol). The CoAR, reflecting SNS and PNS 
co-activation, did not associate with any of the metabolic measures.  










Table 4. Adjusteda associations between the stress systems and the individual components of  










  β p β p β p β p β p 
Autonomic nervous system           
    RSA, ms -.078 .005 -.092 .002  .003 .93 -.111 <.001 -.066 .02 
    HR, bpm  .111 <.001  .186 <.001 -.062 .01  .151 <.001  .140 <.001 
    PEP, ms -.143 <.001 -.081 .001  .031 .20 -.115 <.001 -.031 .20 
    CAB -.155 <.001 -.113 <.001  .023 .36 -.150 <.001 -.056 .02 
    CoAR  .083 .01  .019 .49 -.030 .26  .038 .12 -.011 .69 
HPA axis           
    AUCg, nmol/l -.028 .21  .024 .31  .021 .36  .000 .99 -.015 .52 
    AUCi, nmol/l -.039 .07  .013 .57 -.015 .50 -.014 .50 -.016 .47 
    Evening cortisol, nmol/l -.023 .25  .029 .18  .002 .92  .035 .08 -.014 .53 
    Suppression ratio  .023 .25  .003 .91 -.005 .83 -.014 .49  .005 .81 
Abbreviations: HDL, high-density lipoprotein; SBP, systolic blood pressure; β, standardized beta; 
RSA, respiratory sinus arrhythmia; HR, heart rate; PEP, pre-ejection period; CAB, cardiac 
autonomic balance; CoAR, cardiac autonomic regulation; HPA, hypothalamic-pituitary-adrenal, 
AUCg/i, area under the curve with respect to the ground/increase. 
a: based on linear regression analyses adjusted for age, sex, education, oral contraceptive use, 
menopause, cardiovascular disease, physical activity, smoking, alcohol use, use of betablockers 
and other heart medication. For HPA axis, analyses are additionally adjusted for working, 
awakening time, season and sleep. 
b: log transformed. 
 
6.4  DISCUSSION 
In this large study, we found that decreased PNS and increased SNS 
activity were associated with metabolic syndrome and its components, 
whereas HPA axis measures were not. The activity of the ANS and HPA 
stress systems was not correlated. These results suggest that in contrast 
to HPA axis dysregulation, ANS dysregulation is strongly associated with 
metabolic syndrome and might therefore partly be involved in its 
unfavorable consequences such as the incidence of cardiovascular disease. 
  The association of low PNS activity with the metabolic syndrome 
corroborates the findings of some groups216
,218 and contrasts with other 
groups reporting no association. Previous studies had also reported on the 
associations between measures of SNS activity and metabolic syndrome, 
but the evidence was scarce and results were inconsistent.122
,215 The 
present study provides consistent evidence for an association of increased 
SNS activity (i.e., lower PEP) with the metabolic syndrome and individual 
metabolic components. 
  Although the effects of PEP and RSA on metabolic syndrome and its 
components were partly independent, a pattern of parallel high SNS and 
low PNS activity was most strongly associated with metabolic syndrome. In 
contrast, a pattern of low SNS activity and low PNS activity or high SNS 
activity with high PNS activity did not show association with the metabolic 
syndrome. Our findings are strikingly congruent to results of Berntson et 
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al.230, who reported a similar relationship between ANS and diabetes. 
Taken together, these results suggest that especially the combination of 
increased SNS activity and decreased PNS activity is related to the 
metabolic syndrome, whereas high SNS activity in the presence of high 
PNS activity or low PNS activity in the presence of low SNS activity are not. 
  In line with several studies,122
,221 we found no relationship between 
salivary HPA axis measures and the metabolic syndrome or its 
components. These results suggest that the HPA axis is not dysregulated 
in persons with metabolic syndrome. Most studies that did find 
associations between salivary cortisol measures and several metabolic 
syndrome components were not comparable with our study because they 
studied solely men, used small samples, included only obesity measures, 
or used just one or two morning samples.225
,226 Important work has been 
done by Rosmond et al.237, who reported that in men, a reduced variation 
in the diurnal cortisol pattern was associated with metabolic 
dysregulations and predicted higher risk of cardiovascular events after 5 
years. However, it is unclear how this abnormal cortisol pattern relates to 
our salivary cortisol measures. Other studies have found metabolic 
syndrome to be more frequently accompanied by increased urinary cortisol 
rather than plasma or saliva cortisol (e.g., Ref.122), which could be a result 
of increased cortisol excretion in combination with increased metabolism. 
Alternatively, HPA axis hyperresponsiveness after corticotrophin releasing 
hormone stimulation238 or acute stress might be more strongly related to 
metabolic abnormalities, whereas basal activity remains intact. 
  It is a general belief that the autonomic nervous system and the 
HPA axis stress systems are highly intertwined239 because both systems 
are centrally activated in response to stress, e.g., by the hypothalamus. In 
addition, both stress systems arouse each other: CRH, which drives HPA 
axis activity, also seems to stimulate sympathetic flow,240 and central 
catecholamines, an ANS marker, seem to stimulate the HPA axis.241 
Although many hypotheses linking the two systems have emerged, 
previous studies directly correlating ANS and HPA axis measures under 
resting conditions are scarce. Our results suggest that both systems do not 
correlate very strongly, and only ANS activity is associated with an 
unfavorable metabolic state. Both stress systems are responsive and 
dynamic systems with different temporal courses. Previous studies showed 
that ANS activity remained high after repeated stress, whereas the HPA 
axis was desensitized and did not respond with hyperactivity,242 which 
might explain why the ANS and HPA axis did not correlate in our study. In 
addition, results of a study on the metabolic syndrome in relation to HPA 
axis and ANS measures in a sample of 180 men122 are in accordance with 
ours; they reported strong associations between ANS measures and the 
metabolic syndrome, whereas HPA axis measures were not associated. 
Finally, it is possible that correlations between the ANS and the HPA axis 
become more apparent in response to acute stress but are lower when 
subjects are not experiencing acute stress, such as in our study. 
METABOLIC ABNORMALITIES, 




  Our study had several strengths, including a large sample size and 
multiple measures of the HPA axis and sympathetic as well as 
parasympathetic activity. In addition, it was presented that a specific 
pattern of parallel decrease in parasympathetic and increase in 
sympathetic activity was most strongly associated with metabolic 
dysregulations and the metabolic syndrome. Furthermore, all components 
that constitute the metabolic syndrome were separately analyzed, and the 
inter-correlation of both stress systems was investigated. Finally, our 
sample size enabled us to take important covariates into account. 
However, some limitations have to be acknowledged as well. First, because 
analyses were cross-sectional, our results do not indicate any causal 
direction of the associations found. Future longitudinal studies are 
warranted to further examine the relationship between the HPA axis, the 
ANS and metabolic dysregulations. Second, noncompliance with cortisol 
sampling could have occurred because it was logistically and financially 
not feasible to electronically monitor compliance. 
  To conclude, although the ANS was strongly associated with 
metabolic syndrome and its individual components, the HPA axis was not. 
In particular, a parallel decrease in parasympathetic and increase in 
sympathetic activity were associated with metabolic dysregulations and 
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Dyslipidemia and obesity have been observed in persons with severe 
anxiety or depression, and in tricyclic antidepressant (TCA) users. This 
likely contributes to the higher risk of cardiovascular disease (CVD) in 
anxiety and depressive disorders. We aimed to elucidate whether biological 
stress systems or lifestyle factors underlie these associations. If so, they 
may be useful targets for CVD prevention and intervention.  
  
Methods 
Within 2850 Netherlands Study of Depression and Anxiety (NESDA) 
participants, we evaluated the explaining impact of biological stress 
systems (i.e., the hypothalamic-pituitary-adrenal [HPA] axis, autonomic 
nervous system [ANS] and inflammation) and lifestyle factors (i.e., tobacco 
and alcohol use, and physical activity) on adverse associations of anxiety 
and depression severity and TCA use with high and low-density lipoprotein 
cholesterol, triglycerides, body mass index and waist circumference. 
Through linear regression analyses, percentual change (%Δ) in β was 
determined and considered significant when %Δ>10.  
 
Results 
The inflammatory marker C-reactive protein had the most consistent 
impact (explaining 14 to 53% of the associations of anxiety and depression 
severity and TCA use with lipid and obesity levels), followed by tobacco use 
(explaining 34 to 43% of the associations with lipids). The ANS mediated 
all associations with TCA use (explaining 32 to 61%). The HPA axis 
measures did not explain any of the associations. 
 
Conclusions 
Increased dyslipidemia and (abdominal) obesity risk in patients with more 
severe anxiety disorders and depression may be partly explained by 
chronic low-grade inflammation and smoking. TCAs may increase 
metabolic risk through enhanced sympathetic and decreased 
parasympathetic ANS activity. That the HPA axis had no impact in our 
sample may reflect the possibility that the HPA axis only plays a role in 
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7.1  INTRODUCTION 
The classical cardiovascular disease (CVD) risk factors dyslipidemia (i.e., 
high total, low-density lipoprotein [LDL] cholesterol or triglycerides, or low 
high-density lipoprotein [HDL] cholesterol) and (abdominal) obesity are 
found to be more common in patients with anxiety disorders and 
depression.23-26
,43,45,106,107,200  Previously, we demonstrated that not all 
anxious or depressed patients display higher dyslipidemia and obesity 
risk. Dyslipidemia and obesity appeared to be particularly present in those 
with more severe anxiety or depression symptomatology,117 and in users of 
tricyclic antidepressants (TCAs).150 Dyslipidemia and obesity were not 
related to the use of selective serotonin re-uptake inhibitors (SSRIs) or 
other antidepressants. The associations of dyslipidemia and obesity with 
more severe symptoms of depression and anxiety and with TCA use likely 
contribute to the generally increased prevalence of CVD100
,101 and diabetes 
mellitus243 in persons with depressive and anxiety disorders. In order to 
create anchor points in prevention and treatment of CVD and diabetes, it 
is of importance to understand the underlying mechanisms. 
 Several underlying mechanisms may be involved. Hypothalamic-
pituitary-adrenal (HPA) axis dysregulation67,69 as well as decreased 
parasympathetic and increased sympathetic autonomic nervous system 
(ANS) activity200
,227,244 and elevated inflammatory markers such as C-
reactive protein (CRP), interleukin(IL)-672
,73,200 and tumor necrosis factor-
alpha (TNF-α)199 have been detected in anxiety and depression and among 
TCA users.227
,245 Also, unfavourable lifestyle habits such as increased 
tobacco and alcohol use and decreased physical activity74
,118,128,246-248 have 
been observed in patients with mood disorders. In turn, these HPA 
axis,120,209,249 ANS,250 inflammatory51 and lifestyle75
,97,130 alterations are 
thought to induce dyslipidemia and (abdominal) obesity. Those 
mechanisms could therefore lie in the causal pathway, ultimately 
increasing CVD risk in people with anxiety and depressive disorders. If so, 
they may be useful targets for prevention and intervention. 
  Within the Netherlands Study of Depression and Anxiety (NESDA) 
we aim to identify the mechanisms that underlie the relationship of anxiety 
and depressive severity and TCA use with dyslipidemia and obesity, with 
possible candidates being biological stress system (i.e., HPA axis, ANS and 
inflammation) perturbations or lifestyle (i.e., tobacco or alcohol use and 
physical activity). We are the first to evaluate the role of those potential 
mechanisms in concert, in a large cohort study.  
 
7.2  METHODS 
Subjects 
Subjects participated in the baseline assessment of the Netherlands Study 
of Depression and Anxiety (NESDA), an 8-year longitudinal cohort study 
including 2981 persons aged 18 to 65 years. Subjects were recruited from 
community, primary care, and mental health care in the Netherlands. 
Persons with depressive and anxiety disorders as well as healthy controls 
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were included. For the current study, only cross-sectional baseline data 
were available. The baseline assessment comprised a face-to-face 
interview, written questionnaires and biological measurements. The study 
design has been described in detail elsewhere.95 The study protocol was 
approved by the Ethical Review Board of each participating centre, and all 
subjects signed informed consent at the baseline assessment. 
  For the current analyses, we excluded 40 (1.3%) subjects with 
missing values on anxiety or depression severity or on TCA use (see below), 
and 91 (3.1%) subjects with missing values on lipid or obesity measures 
(see below), which resulted in a sample of 2850 (95.6%) subjects. In 
analyses on TCA use, subjects who used TCAs (n=78) were compared with 
subjects who did not use any antidepressant at all (n=2138), whereas all 
other analyses were conducted in the entire group (n=2850). 
 
Anxiety and depression severity and TCA use 
Anxiety severity was assessed by the 21-item self-report Beck Anxiety 
Inventory (BAI) ranging from 0 to 63.171 Depression severity was assessed 
by the 30-item Inventory of Depressive Symptoms self-report (IDS-SR) 
ranging from 0 to 84.110 TCA use (Anatomical Therapeutic Chemical 
[ATC]111 code N06AA) within the past month was registered by observation 
of drug containers brought in. 
 
Lipid and obesity measures 
HDL and LDL cholesterol, triglycerides, body mass index (BMI) and waist 
circumference (WC) were previously found to be associated with the 
aforementioned anxiety and depression characteristics in NESDA.117
, 150 
HDL, LDL cholesterol and triglyceride levels were determined from fasting 
blood samples using routine standardised laboratory methods. To account 
for medication use, HDL cholesterol, LDL cholesterol and triglyceride 
values were adjusted according to medication effects observed in trials, as 
previously performed.25 Medication use within the past month was 
registered by observation of drug containers brought in, and ATC coded.111 
For persons using fibrates, 0.10 mmol/L was subtracted from HDL 
cholesterol, and 0.67 mmol/L was added to triglycerides. For persons 
using nicotid acid, 0.15 mmol/L was subtracted from HDL cholesterol, and 
0.19 mmol/L was added to triglycerides.167
,168 For persons using LDL-
lowering medication, 0.74 mmol/L was added to LDL cholesterol.194 Height 
and weight were measured to calculate BMI (=weight(kg)/height(m)²). WC 
was measured with a measuring tape at the central point between the 
lowest front rib and the highest front point of the pelvis, upon light 
clothing. The distribution of residuals was normalized by natural log-





IMPACT OF STRESS SYSTEMS AND LIFESTYLE 113 
 
  
Biological stress systems 
The four HPA axis measures included area under the curve with respect to 
the increase (AUCi) and with respect to the ground (AUCg), mean evening 
cortisol and a cortisol suppression ratio after 0.5 mg dexamethasone 
intake. HPA axis measures were based on seven saliva samples taken by 
subjects at home. Details of assessment and analyses of HPA axis 
measures have been described in detail elsewhere.231 The AUCg is an 
estimate of total cortisol secretion over the first hour after awakening, and 
the AUCi is a measure of the dynamic of the cortisol awakening response, 
more related to the sensitivity of the system, emphasizing changes over 
time.234 
  The five ANS measures included heart rate (HR), pre-ejection period 
(PEP) and respiratory sinus arrhythmia (RSA). Assessment and analyses of 
ANS measures are described in detail elsewhere.176 HR is an indicator of 
combined sympathetic (SNS) and parasympathetic (PNS) nervous system 
activity; high PEP reflects low SNS activity; RSA reflects cardiac PNS 
activity. 
 The three inflammation markers included CRP, IL-6 and TNF-α. 
CRP, IL-6 and TNF-α were determined from initially frozen (at -80°C) 
serum. High-sensitivity plasma levels of CRP were measured in duplicate 
by an in-house ELISA based on purified protein and polyclonal anti-CRP 
antibodies (Dako, Glostrup, Denmark). Plasma IL-6 levels were measured 
in duplicate by a high-sensitivity enzyme-linked immunosorbent assay 
(PeliKine CompactTM ELISA, Sanquin, Amsterdam). Plasma TNF-α levels 
were assayed in duplicate at Good Biomarker Science, Leiden, The 
Netherlands, using a high-sensitivity solid phase ELISA (Quantikine® HS 




Number of tobacco (i.e., cigarette, cigar or pipe) and alcohol consumptions 
(i.e., glasses) a day were assessed through standardised questionnaires. 
Physical activity was assessed using the International Physical Activity 
Questionnaire,112 and expressed in 1000 metabolic equivalent of task 
(MET)-minutes in the past week. MET-minutes reflect the ratio of the 
associated metabolic rate for specific activities divided by the resting 
metabolic rate, multiplied by minutes performed activity. 
 
Covariates  
Sociodemographic variables included age and sex. Use of corticosteroids 
(i.e., ATC code H02, R03BA, R03AK and D07, used more than 50% of the 
time), beta-blockers (i.e., ATC code C07, used more than 50% of the time), 
other heart medication (i.e., ATC-codes C01, C02, C03, C04, C05, C08 or 
C09) and anti-inflammatory (i.e., ATC-codes M01A, M01B, A07EB and 
A07EC) medication (no/yes) in the past month was identified.  
 




Data were missing completely at random (MCAR: Little’s MCAR test χ2 = 
140.709, df = 334, p = 1.0) on ANS (n=146; 5.2%), HPA axis (n=936; 
33.1%), inflammation (n=21; 0.7%) and lifestyle (n=151; 5.4%) variables. 
Multiple imputation by the iterative Markov chain method was therefore an 
appropriate way to impute missing data.251 Age, sex, anxiety severity, 
depression severity, medication adjusted HDL, LDL cholesterol and 
triglyceride values, BMI, WC, use of TCAs, corticosteroids, beta-blockers, 
other heart medication and anti-inflammatory medication were considered 
as predictors.  
  Sample characteristics were summarized using means and 
standard deviations for quantitative variables and percentages for 
categorical variables. Linear regression analyses, basically adjusted for 
age, sex and medication use (see Covariates) were conducted to assess the 
basic associations of anxiety severity, depression severity and TCA use (all 
independent variables) with lipid (i.e., HDL and LDL cholesterol and 
triglycerides) and obesity measures (i.e., BMI and WC: all dependent 
variables). This resulted in basically adjusted beta-coefficients (βas). 
Factors that could explain such an association should be associated with 
both the independent and the dependent variable.252 Within the NESDA 
study we previously found that certain biological stress systems and 
lifestyle factors relate to anxiety, depression and TCA use,62,68,69,227,253 as 
well as to lipids and obesity.176 It is therefore feasible that biological stress 
systems and lifestyle factors (partially) explain associations of anxiety 
severity, depression severity and TCA use with lipids and obesity. To study 
this hypothesis, linear regression analyses were repeated, in turn 
including biological stress system (i.e., HPA axis, ANS or inflammation) 
and lifestyle measures (i.e., alcohol or tobacco consumption, or physical 
activity). When biological stress systems or lifestyle influenced βas 
substantially (defined as a change = [βb * 100%]/ βa  of more than 10%, 
i.e., % Δ > 10), the impact of their separate components was additionally 
studied. Then, the joint impact of all significant biological stress system 
and lifestyle mechanisms was studied by including them collectively. In 
order to more thoroughly evaluate the influence of CVD and diabetes, all 
262 subjects with prevalent medicated CVD (i.e., stroke, myocardial 
infarction, angina pectoris or coronary heart disease, as assessed by 
standardized questionnaires and observation of drug containers brought 
in) or diabetes (a glucose value of ≥ 7.0 mmol/L or anti-diabetic medication 
use) were excluded in a sensitivity analysis. To more thoroughly exclude 
the possible effects of medication, all 698 (=24.5%) subjects using 
corticosteroids, anti-inflammatory drugs, beta-blockers, other heart 
medication or lipid-lowering medication were excluded in a second 
sensitivity analysis. In a third sensitivity analysis on anxiety and 
depression severity, all 78 subjects who used TCAs were excluded. All 
statistical analyses were undertaken with SPSS 18.0 (IBM Company, 
Chicago, Illinois, USA). 
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7.3  RESULTS 
Table 1 shows the sample characteristics. The mean age of the sample was 
42.0 years (SD 13.0) and 33.4% were male. 2.7% used TCAs, whereas 
75.0% used no antidepressant at all. 
 
Table 1. Sample characteristics among 2850 subjects with and without anxiety     
              and depressive disorders 
Anxiety and depression severity and TCA use  
         Anxiety severity (BAI score) 12.1       (10.7) 
         Depression severity  (IDS-SR score) 21.5       (14.1) 
         Use of tricyclic antidepressants (%) 2.7 
         No antidepressant use (%) 75.0 
Lipid and obesity measures  
         High-density lipoprotein (HDL) cholesterol (mmol/L)  1.6         (0.4) 
         Low-density lipoprotein (LDL) cholesterol (mmol/L)    3.2         (1.0) 
         Triglycerides (mmol/L) 1.3         (0.8) 
         Lipid lowering medication use (%) 7.1 
         Body mass index (kg/m2) 25.6       (5.0) 
         Waist circumference (cm) 89.1       (14.0) 
Biological stress systems  
         Hypothalamic-Pituitary-Adrenal (HPA) axis   
             AUCg (nmol/L/h) 18.8       (7.2) 
             AUCi (nmol/L/h) 2.3         (6.4) 
             Mean evening level (nmol/L) 5.6         (3.4) 
             Cortisol suppression ratio*  2.8         (1.7) 
         Autonomic Nervous System (ANS)  
             Heart rate (HR, bpm) 72.0       (9.7) 
             Pre-ejection period (PEP, ms) 119.5     (18.3) 
             Respiratory sinus arrhythmia (RSA, ms) 44.4       (25.9) 
         Inflammation  
             C-reactive protein (CRP, mg/L) 2.8         (5.0) 
             Interleukin (IL)-6  (pg/mL) 1.3         (3.1) 
             Tumor necrosis factor-alpha (TNF-α, pg/mL) 1.1         (1.4) 
Lifestyle  
         Tobacco consumptions (n per day) 5.1         (8.8) 
         Alcohol consumptions (glasses per day) 0.9         (1.5) 
         Physical activity (in 1000 MET-minutes last week) 3.5         (3.1) 
Covariates  
         Age (years) 42.0       (13.0) 
         Sex (% men) 33.4 
         Use of corticosteroids (%) 5.5 
         Use of anti-inflammatory medication (%) 4.5 
         Use of beta-blockers (%) 7.9 
         Use of other heart medication (%) 11.5 
         Cardiovascular disease (%) 5.7 
         Diabetes (%) 4.9 
Abbreviations: AUCg, area under the curve with respect to the ground; AUCi, area under the 
curve with respect to the increase; BAI, Beck Anxiety Inventory; IDS-SR, Inventory of 
Depressive Symptoms self-report; MET, metabolic equivalent of task. 
Means (standard deviations) are given for quantitative variables. Percentages are given for 
categorical variables. 
*: cortisol at awakening divided by cortisol at awakening the next day after 0.5 mg 
dexamethasone ingestion. 
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Tables 2 to 4 show the basically adjusted associations of anxiety or 
depression severity and TCA use with lipid and obesity measures (i.e., 
basically adjusted beta-coefficient [βa]), their associations adjusted for 
every biological stress system and lifestyle factor, and the relative change 
of these adjusted βs with respect to βa (i.e., % Δ).  
  The associations of anxiety severity with lipid and especially obesity 
measures (Table 2) were significantly diminished when inflammation was 
taken into account, with a significant individual contribution of mainly 
CRP (% Δ ranged from 14.0 concerning LDL to 33.7 concerning BMI).  HPA 
axis and ANS measures did not influence associations significantly. 
Tobacco use significantly influenced the associations of anxiety severity 
with lipids (% Δ ranged from 33.7 to 41.5). Alcohol use and physical 
activity did not explain these associations substantially. All significant 
mechanisms jointly reduced associations from 29.2 (for WC) to 53.7% (for 
HDL cholesterol). However, these mechanisms did not sufficiently explain 
the associations of anxiety severity with HDL cholesterol, triglycerides, BMI 
and WC: solely the association of anxiety severity with LDL cholesterol lost 
statistical significance. 
  The associations of depression severity with lipid and especially 
obesity measures (Table 3) were significantly diminished by inflammation, 
CRP (by 14.0% concerning LDL to 31.6% concerning BMI) in particular. 
HPA axis and ANS measures did not influence these associations 
significantly. Tobacco use significantly influenced the associations of 
depression severity with lipids (% Δ ranged from 24.6 to 42.6). Alcohol use 
and physical activity did not influence these associations substantially. All 
significant mechanisms jointly reduced associations from 27.4 (for WC) to 
69.1% (for HDL cholesterol), but only the association of depression severity 
with HDL cholesterol lost statistical significance. 
 The associations of TCA use with lipid and especially obesity 
measures (Table 4) were significantly diminished (by 11.0 to 52.9%) by 
CRP. Associations were not significantly influenced by HPA axis measures. 
By addition of ANS measures, a significant reduction was established in 
the associations of TCA use with HDL cholesterol (% Δ = 42.2), LDL 
cholesterol (% Δ = 31.5), triglycerides (% Δ = 60.9), BMI (% Δ = 58.8) and 
WC (% Δ = 34.9). All individual ANS elements (i.e., HR, PEP and RSA) had 
significant impact. Tobacco use significantly influenced the associations of 
TCA use with HDL cholesterol (% Δ = 24.4) and triglycerides (% Δ = 18.8). 
Alcohol use and physical activity did not considerably affect associations. 
These mechanisms sufficiently explained the associations of TCA use with 
HDL cholesterol, triglycerides and BMI, although the associations of TCA 
use with LDL cholesterol and WC did not lose statistical significance.  
  Analyses on the original data (i.e., excluding subjects with imputed 
data; data not shown) showed largely similar results as compared to the 
analyses on multiple imputated data. Sensitivity analyses in which all 262 
subjects with CVD or diabetes were excluded, sensitivity analyses in which 
 
  
           Table 2. Influence of biological stress systems and lifestyle factors on the relationship of anxiety severity with lipids and obesity (n=2850) 
 HDL cholesterol LDL cholesterol Triglycerides Body mass index Waist circumference  
 β % Δb Β % Δb β % Δb Β % Δb β % Δb 
Anxiety severitya  -.082**  .050*  .098**  .089**  .096**  
Adjusted for all biological stress systems -.057* -30.5 .043* -14.0 .065** -33.7 .067** -24.7 .073** -24.0 
    HPA axis -.079** -3.7 .049* -2.0 .093** -5.1 .092** +3.4 .099** +3.1 
    ANS -.080** -2.4 .050* +0.0 .090** -8.2 .093** +4.5 .097** +1.0 
    Inflammationc -.059** -28.0 .043* -14.0 .072** -26.5 .056* -37.1 .065** -32.3 
        CRP -.064** -21.9 .043* -14.0 .075** -23.5 .059** -33.7 .068** -29.2 
        IL-6 -.075** -8.5 .048* -4.0 .092** -6.1 .080** -10.1 .087** -9.4 
        TNF-α -.076** -7.3 .050* +0.0 .093** -5.1 .085** -4.5 .092** -4.2 
Adjusted for lifestylec -.038* -53.7 .031 -38.0 .062** -36.7 .093** +4.5 .092** -4.2 
    Tobacco use  -.048* -41.5 .033 -34.0 .065** -33.7 .097** +9.0 .094** -2.1 
    Alcohol use -.081** -1.2 .050* -0.0 .098** -0.0 .089** -0.0 .096** -0.0 
    Physical activity -.080** -2.4 .050* -0.0 .094** -4.1 .087** -2.2 .094** -2.1 
Adjusted for significant mechanisms -.038* -53.7 .029 -42.0 .052* -46.9 .057** -35.9 .068** -29.2 
Abbreviations: ANS, autonomic nervous system; β, standardized beta by multivariate linear regression analysis; CRP, C-reactive protein; HDL, high-
density lipoprotein; HPA, hypothalamic-pituitary-adrenal; IL-6, interleukin-6; LDL, low-density lipoprotein; TNF-α, tumor necrosis factor-alpha.  
a: basically adjusted for age, sex and medication use.  
b: percent change (% Δ) of β with respect to basically adjusted βa as an effect size of the magnitude of influence. Percentages >10% have been marked 
bold and are considered as significant. 
c: when a biological stress system or lifestyle influenced βas substantially (i.e., % Δ > 10), the impact of their separate components was additionally 
studied. 
*: statistically significant β at the p<.05 level. 













Table 3. Influence of biological stress systems and lifestyle factors on the relationship of depression severity with lipids and obesity (n=2850) 
 HDL cholesterol LDL 
cholesterol 
Triglycerides Body mass index Waist 
circumference  
 β % Δb β % Δb β % Δb Β % Δb β % Δb 
Depression severitya  -.068**  .057*  .085**  .098**  .102**  
Adjusted for all biological stress systems -.041* -39.7 .049* -14.0 .054* -36.5 .073** -25.5 .077** -24.5 
    HPA axis -.065** -4.4 .056* -1.7 .081** -4.7 .101** +3.1 .106** +3.9 
    ANS -.067** -1.5 .057* +0.0 .081** -4.7 .103** +5.1 .105** +2.9 
    Inflammationc -.043* -36.8 .049* -14.0 .057** -32.9 .062** -36.7 .069** -32.3 
        CRP -.049* -27.9 .049* -14.0 .061** -28.2 .067** -31.6 .074** -27.4 
        IL-6 -.060** -11.8 .054* -5.3 .078** -8.2 .087** -11.2 .092** -9.8 
        TNF-α -.061** -10.3 .057** -0.0 .080** -5.9 .093** -5.1 .098** -3.9 
Adjusted for lifestylec -.028 -58.8 .040* -29.8 .053* -37.6 .099** +1.0 .097** -4.9 
    Tobacco use  -.039* -42.6 .043* -24.6 .057* -32.9 .104** +6.1 .101** -1.0 
    Alcohol use -.066** -2.9 .057* +0.0 .086** +1.2 .097** -1.0 .102** -0.0 
    Physical activity -.066** -2.9 .057* +0.0 .079** -7.1 .096** -2.0 .099** -2.9 
Adjusted for significant mechanisms -.021 -69.1 .038* -33.3 .041* -51.8 .064** 34.7 .074** -27.4 
Abbreviations: ANS, autonomic nervous system; β, standardized beta by multivariate linear regression analysis; CRP, C-reactive protein; 
HDL, high-density lipoprotein; HPA, hypothalamic-pituitary-adrenal; IL-6, interleukin-6; LDL, low-density lipoprotein; TNF-α, tumor necrosis 
factor-alpha.  
a: basically adjusted for age, sex and medication use.  
b: percent change (% Δ) of β with respect to basically adjusted βa as an effect size of the magnitude of influence. Percentages >10% have been 
marked bold and are considered as significant. 
c: when a biological stress system or lifestyle influenced βas substantially (i.e., % Δ > 10), the impact of their separate components was 
additionally studied. 
*: statistically significant β at the p<.05 level. 










Table 4. Influence of biological stress systems and lifestyle factors on the relationship of TCA use with lipids and obesity (n=2203) 
  HDL 
cholesterol 




 n^ β % Δb β % Δb β % Δb β % Δb β % Δb 
TCA usea 78 -.045*  .073**  .069*  .051*  .083**  
Adjusted for all biological stress systems  -.019 -57.8 .050* -31.5 .017 -75.4 .013 -74.5 .046* -44.6 
    HPA axis  -.046* +2.2 .073** +0.0 .066* -4.3 .052* +2.2 .083** +0.0 
    ANSc  -.026 -42.2 .050* -31.5 .027 -60.9 .021 -58.8 .054* -34.9 
        HR  -.029 -35.6 .057* -21.9 .030 -56.5 .030 -41.2 .062** -25.3 
        PEP  -.040* -11.1 .062* -15.1 .059* -14.5 .033 -35.3 .068** -18.1 
        RSA  -.039* -13.3 .063* -13.7 .057* -17.4 .043 -15.7 .074** -10.8 
    Inflammationc  -.025 -44.4 .066* -9.6 .046* -33.3 .023 -54.9 .057* -31.3 
        CRP  -.029 -35.6 .065* -11.0 .048* -30.4 .024 -52.9 .059** -28.9 
        IL-6  -.042* -6.7 .072** -1.4 .066** -4.3 .047* -7.8 .079** -4.8 
        TNF-α  -.039* -13.3 .073** -0.0 .065** -5.8 .048* -5.9 .080** -3.6 
Adjusted for lifestylec  -.020 -55.6 .065* -11.0 .054* -21.7 .047* -7.8 .079** -4.8 
    Tobacco use   -.034 -24.4 .067** -8.2 .056* -18.8 .052* +2.2 .081** -2.4 
    Alcohol use  -.037* -17.8 .072** -1.4 .071** +2.9 .048* -5.9 .083** +0.0 
    Physical activity  -.044* -2.2 .073** -0.0 .066** -4.3 .051* +0.0 .082** -1.2 
Adjusted for significant mechanisms   .003 -93.3 .048* -34.2 .012 -82.6 .013 -74.5 .046* -44.6 
Abbreviations: ANS, autonomic nervous system; β, standardized beta by multivariate linear regression analysis; CRP, C-reactive protein; HDL, 
high-density lipoprotein; HPA, hypothalamic pituitary, adrenal; HR, heart rate; IL-6, interleukin-6; LDL, low-density lipoprotein; PEP, pre-
ejection period; RSA, respiratory sinus arrhythmia; TCA, tricyclic antidepressant; TNF-α, tumor necrosis factor-alpha.  
a: basically adjusted for age, sex and medication use.  
b: percent change (% Δ) of β with respect to basically adjusted βa as an effect size of the magnitude of influence. Percentages >10% have been 
marked bold and are considered as significant. 
c: when a biological stress system or lifestyle influenced βas substantially (i.e., % Δ > 10), the impact of their separate components was 
additionally studied. 
^: number of subjects that used TCAs. 
*: statistically significant β at the p<.05 level. 
**: statistically significant β at the p<.001 level. 
Subjects who used TCAs (n=78) were compared with subjects who did not use antidepressants at all (n=2138). Subjects that used other 
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all 698 subjects using corticosteroids, anti-inflammatory drugs, beta-
blockers, other heart medication or lipid-lowering medication were 
excluded, and sensitivity analyses on anxiety and depression severity in 
which all 78 subjects who used TCAs were excluded, also gave largely 
similar results (data not shown). 
  
7.4  DISCUSSION 
In this large study, we investigated the impact of biological stress systems 
(i.e., HPA axis, ANS and inflammation) and lifestyle factors (i.e., tobacco or 
alcohol use, and physical activity) on the associations of anxiety and 
depression severity and TCA use with dyslipidemia and obesity. The 
increased risk of dyslipidemia and especially of obesity among persons 
with more severe anxiety and depression symptoms may have been 
mediated by low-grade inflammation as marked by higher levels of CRP. 
Our data also suggest that lipid levels in persons with more severe 
symptoms of depression or anxiety were adversely affected by current 
smoking, which was more common among this group. We also found 
support for the hypothesis that TCA users are prone to obesity and 
dyslipidemia through the combined effects of inflammation, tobacco use 
and ANS alterations. HPA axis functioning did not explain increased 
dyslipidemia and obesity risk among those with severe anxiety or 
depression symptoms and in TCA users. 
 The higher risk of dyslipidemia and obesity among persons with 
more severe anxiety and depression symptoms may have been mediated by 
low-grade inflammation as defined by the inflammatory marker CRP 
among the anxious and depressed. Higher levels of inflammation have 
been observed in persons with anxiety73 and depression.72
,199,200,254 This is 
supported by an overrepresentation of inflammation genes in depression255 
and a higher risk of depression in users of pro-inflammatory medication 
like interferon-alpha.256 In turn, inflammation may induce dyslipidemia, by 
stimulating lipid release into the blood stream to fuel host defense and to 
block cytotoxic effects of inflammogens by binding to them.51 Adipose 
tissue cells are highly sensitive to inflammatory signals, and release 
inflammatory markers themselves,257 thereby further stimulating 
dyslipidemia. So, complex and bidirectional associations exist between 
inflammation, psychopathology, dyslipidemia and obesity. Consequently, 
increased inflammation among the severely anxious and depressed may 
induce dyslipidemia and obesity. The fact that we found CRP and not the 
cytokines IL-6 or TNF-α to be important, might be explained by the fact 
that CRP is the strongest inflammatory correlate of at least depression,254 
and because CRP is the most accurate and stable marker of systemic 
inflammation.258 This probably made the results on CRP more cohesive. 
  The lifestyle factor tobacco use, and not alcohol use or physical 
activity, may also elucidate part of the association of depression and 
anxiety severity with dyslipidemia. Persons with anxiety disorders, and to a 
greater extent those with depression, smoke much more often than those 
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without psychopathology.118 This is possibly due to an increased risk of 
smoking initiation, decreased cessation motivation, self-medication by 
nicotine197 or shared (e.g., genetic) etiological factors.259 Smoking is well 
known to detrimentally influence lipid levels.75
,97 It thus is a feasible 
mechanism in the association between psychopathology and dyslipidemia, 
and smoking cessation may be of great benefit. 
  The joint impact of CRP and tobacco use on the associations of 
anxiety and depression severity and TCA use with lipid measures was 
generally lower than the sum of their separate influences. This suggests 
some mechanistic overlap. Smoking is a major environmental factor that 
raises CRP levels.260 Tobacco use might therefore have induced part of the 
increased CRP levels in psychopathology, which successively triggered 
dyslipidemia. Smoking cessation might therefore additionally reduce 
dyslipidemic effects through a diminution of inflammatory reactions. 
  Dyslipidemia and obesity in TCA users may have been partly 
mediated by increased CRP levels and smoking, but also by ANS 
alterations among TCA users. TCA use has already been associated with 
increased CRP levels.60 Also, persons with depressive symptomatology who 
smoke, more often use antidepressants than depressed non- or former 
smokers.261 As to the ANS, TCAs might reduce parasympathetic activity 
while increasing sympathetic activity,227
,244 which may also lead to 
metabolic alterations like dyslipidemia and obesity.176 
  Dyslipidemia and obesity among persons with severe anxiety and 
depression symptoms and in TCA users were not explained by HPA axis 
alterations. HPA axis deregulations have been associated though with 
anxiety and depressive disorders,67
,68,262 and with TCA use.263 HPA axis 
deregulations have also been associated with visceral adipose tissue 
accumulation as well as with (subsequent) dyslipidemia.209,120,249 Yet, 
several former studies on the association of HPA axis activity with 
psychopathology264 or with dyslipidemia and obesity221,176 did not report 
any association. The inconsistencies in earlier research in addition to our 
null finding might indicate that HPA axis alterations only play a role in 
certain subgroups.25 It is also possible that the HPA axis only relates 
anxiety and depression to dyslipidemia and obesity in acute stress 
situations and not under basal conditions, such as in our study. 
Otherwise, urinary rather than salivary cortisol might play a role.122 
 Generally, no combination of putative pathways wholly seemed to 
explain the associations under study, since most associations of anxiety 
and depression severity and TCA use with lipid and most strongly with 
obesity measures remained statistically significant after adjustment for all 
influential mechanisms. Other mechanisms, such as poor diet rich in 
carbohydrates and saturated fat among those with anxiety and 
depression,118 might (partly) account for residual associations. Also, 
insomnia and hypersomnia in patients with depression may have 
promoted obesity and dyslipidemia,265-267 possibly through altered 
neuroendocrine processes such as insulin resistance.
268
 
122 CHAPTER 7 
 
 
There are some limitations of our study that need to be discussed. A first 
limitation is the cross-sectional design, which did not allow us to make 
causal inferences on how psychopathology, dyslipidemia, obesity and 
biological stress systems or lifestyle are temporarily intertwined. Second, 
the variable concentration of some biological stress markers may have 
distorted our results. Third, we were unable to take all known biological 
stress parameters into account. Lastly, we did not have information on 
other possible mechanisms such as dietary factors. Strengths of our study 
are the large, psychopathology-based sample, and the assessment of 
various psychopathological characteristics as well as lipid and obesity 
measures. HPA axis, ANS and inflammatory factors were measured 
through well-validated methods. Moreover, we were the first to assess the 
role of various biological stress systems and lifestyle factors in concert. 
  In conclusion, the current study provides evidence for an 
influential role of low-grade inflammation (as defined by increased CRP 
levels) in the associations of anxiety and depression and TCA use with 
(abdominal) obesity and dyslipidemia, and of tobacco use in the 
association of psychopathology with dyslipidemia. ANS alterations may 
have played an additional role in dyslipidemia and obesity among TCA 
users. HPA axis functioning was not a significant mediator. Although our 
findings need to be confirmed, they increase our understanding of the 
possible mechanisms behind the increased dyslipidemia and obesity risk 
in mood disorders. If these mechanisms are indeed fundamental, 
interventions that dampen inflammation (e.g., smoking cessation, physical 
activity or antioxidant supplementation) and normalize ANS function (e.g., 
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Personality and childhood trauma may affect cardiovascular disease (CVD) 
risk. However, evidence for an association with metabolic risk factors for 
CVD is limited and ambiguous. Moreover, despite their interrelatedness, 
personality and childhood trauma were not yet studied simultaneously. 
Therefore, we aimed to explore whether personality and childhood trauma 
are correlates of metabolic risk factors.  
 
Methods 
Among 2755 participants of the Netherlands Study of Depression and 
Anxiety (NESDA), we investigated through linear regression models 
whether Big Five personality traits (i.e., extraversion, openness, 
agreeableness, neuroticism and conscientiousness) and childhood trauma 
type (i.e., emotional neglect, and psychological, physical and sexual abuse) 
were correlates of metabolic risk factors (i.e., lipids, waist circumference 
(WC), glucose and blood pressure). Basic covariates (i.e., age, sex and 
income level), lifestyle, severity of depressive symptoms and years of 
education were taken into account. 
 
Results 
Openness was the most robust favorable correlate, and sexual abuse was 
an unfavorable correlate of lipids and WC, and of overall metabolic risk (β 
= .035; p = .04 and β = –.070; p <.001, respectively). 
  
Conclusions 
People with a low openness trait and those who experienced childhood 
sexual abuse are at higher risk of dyslipidemia and abdominal obesity.  
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8.1  INTRODUCTION 
Cardiovascular disease (CVD) is a major and growing global health 
problem.98 Therefore, it is important to identify persons at increased risk of 
CVD. Lower levels of conscientiousness76
, 269-271 and openness,77 and 
higher levels of neuroticism269 have been related to CVD and general 
morbidity and mortality. Furthermore, emotional neglect, and sexual or 
physical abuse during infancy increase risk of CVD in adult women.272  
  Personality and childhood trauma may affect risk of CVD through 
changes in metabolic risk factors for CVD that include dyslipidemia, 
abdominal obesity, hyperglycemia and hypertension. As these factors 
collectively predict over half of CVD cases,16
,17 they are important targets in 
CVD prevention and treatment.18 Therefore, it is valuable to know which 
personality and childhood trauma characteristics are their strongest 
correlates. 
  Personality may influence metabolic risk factors97 through 
engagement in healthier lifestyles.78 This might for instance be via the 
search for external stimulation and social events, vulnerability for 
depressive symptoms,79 and amount of self-discipline.80
,81 Trauma may 
increase risk of CVD through a related lower socio-economic status and 
unhealthy lifestyles, a higher prevalence of psychopathology due to a 
fragile character structure,82-84 or by adverse (early) programming of the 
biological stress system,120
,273,274 for instance accompanying posttraumatic 
stress disorder.275
,276  
   Several studies on the association of personality traits or childhood 
trauma with metabolic risk factors have been reported. Openness277 and 
conscientiousness277
,278 have been favorably associated with lipid values 
and abdominal obesity. However, extraversion,279-283 neuroticism279-284 and 
agreeableness283
,284 were ambiguously related to lipids, obesity and blood 
pressure. Neglect,85-87 as well as emotional,85 physical88 and sexual 
abuse87
,89,90 during childhood were related to (abdominal) obesity in 
adulthood. 
 Personality and trauma are bi-directionally related. Twin studies 
showed that over 20 percent of the variance in (traumatic) life events is 
due to genetic influences91 that are largely mediated by personality.92 
Personality shapes ones personal environment and thus protects for or 
facilitates the experience of certain (traumatic) events.92 Also, personality 
affects the appraisal of traumatic events.93 The other way around, trauma 
affects ones perceptions and beliefs. As perceptions and beliefs are 
building blocks of personality structure, trauma may facilitate unfavorable 
personality development.94  
  No previous studies jointly investigated both personality 
characteristics and childhood trauma in relation to metabolic risk factors. 
The current study is based on a large cohort of subjects with extensive 
assessment of personality and childhood trauma. We aim to explore 
whether Big Five personality traits and childhood trauma are independent 
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correlates of metabolic risk factors for CVD within the Netherlands Study 
of Depression and Anxiety (NESDA).  
 
8.2  METHODS 
Subjects 
Subjects participated in the baseline assessment of the Netherlands Study 
of Depression and Anxiety (NESDA), a cohort study including 2981 
persons aged 18 to 65 years. NESDA subjects were recruited from 
community, primary care and specialized mental health care, and selected 
to represent a range of depressive and anxiety symptoms with subjects 
having no depressive or anxiety disorder (‘controls’), having had disorders 
in the past, or having a current depressive or anxiety disorder. All subjects 
completed the baseline assessment, which comprised a face-to-face 
interview, written questionnaires and biological measurements. A detailed 
description of the study design can be found elsewhere.95 For the current 
study, only cross-sectional baseline data were available. The study protocol 
was approved by the Ethical Review Board of each participating centre, 
and all subjects signed informed consent. 
  Earlier, we found that persons using tricyclic antidepressants 
(TCAs) have a different metabolic risk profile than other NESDA 
subjects.150 We did not find any associations between the use of other 
antidepressants and metabolic risk factors. The distinctive profile in TCA 
users is likely induced by TCA side effects, as it was not explained by more 
severe depressive symptoms in TCA users. Because of their distinct 
metabolic risk factor profile, TCA users were excluded from the analyses. 
Of the remaining 2901 subjects, subjects with missing values on 
personality traits, childhood trauma or metabolic risk factors (see below) 
were excluded, resulting in the current sample of 2755 subjects. Included 
subjects (n=2755) did not differ significantly from excluded subjects 
(n=226) with regard to age (mean 41.9 versus 42.1, p = .80), sex (both 
33.6% male, p = 1.00), or CVD prevalence (6.0% versus 4.9%, p = .48). 
 
Personality traits 
The Big Five personality traits extraversion, openness, agreeableness, 
neuroticism and conscientiousness were measured with the Dutch 
version285 of the NEO-Five Factor Inventory (NEO-FFI).286 The NEO-FFI was 
sent to participants by mail, and completed before the start of the 
interview. The NEO-FFI consists of 60 five-point Likert-scaled items, with 
answer categories from 0 (“strongly disagree”) to 4 (“strongly agree”). Each 
of the personality traits is addressed by 12 items. Cronbach’s alphas were 
.84 for extraversion, .69 for openness, .71 for agreeableness, .90 for 
neuroticism, and .75 for conscientiousness in the current sample. Those 
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Frequency of emotional neglect, psychological abuse, physical abuse and 
sexual abuse was assessed retrospectively by the Childhood Trauma 
Interview that was previously used in the Netherlands Mental health 
Survey and Incidence Study (NEMESIS).13
,82 Subjects were asked the 
following questions concerning their first 16 years of life: 1) ”Were you 
emotionally neglected, meaning nobody ever listened to you at home, your 
problems and experiences were ignored, and you felt that there was no 
attention or support from your parents?”, 2) “Were you psychologically 
abused, meaning being yelled at, falsely punished, subordinated to your 
siblings, or being blackmailed?”, 3) “Were you being abused physically, 
meaning being hit, kicked, beaten up or other types of physical abuse?”, 
and 4) “Were you sexually abused, meaning being touched or having to 
touch someone in a sexual way against your will?”. Scores for each 
question were categorized into never (score 0), once / sometimes (score 1) 
or regular / (very) often (score 2). 
 
Metabolic risk factors 
High-density lipoprotein (HDL) cholesterol, triglycerides, waist 
circumference (WC), glucose, diastolic (DBP) and systolic (SBP) blood 
pressure, and an overall metabolic risk factor score were included as 
metabolic risk factors. Blood samples were taken after a mean of 11:14 h 
overnight fasting period (SD=1:50 h). HDL cholesterol and triglycerides 
were determined according to routine laboratory methods. To account for 
use of lipid-lowering medication, HDL cholesterol and triglyceride values 
were adjusted according to published changes, as has been done before.25 
Medication use within the past month was registered by observation of 
drug containers brought in, and ATC coded.111 0.10 mmol/L was 
subtracted from HDL cholesterol and 0.67 mmol/L was added to 
triglycerides for persons using fibrates.167
,168 HDL cholesterol was lowered 
by 0.15 mmol/L, and 0.19 mmol/L was added to triglycerides for persons 
using nicotid acid. WC was measured with a measuring tape at the central 
point between the lowest front rib and the highest front point of the pelvis, 
upon light clothing. Glucose levels were determined by routine laboratory 
methods. For persons using anti-diabetic medication with a glucose level 
below 7.0 mmol/L [126 mg/dL] a value of 7.0 mmol/L [126 mg/dL] was 
used in the analyses, as was done before.25 DBP and SBP were both 
averaged over two measurements during supine rest on the right arm by 
the OMRON M4 IntelliSense (HEM-752A, Omron Healthcare, Inc., 
Bannockburn, Illinois, US). For persons using antihypertensive 
medication, 5 mmHg was added to DBP, and 10 mmHg to SBP, as 
described previously.25 These values represent the average decline in blood 
pressure in antihypertensive medication trials.169
,170 In order to normalize 
residuals, HDL cholesterol, triglyceride, WC, glucose, DBP and SBP levels 
were naturally log-transformed. As a measure of severity of metabolic 
abnormalities, a continuous overall metabolic risk score was computed by 
130 CHAPTER 8 
 
 
mediating z-scores (i.e., standardized scores) of a HDL cholesterol and 
triglycerides index (i.e., (-zHDL cholesterol + zTriglycerides) / 2), WC, 
glucose, and a blood pressure index (i.e., (zDBP + zSBP) / 2).  
 
Covariates 
Sociodemographic variables included age, sex and income level. Prevalent 
medicated CVD (i.e., stroke, myocardial infarction, angina pectoris or 
coronary heart disease) was assessed by standardized questionnaires and 
observation of drug containers brought to the interview. Personality and 
childhood trauma affect lifestyle,80
,81 and thereby metabolic risk 
factors.78
,97 Therefore, lifestyle factors were taken into account; number of 
tobacco (i.e., cigarettes, cigars or pipe) and alcohol consumptions a day were 
assessed through standardized questionnaires; physical activity was 
assessed using the International Physical Activity Questionnaire,112 and 
expressed in units of 1000 metabolic equivalent of task (MET)-minutes in 
the past week. MET minutes reflect the ratio of the associated metabolic 
rate for specific activities divided by the resting metabolic rate, multiplied 
by minutes performed activity. Since depression is associated with 
personality,79 childhood trauma82 and metabolic risk factors,117
,150 
depression severity - as assessed by the 30-item Inventory of Depressive 
Symptoms self-report (IDS-SR)133 ranging from 0 to 84 - was taken into 
account as an additional covariate. Years of education were also included 
as an additional covariate. 
 
Statistical analyses 
Sample characteristics were summarized using means and standard 
deviations for normally distributed quantitative variables, medians and 
inter-quartile ranges for non-normally distributed quantitative variables, 
and percentages for categorical variables. Correlations between metabolic 
risk factors (except for the overall metabolic risk score) were calculated by 
Pearson’s correlation coefficient. Separate associations of every personality 
trait, and each type of childhood trauma with individual continuous 
metabolic risk factors and with the overall metabolic risk score were 
assessed by linear regression analyses. Analyses were adjusted for age, 
sex, income and CVD, and for smoking, alcohol use and physical activity. 
To determine the relative importance of personality traits and childhood 
trauma, for all metabolic risk factors regression analyses were carried out, 
adjusted for age, sex, income, CVD, smoking, alcohol use and physical 
activity. Personality traits and childhood trauma types with p<.10 in the 
preceding separate analyses were entered simultaneously into the 
regression model. Adjusted R² was calculated to indicate the amount of 
variance in metabolic risk factors that was explained by the regression 
model. To explore the impact of depressive symptoms on the associations 
of personality and childhood trauma with metabolic risk factors, the latter 
models were additionally adjusted for depression severity. As openness is 
suggested to be related to intelligence,288 it was additionally investigated 
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whether years of education accounted for multivariate associations of 
openness with metabolic risk factors. And since personality traits could 
affect metabolic risk factors especially in those who experienced childhood 
trauma, their interaction was tested by entering personality trait x 
childhood trauma interaction terms in fully adjusted models. In order to 
more thoroughly evaluate the influence of CVD, all 166 subjects with CVD 
(see Covariates) were excluded in sensitivity analyses. All statistical 
analyses were undertaken with SPSS 17.0 (IBM Company, Chicago, 
Illinois, USA). 
 
8.3  RESULTS 
Sample characteristics are presented in Table 1. The mean age of the 
sample was 41.9 years (SD = 13.1) and 33.6% was male. 6.0% of the 
sample had prevalent CVD. Emotional neglect was more frequently 
experienced regular or (very) often (20.4%) than once or sometimes 
(17.6%). Psychological, physical and sexual abuse were more frequently 
experienced once or sometimes (13.4, 9.9 and 9.3% respectively) than 
regular or (very) often (10.8, 2.8 and 1.3% respectively). 
Correlations between metabolic risk factors ranged from -.09 
(between HDL cholesterol and DBP) through .78 (between DBP and SBP). 
Table 2 shows the separate associations of personality traits and childhood 
trauma with continuous metabolic risk factors. Since associations did not 
differ importantly between the model that was adjusted for age, sex, 
income and CVD, and the model that was additionally adjusted for 
smoking, alcohol use and physical activity, solely the crude and the fully 
adjusted models are reported. In the fully adjusted model, extraversion 
was associated with a higher SBP. Openness was associated with higher 
HDL cholesterol levels, and with lower triglycerides, WC, SBP and overall 
metabolic risk. Agreeableness was associated with lower triglyceride levels, 
WC and overall metabolic risk. Neuroticism was associated with a higher 
DBP. Conscientiousness was associated with none of the metabolic risk 
factors. Regarding childhood traumas, emotional neglect was associated 
with lower SBP. Psychological and physical abuse both were related to 
lower levels of HDL cholesterol and to a higher WC and overall metabolic 
risk. Sexual abuse was associated with lower levels of HDL cholesterol, 
and with higher WC and overall metabolic risk. The amplification of 
associations of sexual abuse with HDL cholesterol, WC and overall 
metabolic risk, and of emotional neglect with SBP after adjustment, was 
determined by childhood traumas being more prevalent among women. 
Figure 1 illustrates that HDL cholesterol levels increase, and triglycerides 
and WC decline with a higher score on openness. It also exemplifies that 
HDL cholesterol diminishes and WC increase with a higher frequency of 
childhood sexual abuse. 
   In Table 3, the multivariate association model is presented. 
Personality traits and childhood trauma types with p<.10 in separate 
linear regression analyses (see adjusted model in Table 2) were entered  
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Table 1. Sample characteristics in 2755 subjects 
Characteristics  
Age 41.9      (13.1) 
Sex (% men) 33.6 
Income (per month, in Euros) 2100.0  (1300.0-2900.0) 
CVD (%) 6.0 
Tobacco consumptions (n per day) 0.0       (0.0-8.6) 
Alcohol consumptions (n per day) 0.4       (0.02-1.3) 
Physical activity (1000 MET-minutes last week) 3.0       (1.4-4.9) 
Depression severity (IDS-SR score) 19.0     (9.0-31.0) 
Metabolic risk factors  
    HDL cholesterol (mmol/L)a 1.6       (1.3-1.9) 
     Triglycerides (mmol/L)b 1.1       (0.8-1.5) 
     Lipid-lowering medication use (%) 6.9 
     Waist circumference (cm) 87.0     (79.0-97.0) 
     Glucose (mmol/L)c 5.0       (4.7-5.5) 
     Antidiabetic medication use (%) 3.2 
     Diastolic blood pressure (mmHg) 80.0     (73.5-88.5) 
     Systolic blood pressure (mmHg) 132.0   (121.5-147.5) 
     Antihypertensive medication use (%) 14.4 
Personality traits  
     Extraversion 25.0     (7.3) 
     Openness 26.2     (6.0) 
     Agreeableness 31.8     (5.3) 
     Neuroticism 24.1     (9.4) 
     Conscientiousness 30.2     (6.1) 
Childhood trauma  
        Emotional neglect (%)  
            Once / sometimes 17.6 
            Regular / (very) often 20.4 
        Psychological abuse (%)  
            Once / sometimes 13.4 
            Regular / (very) often 10.8 
        Physical abuse (%)  
            Once / sometimes 9.9 
            Regular / (very) often 2.8 
        Sexual abuse (%)  
            Once / sometimes 9.3 
            Regular / (very) often 1.3 
Means (standard deviations) and medians (inter-quartile ranges) are given  
respectively for normally and non-normally distributed quantitative 
variables. 
Percentages are given for categorical variables.  
a To convert to mg/dL, multiply by 39; b To convert to mg/dL, multiply by 
89;  
c To convert to mg/dL, multiply by 18 
Abbreviations: CVD, cardiovascular disease; HDL, high-density  
lipoprotein; IDS-SR,  Inventory of Depressive Symptoms self-report;  




Table 2. Separate crude associations of personality traits and childhood trauma with metabolic risk factors in 2755 subjects 
 HDL 
cholesterol 
Triglycerides WC Glucose DBP SBP Overall 
metabolic risk   
 βa p βa p βa p βa p βa p βa p βa p 
Crude               
Personality traits               
  Extraversion  .050 .01 -.061 .001 -.066 .001 -.070 <.001 -.077 <.001 -.037 .05 -.087 <.001 
  Openness  .098 <.001 -.074 <.001 -.131 <.001 -.043 .02 -.065 .001 -.079 <.001 -.119 <.001 
  Agreeableness  .136 <.001 -.099 <.001 -.115 <.001 -.062 .001 -.031 .11 -.045 .02 -.135 <.001 
  Neuroticism -.008 .67 -.004 .82 -.043 .03 -.053 .01 -.025 .18 -.100 <.001 -.042 .03 
  Conscientiousness  .049 .01 -.028 .15  .001 .96  .019 .31  .011 .56  .052 .01 -.008 .66 
Childhood trauma                
  Emotional neglect  .029 .12  .014 .46  .042 .03  .066 .001  .049 .01 -.011 .57  .045 .02 
  Psychological abuse -.032 .09  .041 .03  .083 <.001  .062 .001  .046 .02  .012 .51  .082 <.001 
  Physical abuse -.040 .04  .043 .02  .071 <.001  .038 .05  .021 .28  .006 .73  .069 <.001 
  Sexual abuse -.006 .75  .008 .66  .022 .24  .004 .85  .022 .25 -.041 .03  .015 .43 
a β coefficients indicate the standardised beta by linear regression analysis. Statistically significant (p<.05) associations are marked bold. 
b Adjusted for age, sex, income, CVD, tobacco use, alcohol use and physical activity. 













Table 3. Multivariate association model of personality traits and childhood trauma in relation to metabolic risk factors in 2755 subjects  
 HDL cholesterol Triglycerides WC Glucose DBP SBP Overall 
metabolic risk   
 βa p βa p βa p βa p βa p βa p βa P 
Personality traits               
  Extraversion            .030 .08   
  Openness .071 <.001 -.036 .04 -.092 <.001   -.031 .07 -.040 .01 -.070 <.001 
  Agreeableness .018 .32 -.041 .03 -.023 .20       -.031 .06 
  Neuroticism      .002 .93    .040 .02     
  Conscientiousness               
Childhood trauma                
  Emotional neglect   -.034 .06        -.038 .03   
  Psychological abuse -.018 .37    .042 .03  .031 .07      .033 .08 
  Physical abuse -.012 .56    .025 .21        .019 .31 
  Sexual abuse -.043 .02     .041 .02         .035 .04 
Adjusted R2  .22   .16   .29   .21   .21   .29   .34  
a β coefficients indicate the standardised beta by enter method linear regression analysis. Solely personality traits and childhood trauma types with 
p<.10 in separate analyses (see Table 2) were included. Statistically significant (p<.05) associations are marked bold. 
Analyses were adjusted for age, sex, income, CVD, tobacco use, alcohol use and physical activity. 
Abbreviations: CVD, cardiovascular disease; DBP, diastolic blood pressure; HDL, high-density lipoprotein; SBP, systolic blood pressure; WC, waist 
circumference.  
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The mean levels on logarithmic scales (with error bars representing standard errors) for HDL cholesterol, triglycerides and  
waist circumference according to categories of openness and for HDL cholesterol and waist circumference according to  
categories of childhood sexual abuse. The dotted lines indicate regression lines. The size of each square is proportional  
to the number of subjects. β coefficients and their p values indicate standardized betas by linear regression analyses.  






136 CHAPTER 8 
 
 
simultaneously. The model was adjusted for age, sex, income, CVD, 
smoking, alcohol use and physical activity. Models were additionally 
adjusted for depression severity (data not shown). Openness was 
significantly associated with higher HDL cholesterol levels, and with lower 
triglycerides, WC, SBP and overall metabolic risk. Additional adjustment 
for depression severity did not reduce these associations considerably (i.e., 
by less than 10%). Agreeableness was associated with lower triglyceride 
levels, which was significantly determined by depression severity (β -.041 
to -.025, i.e., 39.0% decrease). Neuroticism was associated with a higher 
DBP, which was significantly determined by depression severity (β .040 to -
.016, i.e., 140.0% decrease). Emotional neglect was associated with a lower 
SBP. Psychological abuse related to a higher WC. Additional adjustment 
for depression severity considerably reduced this latter association (β .042 
to .033, i.e., 21.4% decrease) to statistically non-significant. Physical 
abuse was not related to any of the metabolic risk factors any more. 
Sexual abuse remained associated with lower HDL cholesterol, and with 
higher WC and overall metabolic risk values. Additional adjustment for 
depression severity considerably reduced the associations of sexual abuse 
with WC (β .041 to .036 [p = .04], i.e., 12.2% decrease) and overall 
metabolic risk (β .035 to .031 [p = .06], i.e., 11.4% decrease). Adjusted R2s 
ranged from .01 to .06 in crude models, and from .16 to .34 in adjusted 
models. Years of education significantly influenced associations of 
openness with HDL cholesterol (β .071 to .042 [p = .02], i.e., 40.9% 
decrease), triglycerides (β -.036 to -.007 [p = .72], i.e., 80.6% decrease), WC 
(β -.092 to -.052 [p = .003], i.e., 43.5% decrease), SBP (β -.040 to -.007 [p = 
.71], i.e., 82.5% decrease) and overall metabolic risk (β -.070 to -.032 [p = 
.06], i.e., 54.3% decrease). Interactions between personality traits and 
childhood trauma types in their associations with metabolic risk factors 
were all non-significant (all p >.05). Sensitivity analyses in which all 166 
subjects with CVD or all 485 subjects on lipid-lowering, antidiabetic or 
antihypertensive medication were excluded yielded largely similar results 
(data not shown). 
 
8.4  DISCUSSION 
In this large study, we most robustly found higher levels of openness to 
protect people from, and childhood sexual abuse to make people 
vulnerable to adverse levels of the metabolic CVD risk factors dyslipidemia 
and abdominal obesity. Our findings were largely independent of the 
lifestyle factors smoking, alcohol use and physical activity, and of each 
other. To date, several studies have addressed these relationships,25
,85,279-
282,284,289-294 with ambiguous results. More essentially, the current focus on 
personality as well as on childhood trauma is of great importance as 
theoretical evidence suggests a bidirectional influence between personality 
and trauma. Our findings might help identifying persons at increased risk 
of CVD in the future. 
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First, we will discuss the most important favorable correlate of metabolic 
risk factors: openness. More openness was associated with favorable HDL 
cholesterol, triglyceride and SBP levels, and with a lower WC. One former 
study also found facets of openness to be related to a lower WC.277 Other 
studies did not report specific associations of openness with metabolic risk 
factors.282
,284 However, our findings are in line with the fact that persons 
with a high trait of openness have a better physical (including 
cardiovascular) health.78 This may be mediated by a higher average 
intelligence level.295 Indeed, years of education - as a proxy of intelligence - 
explained a substantial part of the associations of openness with HDL 
cholesterol, triglycerides, SBP and WC. The associations with HDL 
cholesterol and WC remained statistically significant and were therefore 
not sufficiently explained by education. Other influential factors may be 
increased interest in adopting physical activities, and more openness to 
public health recommendations. Although the relationship of openness 
with lipids and WC was of limited strength, it may explain part of the 
association between high openness and a lower overall mortality risk.76 
  The most important unfavorable correlate of metabolic risk factors 
was childhood sexual abuse. People with a history of sexual abuse were 
prone to abdominal obesity and lower HDL cholesterol levels. People 
experiencing such childhood trauma might be more prone to an adverse 
metabolic profile through a lower socioeconomic status296 and 
accompanying unhealthy lifestyle habits. However, adjustment for 
socioeconomic status and lifestyle did not substantially alter associations. 
Alternatively, traumatic events during childhood might cause 
epigenetically modified activation of multiple genes involved in abdominal 
obesity and HDL cholesterol phenotyping. Animal studies have revealed 
that environmental adversities early in development profoundly affect 
epigenetic DNA methylation and histone deacetylation processes.297 An 
example of epigenetic modification by childhood trauma may be silencing 
of glucocorticoid receptor gene expression298 and a corresponding chronic 
adaptation of the stress system.273
,299 The accompanying higher levels of 
circulating cortisol274 could contribute to metabolic alterations like 
abdominal obesity and lower HDL cholesterol levels.25
,120 However, 
probably only the accumulated epigenetic modification of multiple genes 
by childhood sexual abuse could adversely affect obesity and HDL 
cholesterol levels. Other gene regions that may be involved are those that 
are part of other pathways for stress regulation like inflammation300 and 
autonomic nervous system functioning. Increased depressive symptoms 
among people who experienced childhood trauma82
,84 might also account 
for an adverse metabolic profile. Childhood trauma may adversely affect 
the set points of several endocrine systems and thereby cause among 
others a persistent elevation of prolactin301 or thyroid dysregulation.302 
This might subsequently reduce serotonergic neurotransmission301
,303 and 
thereby cause depressive symptoms. Depression severity, however, did 
only explain part of the association in the current study. An obesity 
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tendency among sexually abused people was already found in some – 
although not all88 – studies,87
,89,90 and might reduce HDL cholesterol 
levels.51 Suggested sequelae of sexual abuse that might lead to adverse 
metabolic risk factor values are posttraumatic stress disorder,276 eating 
disorders,304 disrupted reproductive hormone regulation and increased 
feelings of anger.87 Obesity might also serve as a defense posture that 
blocks unwanted sexual interest.305 
  Other personality traits and childhood traumas were also related to 
adverse metabolic risk, although less prominently. Agreeableness was 
associated with higher levels of triglycerides, neuroticism and emotional 
neglect were related to a higher blood pressure, and psychological abuse to 
abdominal obesity. Most of these associations were however significantly 
determined by an increased amount of depressive symptoms associated 
with these personality and trauma characteristics in our study,84
,306 which 
is also well-known from the literature.307 It is noteworthy that 
conscientiousness was not associated with metabolic risk factors at all. In 
another large adult sample, conscientiousness was associated with 
favorable lipid278 and abdominal obesity277 levels. However, within this 
former study only certain facets of conscientiousness were related to less 
abdominal obesity. Also, conscientiousness is related to increased physical 
activity.308 But physical activity was not taken into account in this former 
study. This might have attenuated the former associations of 
conscientiousness with lipid values,278 as physical activity partly explained 
these associations in the current study. Theoretically, personality and 
childhood trauma seem to be bi-directionally connected. However in the 
current study, associations of metabolic risk factors with personality were 
not modified by childhood trauma, and vice versa associations of metabolic 
risk factors with childhood trauma were not modified by personality. 
 Our analyses have several limitations. First, the cross-sectional 
design does not allow us to make causal inferences on whether personality 
and trauma precede metabolic risk factors or vice versa. Second, although 
the experience of childhood trauma is rather stable, it has been 
retrospectively reported. This may have introduced recall bias. Third, the 
exploration of several hypotheses has increased the risk of false positive 
findings (i.e., type 1 error). Strengths of our study are the large sample size 
and the extensive assessment of personality, childhood trauma and 
metabolic risk factors. Another strength is the joint investigation of 
personality and childhood trauma as correlates of metabolic risk factors. 
  In conclusion, we found that persons with a low openness trait as 
well as persons who experienced childhood sexual abuse are at higher risk 
of adverse metabolic risk factor profiles, especially dyslipidemia and 
abdominal obesity. Future research is required to verify these results. 
These could eventually guide the development of CVD prevention and 
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9.1  SUMMARY 
Depressive and anxiety disorders as well as cardiovascular disease (CVD) 
are highly prevalent and their major contribution to the worldwide burden 
of disease will continue to increase. Substantial evidence implies that 
depressive and anxiety disorders increase the risk of CVD. There is a 
growing interest in whether depression and anxiety increase the risk of 
metabolic adversities as well. Metabolic adversities like dyslipidemia, 
abdominal and overall obesity, hypertension and hyperglycemia tend to 
cluster in individuals as the metabolic syndrome. Because these metabolic 
adversities predict over half of CVD cases, they may help to explain the 
increased risk of CVD in depression and anxiety. So far, findings on the 
association of metabolic risk factors for CVD with depressive and anxiety 
disorders are equivocal. 
  It was the overarching intend of this thesis to study which 
characteristics (that is, disorders, severity or dimensions) of depression 
and anxiety make people prone to certain metabolic risk factors for CVD. 
The association of antidepressant use with metabolic risk factors was also 
examined. Moreover, the contribution of biological stress systems and 
lifestyle to these associations was explored. Additionally, the relationship 
of personality traits and childhood trauma with metabolic risk was 
addressed. Studies were based on the Netherlands Study of Depression 
and Anxiety (NESDA), a large longitudinal cohort study involving 2329 
people with lifetime depressive and/or anxiety disorders and 652 healthy 
controls. 
 
First, we concentrated on the question whether characteristics of 
depression and anxiety were cross-sectionally associated with metabolic 
risk factors. In chapter 2, it was described that, overall, people with a 
current major depressive disorder (MDD) and/or an anxiety disorder were 
not at an increased risk of the metabolic syndrome or its components as 
compared to controls. However, people with more severe symptoms of 
depression and to a lesser extent those with more severe symptoms of 
anxiety were at increased risk of the metabolic syndrome. This increased 
risk of the metabolic syndrome was driven by a higher prevalence of 
abdominal obesity, low high-density lipoprotein (HDL) cholesterol and 
elevated triglycerides. First, these findings illustrated that scales that 
assess the severity of symptoms of depression or anxiety better reflect 
individual metabolic derangements than categorical diagnoses. Therefore, 
severity scales allow determining more precise associations of depression 
and anxiety with metabolic risk. Second, these findings showed that 
symptoms of depression and anxiety are not related to an increased risk of 
the metabolic syndrome as such but to the metabolic risk factors 
abdominal obesity and dyslipidemia in particular. That especially the 
components abdominal obesity and dyslipidemia are related to depression 
and anxiety may explain the mixed findings of previous research on the 
whole metabolic syndrome in depression or anxiety.  
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Another finding was that users of tricyclic antidepressants (TCAs) were 
prone towards abdominal obesity, hypertriglyceridemia and hypertension. 
This was independent of depressive symptoms, and therefore may reflect 
TCA-specific side effects.  
  In chapter 3 the focus was on the cross-sectional association of 
dyslipidemia with depression and anxiety. HDL cholesterol levels were 
lower, and triglyceride levels higher in people with a current MDD than in 
those with a remitted MDD or controls. People with more severe symptoms 
of depression had higher levels of total and low-density lipoprotein (LDL) 
cholesterol and of triglyceride and lower levels of HDL cholesterol and were 
thus prone towards dyslipidemia.  
  Whether specific depression and anxiety symptom dimensions of 
the tripartite theoretical model related specifically to metabolic risk factors 
was explored in chapter 4. Somatic arousal was, independent of lifestyle 
factors, associated with increased abdominal obesity, triglyceride levels 
and blood pressure.  
  Longitudinal associations of depression and anxiety with metabolic 
risk factors were addressed in chapter 5. More severe symptoms of 
depression and anxiety at baseline predicted a decrease in HDL cholesterol 
levels and an increase of abdominal obesity over the subsequent 2 years. A 
reduction of symptoms of depression and anxiety over this time period was 
not related to amelioration of lipid or abdominal obesity values. This 
indicated that people who are vulnerable to symptoms of depression or 
anxiety may display a progression of dyslipidemia and abdominal obesity 
rather than a decline, even if they have an improvement in mood state. If 
depression or anxiety were directly related to dyslipidemia and obesity, one 
would expect that fluctuations in mood state would go together with 
similar fluctuations in lipid and obesity values. Since such convergence 
was not objectified, it was concluded that severe symptoms of depression 
or anxiety may not be directly related to dyslipidemia and abdominal 
obesity. Rather stable etiological factors – such as sustained smoking, 
unhealthy diets, inflammation or shared genetic substrates – may connect 
them.  
  As described above, people with more severe symptoms of 
depression and anxiety as well as TCA users were at increased risk of 
dyslipidemia and of abdominal and overall obesity. Subsequently, it was 
investigated whether biological stress systems and lifestyle contributed to 
these cross-sectional associations. Associations of the autonomic nervous 
system (ANS) and hypothalamic-pituitary-adrenal (HPA) axis with 
metabolic risk were portrayed in Chapter 6. Increased sympathetic 
nervous system (SNS) and decreased parasympathetic nervous system 
(PNS) activity but not basal HPA axis functioning were related to the 
metabolic syndrome and all of its components. This indicated that ANS 
dysfunctioning but not HPA axis dysregulation relates to metabolic risk.  
  In chapter 7 it was reported that elevated levels of the systemic 
inflammatory marker C-reactive protein (CRP) as well as smoking 
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substantially explained the increased prevalence of dyslipidemia and 
obesity among people with more severe symptoms of depression or anxiety. 
ANS dysregulations additionally contributed to the metabolic risk among 
TCA users. ANS dysregulations may be a side effect of TCAs. These 
findings enhance our understanding of the mechanisms behind the 
increased risk of dyslipidemia and obesity in depressive and anxiety 
disorders. Because these putative pathways did not completely explain 
dyslipidemia or (abdominal) obesity among severely depressed or anxious 
people, other contributors (e.g., dietary or genetic factors) to these 
associations remain to be identified. 
  In chapter 8 the relation of Big Five personality traits (i.e., 
extraversion, openness, agreeableness, neuroticism and 
conscientiousness) and childhood trauma type (i.e., emotional neglect, and 
psychological, physical or sexual abuse) with metabolic risk factors was 
additionally studied. Less openness as well as sexual abuse during 
childhood were independently associated with lower HDL cholesterol and 
with abdominal obesity. In addition, less openness was related to a higher 
blood pressure.  
Altogether, the findings of chapters 2 through 8 indicate that symptom 
severity measures of depression and anxiety are more strongly and 
consistently related to metabolic risk than disorder classifications. 
Moreover, it was shown that more severe symptoms of depression and 
anxiety were related to progressive dyslipidemia and obesity but not to 
hypertension or hyperglycemia. Low-grade systemic inflammation as well 
as smoking partly contributed to these associations. The use of TCAs was 
related to an increased risk of dyslipidemia, obesity and hypertension, 
partly due to enhanced sympathetic and decreased parasympathetic ANS 
activity. Somatic arousal, childhood sexual abuse and less openness were 
associated with an increased metabolic risk as well. 
  If future research confirms these findings, this may help to identify 
the particular patients who are at a high risk of metabolic adversities and 
thereby of CVD, and indicate that screening and treatment of metabolic 
risk factors may be of benefit. Moreover, the factors that contributed to 
these associations (that is, smoking, inflammation and ANS imbalance) 
may facilitate the development of new and more fundamental treatment 
options to reduce CVD risk in patients with depressive or anxiety 
disorders.   
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9.2   GENERAL DISCUSSION 
In this general discussion the main findings of this thesis will be reviewed, 
which may contribute to a more comprehensive theory of the role of 
depression and anxiety in metabolic risk. Also, methodological 
considerations, and potential implications for future research and clinical 
practice will be delineated. 
 
9.2.1  THE METABOLIC SYNDROME AND ITS COMPONENTS 
The metabolic syndrome has been hypothesized to connect depression and 
anxiety with CVD. Consequently, several former studies investigated the 
relationship of depression or anxiety with the whole metabolic syndrome 
rather than with its individual metabolic components. 
However, debate exists whether the metabolic syndrome is a valid 
concept.116
,309 A first point of criticism is that the metabolic syndrome 
might be too heterogeneous to define it as a single disorder: combinations 
of metabolic risk factors vary considerably between individuals. Second, 
probably no single pathophysiological mechanism underlies the metabolic 
syndrome. That makes it difficult to develop one treatment that can 
beneficially affect all components of the metabolic syndrome. A third 
subject of debate is that the metabolic syndrome does not seem to add to 
the prediction of CVD beyond the contribution of each individual 
component. To compare our findings with previous research we studied 
the metabolic syndrome in relation to depression and anxiety. But because 
of the questioned validity of the metabolic syndrome concept, we also 
focused on the relative importance of its individual components. 
 The findings of this thesis underscore the criticism that the 
metabolic syndrome may be too heterogeneous to define it as a single 
disorder. We observed that people with symptoms of depression or anxiety 
were at increased risk of the metabolic syndrome. However, this increased 
risk of the metabolic syndrome was driven by a higher prevalence of 
(abdominal) obesity, low HDL cholesterol and elevated triglycerides (i.e., 
dyslipidemia) only. Those people were not prone towards hypertension or 
hyperglycemia. Symptoms of depression and anxiety do thus not 
necessarily relate to the metabolic syndrome as a whole but only to some 
specific components. Our findings do not stand alone. Earlier studies that 
focused on all metabolic syndrome components also mainly reported 
associations of depression and anxiety with dyslipidemia and obesity,20-30
, 
43-46 and more seldom with hypertension21
,27 or hyperglycemia.22
,43,45 
Because depression and anxiety are especially related to (abdominal) 
obesity and dyslipidemia, associations with the whole metabolic syndrome 
could be weakened. This may explain the mixed findings of previous 
research on the metabolic syndrome in depression or anxiety. 
 Why are dyslipidemia and obesity but not hypertension or 
hyperglycemia associated with depression and anxiety? Maybe etiological 
factors associated with depression and anxiety such as smoking, 
inflammation and a sedentary lifestyle mainly affect lipid and obesity 
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values. Further, core symptoms of depression such as changes in appetite, 
a loss of energy and reduced initiative (inducing a sedentary lifestyle) may 
primarily stimulate dyslipidemia and obesity. The other way around, 
obesity may cause pain in overloaded joints143 and a lower self-esteem 
through weight-related prejudices,310 and therefore induce symptoms of 
depression. 
  In sum, compelling evidence exists that symptoms of depression 
and anxiety are particularly associated with dyslipidemia and obesity 
rather than with all metabolic syndrome components. As a consequence, 
we recommend that future studies focus on the individual metabolic risk 
factors and not (only) on the metabolic syndrome as a whole in relation to 
depression and anxiety. This approach will clarify the relative importance 
of individual metabolic risk factors in relation to depression and anxiety.  
 
9.2.2  PSYCHOLOGICAL INDICATORS OF METABOLIC RISK 
9.2.2.1.1 Severity of depression and anxiety and metabolic risk 
It is invaluable to determine which characteristics of depression and 
anxiety are most strongly associated with an increased metabolic risk. 
Subsequently, such information may help to improve prevention and 
intervention programs. 
  Various previous studies examined whether depressive or anxiety 
disorders were related to metabolic risk. Some of these studies reported 
that depressive or anxiety disorders were related to metabolic adversities, 
while others did not find such an association. We also did not consistently 
find that depressive or anxiety disorders were associated with an increased 
overall metabolic risk. Results of studies on metabolic risk in depressive or 
anxiety disorders are thus ambiguous. 
  Patients with a disorder are commonly compared to those without 
the disorder. Reasons for this approach are that it eases comparability to 
previous research, that disorder concepts are simplified, and that studies 
match cut-off points that are used in clinical practice. 
  However, persons differ in their quantity of symptoms of depression 
or anxiety. Consequently, symptoms of depressive and anxiety disorders 
are gradually distributed within the general population without a clear cut-
off between people with or without a disorder.311 By classification into 
diagnostic groups such variation in symptom severity is not taken into 
account, which may result in a loss of valuable information.  
  Considerable methodological literature demonstrates the negative 
consequences of dichotomizing gradual, continuous variables within 
scientific research (see for example: 162
,312,313). The loss of variation causes 
a drop in effect sizes and in power. This increases the risk of not finding a 
significant result when the effect actually is present (that is, type 2 error). 
This may explain why studies on metabolic risk that categorize subjects in 
those with and without dichotomous depressive or anxiety disorders 
yielded inconsistent results.  
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In this thesis, associations of metabolic risk with severity of depressive or 
anxiety symptoms were indeed more consistent and robust than those with 
diagnosis groups. Likewise, an earlier study reported that severity of 
depressive symptoms tended to be associated with abdominal obesity and 
significantly related to lower HDL cholesterol levels. But associations 
between the presence or absence of a depressed mood and metabolic risk 
factors were not observed.25  
  The importance to define psychological state as a continuous 
measure is increasingly recognized. The fact that in developing the new, 
fifth version of the international Diagnostic and Statistical Manual (DMS-
V) of mental disorders, there is high global interest in incorporating a 
dimensional component into the existing categorical binary classification 
system underscores this tendency. 
 A comment should be added to our findings. NESDA participants 
were recruited from general practices and outpatient mental health care. 
Patients with the most severe depressive and anxiety disorders who are 
admitted to inpatient mental health care were therefore not part of our 
sample. As a result, our findings cannot be generalized to the most 
severely depressed and anxious patients. It is conceivable that inpatients 
through more severe and complex psychopathology are more vulnerable to 
dyslipidemia and (abdominal) obesity than outpatients. Alternatively, 
inpatients may have a higher risk of weight loss and malnutrition which 
may reduce body weight and total cholesterol levels. Studies that address 
these associations among inpatients have however been much more 
scarcely reported. In an extension of NESDA, inpatients have been 
recruited.314 Studies on metabolic risk in depression and anxiety within 
this sample are underway. These will clarify whether our findings also 
apply to a more severely depressed and anxious inpatient population.  
   
9.2.2.1.2  The contribution of smoking and inflammation  
Understanding mechanisms linking depression and anxiety to dyslipidemia 
and obesity could provide opportunities for prevention and intervention. 
What factors may have contributed to the liability towards dyslipidemia 
and obesity in people with more severe symptoms of depression and 
anxiety?  
  First, the tendency towards dyslipidemia in people with more severe 
symptoms of depression or anxiety was substantially explained by 
smoking. This might be because they started smoking easier, possibly 
because of shared (e.g., genetic) etiological factors.197 Moreover, people 
with symptoms of depression or anxiety may have had less motivation to 
quit. This is inherent to the lack of motivation accompanying their disease, 
but there is also evidence that nicotine has antidepressant effects.197
,198 
Smoking is thought to increase total and LDL cholesterol as well as 
triglyceride levels and to lower HDL cholesterol75
,97 and hence is an 
important target in the management of dyslipidemia.17 Moreover, smoking 
is strongly linked to other adverse lifestyle factors like increased saturated 
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fat, cholesterol and alcohol intake315 that may exacerbate dyslipidemia. In 
sum, smoking importantly relates to depression and anxiety as well as to 
dyslipidemia. It is thus plausible that smoking partly explained the 
increased risk of dyslipidemia in people with severe symptoms of 
depression or anxiety.  
 Elevated serum levels of the systemic inflammation marker CRP 
additionally explained the increased risk of dyslipidemia and of obesity in 
people with more severe depressive or anxiety symptoms. It is known that 
people with depressive72 or anxiety disorders73 display higher levels of 
inflammatory markers among which CRP. In turn, inflammation may 
induce dyslipidemia. Inflammatory factors stimulate the release of lipids 
into the bloodstream to provide energy for host defense. At the same time, 
inflammation causes a reduction in HDL lipoproteins, resulting in a 
decreased reverse cholesterol transport.51 Adipose tissue cells react to 
these signals by releasing inflammatory markers themselves.257 Thereby, 
adipose tissue additionally promotes dyslipidemia in a vicious circle 
relationship. Elevated CRP levels might also lead to obesity. It is thought 
that circulating CRP binds to leptin, through which the action of leptin is 
reduced (which is called ‘leptin resistance’).201
,202 The hormone leptin 
controls appetite after eating. Leptin resistance leads to insufficient 
suppression of appetite and therefore to increased food intake. This may 
ultimately lead to obesity. 
  To sum up, inflammation is linked to depression and anxiety on the 
one hand and to dyslipidemia and obesity on the other hand. It is therefore 
conceivable that increased inflammation in people with symptoms of 
depression or anxiety partly explained their vulnerability to dyslipidemia 
and obesity. Moreover, since smoking substantially raises CRP levels,260 
smoking could have partly induced the increased inflammation in 
depression and anxiety.   
  Yet, smoking and inflammation did not fully explain dyslipidemia 
and obesity among people with more severe symptoms of depression or 
anxiety. A complexity of factors is eligible as linking mechanism between 
depression and anxiety on the one hand and lipids and body fat on the 
other hand. Therefore, probably multiple factors underlie the liability 
towards dyslipidemia and obesity among people with symptoms of 
depression and anxiety.  
  Our longitudinal findings also supported the idea that depression 
and anxiety were not directly related to dyslipidemia and obesity, but could 
be due to various underlying factors. If depression or anxiety were directly 
related to dyslipidemia and obesity, one would expect that fluctuations in 
mood state over time would go together with similar fluctuations in lipid 
and obesity values. However, an improvement in mood over time did not 
coincide with reductions of dyslipidemia or obesity. Dyslipidemia and 
abdominal obesity even aggravated. This indicates that rather stable 
etiological factors in people who are vulnerable to symptoms of depression 
or anxiety cause a progression of dyslipidemia and abdominal obesity, 
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independent of ameliorations in mood state. From a broader perspective, 
our longitudinal results are in line with the finding that treatment of 
depression does not ameliorate the prognosis of existent CVD.316
,317 This 
observation further stresses the need to gain insight into the mechanisms 
that are responsible for persistent poor cardiovascular outcomes in 
depression and anxiety. 
 Another factor that could further contribute to progressive 
dyslipidemia and obesity is that people who are vulnerable to depression or 
anxiety, independent of their current mental state, continue to eat less 
healthy with more carbohydrates and saturated fat.118 Persistent 
unhealthy dietary habits may lead to increases in dyslipidemia and 
obesity. Moreover, it is possible that symptoms of depression and anxiety 
share genetic substrates with HDL cholesterol and abdominal obesity. For 
instance, complex gene-environment interactions may have activated the 
HPA axis, which subsequently has led to depression as well as to 
aggravation of obesity. Another possibility is that depressed and anxious 
people are less healthy in general. In this thesis only CVD and diabetes 
mellitus were taken into account, and these conditions did not explain the 
associations found. But several other chronic conditions like renal disease, 
rheumatoid arthritis and chronic obstructive pulmonary disease are 
related to depression or anxiety318-320 as well as to metabolic risk 
factors.321-323 Hence, it is conceivable that depression and anxiety are 
accompanied by a poorer overall health status,324 which more robustly 
induces dyslipidemia and obesity.  
Research has only just begun to unravel the mechanisms that 
underlie metabolic risk in depression and anxiety. Besides measurement 
error and random fluctuations, other factors than smoking and 
inflammation could account for the unexplained variance in the 
associations of dyslipidemia and obesity with more severe symptoms of 
depression and anxiety. However, the precise role of these factors remains 
to be elucidated by future research. The identification of these factors is 
essential as these could provide additional leads to better prevent and treat 
dyslipidemia and obesity in depression and anxiety.  
   
9.2.2.2 TCA use and metabolic risk 
Patients who used TCAs were at an increased risk of dyslipidemia, 
abdominal and overall obesity and hypertension, which could be side 
effects of TCAs. These findings fit well with the growing evidence of adverse 
effects of TCAs.58-63 In secondary care, TCAs are commonly prescribed by 
psychiatrists. A detailed understanding of their side effects is important to 
be able to adequately weigh the metabolic risks and the benefits of TCA 
prescription against alternative treatments. Our findings also stress the 
importance to monitor for metabolic risk during TCA treatment.   
  We found that an increased SNS and decreased PNS activity of the 
ANS as well as increased systemic inflammation partly explained the 
tendency towards dyslipidemia and obesity in users of TCAs. A higher rate 
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of smokers among TCA users additionally explained part of their 
vulnerability towards dyslipidemia. Previous research already indicated 
such an ANS imbalance and inflammation as TCA side-effects. It has been 
found that TCAs are agonists for the peripheral α1 adrenergic receptors,63 
which trigger sympathetic activation of the ANS. This sympathetic 
response may have induced dyslipidemia and obesity, and also 
vasoconstriction which increases blood pressure. TCAs also have other 
adverse effects on the cardiovascular system. Their use has also been 
associated with a decreased parasympathetic control of the heart by the 
vagus nerve.62
,244 This reduced cardiac vagal control lowers the variability 
in heart rate. Such beat-to-beat fluctuations in the rhythm of the heart are 
however essential for good cardiac health. For that reason, reduced heart 
rate variability (HRV) predicts greater cardiac mortality.325 Increased 
systemic inflammation was also observed as a side effect in a former 
study,60 although the mechanism that underlies an inflammatory response 
to TCAs is still poorly understood.    
   Our findings also showed that higher smoking rates among TCA 
users explained part of their dyslipidemia. Maybe TCA users initially had a 
more severe form of depression and were therefore more likely to smoke. 
This may have confounded their tendency towards dyslipidemia. 
Depressed NESDA participants on TCAs did not display higher depression 
severity scores than those free of TCAs, but this is probably attributable to 
efficacy of TCAs. According to treatment guidelines, TCAs should only be 
prescribed after unsuccessful administration of SSRIs or serotonin-
norepinephrine reuptake inhibitors (SNRIs).  
 ANS dysregulation, inflammation and smoking did not entirely 
explain associations of TCA use with dyslipidemia, obesity or hypertension. 
Probably other factors are also involved. One such a factor may be 
antihistaminergic effects of TCAs, which may induce weight gain58
,59 and 
subsequently dyslipidemia.131 Another possibility is the abovementioned 
probability that TCA users initially have more severe and longer lasting 
symptoms of depression. These severe and prolonged symptoms together 
with possible side effects of previously used antidepressants may have 
amplified their metabolic risk.  
 
9.2.3  CAUSAL PATHWAYS OF METABOLIC RISK  
   IN DEPRESSION AND ANXIETY 
How can we be sure that depression and anxiety lead to metabolic 
disturbances? Is there a possibility that this association also runs in the 
opposite direction? In other words, can metabolic disturbances lead to 
symptoms of depression or anxiety as well? Insight into cause and 
consequence of these conditions is still limited. Such knowledge is 
essential to determine the direction of preventive and therapeutic 
strategies. Our longitudinal information made it possible to add to the 
literature on the direction of possible causality.  
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We assumed that depression preceded dyslipidemia and obesity. The 
reason for this assumption is that key symptoms of depression are a 
change in appetite or weight. Moreover, depression and anxiety are often 
accompanied by unhealthy lifestyle changes. Furthermore, it is thought 
that depression and anxiety are associated with dysregulated biological 
stress systems. This could aversely affect lipid levels and body fat. In our 
longitudinal analyses, more severe symptoms of depression or anxiety at 
baseline predicted a worsening of dyslipidemia and obesity over time. This 
finding supports our assumption that depression and anxiety precede 
dyslipidemia and obesity. Additional evidence for this temporal sequence is 
derived from meta-analyses that showed that depression preceded 
obesity.195
,326 
  The reverse causal route that dyslipidemia and obesity cause 
depression or anxiety is plausible as well. Although a genetic study 
reported that the apolipoprotein E genotype which anchors basal 
cholesterol levels did not determine depression scores,40 another study 
reported that dyslipidemia did predispose to depression.106 Moreover, a 
meta-analysis195 as well as later studies327
,328 showed that obesity 
increases the risk of future depression. For instance weight-based 
discrimination310 could cause feelings of depression. Other evidence for 
reverse causation comes from a large prospective cohort study which 
reported that a Mediterranean diet – which is preventive for dyslipidemia 
and obesity - protects against depression.247  
  Taken together, it is likely that the association of dyslipidemia and 
obesity with depression and anxiety runs in two directions. Depression 
and anxiety on the one hand and dyslipidemia and obesity on the other 
hand might reinforce each other in a vicious cycle.  
  Because no definite conclusions can be drawn from the relatively 
scarce studies on longitudinal associations of metabolic risk with 
depression and anxiety, there lays a major challenge for future research to 
investigate the possibility of bidirectional causation. In NESDA we studied 
whether symptoms of depression or anxiety preceded dyslipidemia or 
obesity. To verify the hypothesis of bidirectionality, it would be compelling 
to investigate within NESDA data whether lipid or obesity levels predict 
symptoms of depression or anxiety as well. In addition, replication of 
longitudinal research on these causal pathways within other longitudinal 
data collections as well as in treatment trials is warranted.  
 
9.2.4      CLINICAL AND FUTURE RESEARCH IMPLICATIONS 
Health research in the past decades has increasingly focused on the 
interplay between mental and physical health, of which this thesis is an 
example. This research field more and more indicates that mental 
difficulties like depression and anxiety are associated with an array of 
adverse physical outcomes among which diabetes mellitus and CVD. Still, 
in clinical practice a division exists between the care for mental and 
physical illnesses. In the care of people with depression or anxiety, there is 
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not yet a systematic approach to detect and treat co-morbid physical 
conditions. Within this patient group, physical conditions may therefore 
progress unnoticed into severe physical ailments. In line with the growing 
scientific evidence, our findings further stress the need to implement 
physical care in mental health care. Better awareness in mental care for 
physical jeopardies could eventually reduce morbidity and mortality rates 
associated with co-morbid physical conditions such as CVD. 
 The main finding delineated in this thesis is that severe symptoms 
of depression and to a lesser extent of anxiety are associated with an 
increased risk of dyslipidemia and (abdominal) obesity. Because 
depression and anxiety are among the most common mental disorders, 
general practitioners (GPs) and especially mental health care professionals 
regularly treat patients with severe symptoms of depression or anxiety. 
They could therefore play an important role in reducing the risk of 
dyslipidemia and obesity and ultimately of CVD among this patient group.  
  Although weight loss frequently occurs in people with depression, 
weight gain (with obesity and dyslipidemia as end points) is also regularly 
observed in patients with depression. Although weight gain might be seen 
as a normal consequence of depression and of certain antidepressant 
medication use, clinicians should become more aware of the increased 
CVD morbidity and mortality associated with weight gain and related 
dyslipidemia. 
  In future research, it should be determined whether screening for 
dyslipidemia and obesity in severely depressed or anxious patients is 
effective. Severity of depressive and anxiety symptomatology could among 
others be assessed by the Inventory of Depressive Symptoms (IDS) and the 
Beck Anxiety Questionnaire (BAI). The IDS and BAI were applied in NESDA 
and are valid and internationally applied severity scales for depression and 
anxiety that take little time. We found that people with an IDS score from 
49 or a BAI score from 30 displayed a significantly increased risk of 
dyslipidemia or obesity. Although these thresholds are arbitrary and need 
to be verified, they provide an indication for cut-off scores for research on 
dyslipidemia and obesity screening. 
  When patients report severe symptoms of depression or anxiety 
higher than the abovementioned threshold, it may be recommendable that 
GPs and psychiatrists assess their fasting lipid profile and their degree of 
obesity. The leading dyslipidemia guideline97 advices dyslipidemia 
screening in adults at increased risk of CVD at least five-yearly. Overall 
and abdominal obesity should be assessed during intake and regularly 
thereafter. A body mass index (BMI [kg/m2]) of over 25.0,57 and a waist 
circumference (WC) of > 102 cm in men or > 88 cm in women17 are the 
most widely accepted indicators of overall and abdominal obesity.  
  If dyslipidemia or obesity is present, diminution of smoking and 
inflammation might reduce these conditions. Smoking cessation already is 
generally recommended to reduce dyslipidemia and inflammation,17
, 97 and 
this general recommendation may facilitate implementation. The most 
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promising way to reduce smoking dependence within this specific patient 
group is an integrated behavioral and pharmacological approach combined 
with psychological counseling of depression or anxiety.329 Such smoking 
cessation programs should focus on short-term goals, like building up self-
efficacy and motivation to quit, and then stimulating gradual 
abstinence.330 
 Of course, prevention is the best cure. In severely depressed or 
anxious patients without obesity or dyslipidemia, clinicians should focus 
on primary prevention of these conditions, because subsequent weight loss 
and reduction of dyslipidemia through for example quitting smoking are 
more difficult to accomplish. This could be achieved by sensitizing patients 
to the health risks associated with obesity and dyslipidemia and 
detrimental lifestyle habits like smoking, and through encouraging self-
care and self-monitoring in terms of lifestyle and weight.331 
  Future research should determine whether reduction or prevention 
of smoking and inflammation really reduces the risk of dyslipidemia and 
obesity among severely depressed or anxious people. If proven effective, 
screening people with more severe symptoms of depression or anxiety for 
dyslipidemia and obesity and subsequent prevention and modification 
strategies could become part of multidisciplinary guidelines and thereby 
help preventing CVD. Current general332
,333 and mental health care 
guidelines334
,335 only advice to assess whether or not a depressive or 
anxiety disorder is present. The assessment of anxiety and depression 
severity should then be additionally included into these guidelines.  
Other strategies could also beneficially affect dyslipidemia and 
obesity in people with more severe symptoms of depression or anxiety. 
Physical activity and weight reduction are both recommended to reduce 
dyslipidemia,97 obesity17 and inflammation.17 Physical activity further has 
the advantage that it may help to improve mood,336 at least in the short 
term.337 Guided running therapy is therefore already included in 
international guidelines for treatment of mild to severe depression.334
,338  In 
the future it should be examined whether for example stimulating physical 
activity adds to dyslipidemia and obesity management in this specific 
patient group.  
 Another finding of this thesis was that TCA users had an increased 
risk of dyslipidemia, obesity and hypertension. Severity of depression did 
not explain these results, and so these metabolic disturbances could 
reflect side effects of TCAs. Therefore, clinicians should be reticent about 
prescribing TCAs. However, TCAs are usually prescribed after other kinds 
of antidepressants or psychological interventions have failed to sufficiently 
relieve symptoms of depression or anxiety. TCA use is thus one of the last 
resorts, and the few alternatives also have contraindications and side 
effects.334 When there are no better alternatives, it should therefore be 
considered whether, for example based on TCA blood levels, a lowest 
effective dose can be determined. Furthermore, screening TCA users for 
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dyslipidemia, obesity and hypertension at the intake and regularly 
thereafter could be important. 
  Taken together, the findings in this thesis and related literature 
underscore that patients reporting severe symptoms of depression or 
anxiety should be considered as a population at increased risk of 
dyslipidemia and obesity. The close relationship of depression and anxiety 
with dyslipidemia and obesity may justify a more integrated clinical 
approach. Future research should further verify these associations, and 
whether actions aimed at prevention, detection and management of 
dyslipidemia and obesity are of benefit. Such actions may ultimately 
reduce CVD morbidity and mortality in people with depression and 
anxiety.  
 
9.2.5  METHODOLOGICAL CONSIDERATIONS 
Specific limitations of the studies presented in this thesis were already 
addressed in the corresponding chapters. One of the overarching 
limitations comprised the limited ability to conclude about causality 
because of the observational and mainly cross-sectional nature of our 
studies. A second limitation encompassed the unavailability of additional 
explanatory information such as information about diet. 
 In this General discussion, some additional considerations were 
attended to. A first consideration was that due to attrition the most 
severely depressed and anxious people were not optimally represented 
within the NESDA study. As a result, the findings of this thesis are not 
merely generalizable to those most severely ill. The degree of generalization 
to this specific population could however be clarified by data of NESDA 
inpatients.314 A related restriction is that only adults aged 18 through 65 
were included in NESDA. This stands in the way the generalizability of our 
findings to the elderly. In the future, our findings could be verified in 
elderly within the Netherlands Study of Depression in Older persons 
(NESDO)339, which was designed largely comparable to NESDA. 
 A final consideration was that the increased metabolic risk among 
TCA users might not just be a reflection of adverse TCA effects. TCAs are 
normally prescribed only after unsuccessful treatment with SSRIs and 
SNRIs. Therefore, TCA users could have been a subgroup with initially 
more severe and longer lasting symptoms of depression. These severe and 
prolonged symptoms together with possible side effects of previously used 
antidepressants may have contributed to their increased metabolic risk.  
 
9.2.7  GENERAL CONCLUSION  
The aim of this thesis was to clarify which aspects of depression and 
anxiety are related to an increased metabolic risk, and which factors 
contribute to these associations. Taken together, our findings indicate that 
people with more severe symptoms of depression and anxiety are at 
particular risk of progressive dyslipidemia and (abdominal) obesity. The 
higher rates of smoking and systemic inflammation among people with 
depression or anxiety partially accounted for their adverse metabolic 
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profile. Dysregulations of the autonomic nervous system partly explained 
why users of tricyclic antidepressants displayed an increased risk of 
dyslipidemia and (abdominal) obesity as well, and also of hypertension. 
These important findings shed light on useful avenues for future research, 
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176 LIST OF ABBREVIATIONS 
 
 
ANS  Autonomic nervous system 
ATC  Anatomical therapeutic chemical 
AUCg   Area under the curve with respect to the ground 
AUCi  Area under the curve with respect to the increase 
AZS  Autonome zenuwstelsel 
BAI  Beck Anxiety Inventory 
BMI  Body mass index 
CAB  Cardiac autonomic balance 
CI   Confidence interval 
CoAR  Cardiac autonomic regulation 
CVD  Cardiovascular disease 
CRP  C-reactive protein 
DM  Diabetes mellitus 
e.g.  Exempli gratia (meaning: for example) 
GAD  Generalized anxiety disorder 
GP  General practitioner 
HDL  High-density lipoprotein / hoge-dichtheid-lipoproteïnen 
HPA  Hypothalamic-pituitary-adrenal 
HR  Heart rate 
HVZ  Hart- en vaatziekten 
IDS(-SR) Inventory of Depressive Symptoms (Self Report) 
i.e.  Id est (meaning: that is) 
IL-6  Interleukin(IL)-6 
LDL  Low-density lipoprotein / lage-dichtheid-lipoproteïnen 
MASQ  Mood and Anxiety Symptom Questionnaire 
MBP  Mean blood pressure 
MCAR  Missing completely at random 
MDD  Major depressive disorder 
MET  Metabolic equivalent of task 
MI  Myocardial infarction 
NA  Negative affect 
NESDA Netherlands Study of Depression and Anxiety 
PA  Positive affect 
PEP   Pre-ejection period 
PNS  Parasympathetic nervous system 
RSA  Respiratory sinus arrhythmia 
SA  Somatic arousal 
SNRI Serotonin-norepinephrine reuptake inhibitor  
SNS  Sympathetic nervous system 
SSRI  Serotonin re-uptake inhibitor 
TCA  Tricyclic antidepressant 
TNF-α  Tumor necrosis factor-alpha 













Depressieve en angststoornissen komen vaak voor. Bijna twintig procent 
van de mensen krijgt ooit in het leven een depressieve of angststoornis. 
Deze aandoeningen komen in meer dan de helft van de gevallen samen 
voor. Vanwege deze grote samenhang is het belangrijk om ze gezamenlijk 
te onderzoeken.  
  Ook hart- en vaatziekten (HVZ) komen veel voor. HVZ zijn zelfs 
wereldwijd de belangrijkste doodsoorzaak. Zowel depressieve en 
angststoornissen als HVZ veroorzaken veel ziektelast. Daarnaast brengen 
zij veel maatschappelijke kosten met zich mee, voornamelijk door 
arbeidsongeschiktheid. 
  Er bestaat een opmerkelijke samenhang tussen depressie en 
angststoornissen enerzijds en HVZ anderzijds. Onderzoek laat zien dat een 
depressie de kans op het ontwikkelen van HVZ verdubbelt. 
Angststoornissen verhogen het risico op HVZ met veertig procent. Er is 
toenemende interesse in de vraag of depressie en angststoornissen ook 
samenhangen met ‘metabole’ (= stofwisselings) factoren die de kans op 
HVZ vergroten. Dit proefschrift haakt hierop in door de vraagstelling te 
behandelen of bepaalde kenmerken van depressie of angststoornissen ons 
kwetsbaar maken voor metabole risicofactoren voor HVZ, en waarom.  
 
Metabole risicofactoren voor hart- en vaatziekten (HVZ)  
Onder metabole risicofactoren voor HVZ vallen ongunstige 
cholesterolwaardes in het bloed (ook wel ‘dyslipidemie’ genoemd), 
overgewicht, hoge bloeddruk en verhoogde glucosespiegels.  
 Cholesterol is nodig als bouwstof van lichaamscellen en grondstof 
voor hormonen. Cholesterol wordt geproduceerd in de lever, maar ook 
opgenomen via de voeding en beïnvloed door roken, lichamelijke beweging 
en bepaalde medicatie. Cholesterol wordt verpakt in eiwitbolletjes door het 
bloed vervoerd. Deze eiwitbolletjes heten ‘lipoproteïnen’, en de belangrijkste 
soorten zijn lage-dichtheid-lipoproteïnen (LDL) en hoge-dichtheid-
lipoproteïnen (HDL). Een ander belangrijk vet in het lichaam is 
‘triglyceride’. LDL cholesterol en triglyceriden zetten zich af tegen de 
vaatwand en veroorzaken daardoor aderverkalking (ook wel ‘atherosclerose’ 
genoemd). HDL cholesterol gaat juist aderverkalking tegen door het 
verwijderen van cholesterol van de vaatwand. Een verhoogde concentratie 
LDL cholesterol of triglyceriden en/of een verlaagde concentratie HDL 
cholesterol in het bloed bevordert dus aderverkalking. Dergelijke 
dyslipidemie is daarom een belangrijke risicofactor voor HVZ.  
  Bij overgewicht is er sprake van een vergrote hoeveelheid vetweefsel 
in het lichaam. Overgewicht komt steeds vaker voor, een verschijnsel dat 
ook wel de ‘obesitasepidemie’ wordt genoemd. Er wordt vaak een 
onderscheid gemaakt tussen algemeen overgewicht en vetophoping in de 
buik. Vooral buikvet maakt bepaalde stoffen aan, zoals 
ontstekingsfactoren, die het risico op HVZ verhogen.  
  De bloeddruk is de druk op de bloedvaten die ontstaat doordat het 
hart bloed de slagaders in pompt. De bloeddruk neemt toe met de leeftijd 
en door een ongezonde leefstijl, zoals roken en weinig bewegen. Door een 
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langdurig hoge bloeddruk ontstaan er kleine beschadigingen in de wanden 
van slagaders. Hierdoor kan cholesterol zich gemakkelijker afzetten tegen 
de vaatwanden, wat aderverkalking bevordert. Door dit proces worden de 
vaten nauwer en minder elastisch en moet het hart intensiever pompen om 
bloed te verspreiden. Hierdoor neemt de bloeddruk verder toe. Een hoge 
bloeddruk legt een voortdurende druk op het hart en de slagaders en 
vergroot daardoor het risico op HVZ.  
  Glucose in het bloed hebben we nodig als brandstof. Normaal 
gesproken maakt de alvleesklier bij stijgende glucosewaardes het hormoon 
insuline aan. Insuline zet het teveel aan glucose om in glycogeen, wat 
wordt opgeslagen in lever en spieren voor later gebruik. Wanneer er een 
defect is in de opslag van glucose, blijft er te veel van in het bloed achter 
en stijgen de glucosespiegels. Dit is een belangrijk kenmerk van type 2 
diabetes. Verhoogde glucosespiegels veroorzaken via allerlei chemische 
processen schade aan lichaamscellen, waaronder aan cellen in de 
bloedvaten.  
  Dyslipidemie, overgewicht, hoge bloeddruk en verhoogde 
glucosespiegels komen vaak samen voor en beïnvloeden elkaar over en 
weer. Bij drie of meer van deze metabole risicofactoren voor HVZ wordt 
deze clustering ‘het metabool syndroom’ genoemd. Door hun ongezonde 
effecten op het hart- en vaatstelsel voorspellen deze metabole risicofactoren 
samen meer dan de helft van alle gevallen van HVZ.  
 
Depressie en angststoornissen 
Een depressieve stoornis wordt gekenmerkt door een sombere stemming 
en/of interesseverlies die langer dan twee weken aanhoudt. Daarnaast kan 
er sprake zijn van veranderingen in het slaap- en/of eetpatroon, geremde 
of juist opgejaagde bewegingen of gedachten, moeheid of lusteloosheid, 
moeite met concentreren, besluiteloosheid, gevoelens van schuld of 
waardeloosheid, en terugkerende gedachten over de dood. Om aan de 
criteria voor een depressieve stoornis te voldoen, moeten minimaal vijf van 
deze symptomen aanwezig zijn. 
Veel voorkomende angststoornissen zijn sociale fobie, 
paniekstoornis met of zonder agorafobie en de gegeneraliseerde 
angststoornis. Bij sociale fobie is iemand overmatig bang om zich in sociale 
situaties op een genante manier te gedragen. Bij een paniekstoornis is er 
sprake van herhaalde, onverwachte paniekaanvallen. Uit angst voor 
paniekaanvallen gaat een deel van deze mensen situaties vermijden die 
daartoe kunnen leiden. In dat geval kan iemand agorafobie (in de 
volksmond ook wel ‘pleinvrees’ genoemd) ontwikkelen, waarbij diegene 
bang is om zich in situaties te begeven van waaruit ontsnappen moeilijk is 
of waarin geen hulp beschikbaar zou zijn in geval van paniek. De 
gegeneraliseerde angststoornis wordt gekenmerkt door het zich gedurende 
langere tijd buitensporig zorgen maken over allerlei alledaagse situaties.     
Een diagnose van een depressieve of angststoornis is enkel gericht 
op het al dan niet voldoen aan een bepaald aantal criteria. Aangezien 
symptomen van depressie en angst bij iedereen in min of meerdere mate 
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voorkomen, bieden diagnoses een beperkt inzicht in subtiele individuele 
verschillen.  
Een manier om individuele verschillen in depressie en angst beter 
in kaart te brengen is door de ernst van symptomen van depressie of angst 
over een continuüm te bekijken. Ernstvragenlijsten voor depressie en 
angst registreren het aantal en de mate van symptomen en bieden 
daardoor informatie over individuele verschillen in ernst, los van of iemand 
een depressieve of angststoornis heeft.  
Een andere continue depressie- en angstmaat, waarmee 
tegelijkertijd rekening wordt gehouden met de overlap tussen depressie en 
angst, is het model voor symptoomdimensies. Bij deze relatief nieuwe 
benadering wordt ervan uitgegaan dat een gebrek aan positieve emoties, 
waaronder enthousiasme en interesse (zoals samengevat in de positieve 
affectdimensie), specifiek is voor depressie, symptomen van lichamelijke 
prikkeling zoals hartkloppingen en zweten (de lichamelijke 
prikkelingsdimensie) onderscheidend zijn voor angst, en negatieve 
gevoelens zoals angst en schuld (samengevat in de negatieve 
affectdimensie) kenmerkend zijn voor zowel depressie als voor angst.  
 
Depressie, angststoornissen en metabole risicofactoren 
Omdat metabole risicofactoren voor HVZ meer dan de helft van alle 
gevallen van HVZ voorspellen, zouden ze deels verantwoordelijk kunnen 
zijn voor de verhoogde kans op HVZ die depressie en angststoornissen met 
zich meebrengen. En aangezien metabole risicofactoren relatief eenvoudig 
op te sporen en te behandelen zijn, zouden dit dankbare 
aanknopingspunten zijn om het risico op HVZ bij mensen met depressie of 
angst terug te dringen.  
 Voorgaande studies naar dit onderwerp onderzochten veelal of 
metabole risicofactoren vaker voorkwamen bij mensen met een depressie of 
angststoornis dan bij mensen zonder een dergelijke aandoening. Deze 
studies leverden tegenstrijdige resultaten op. Een reden hiervoor kan zijn 
dat het indelen in stoornissen – zoals hiervoor uitgelegd - weinig inzicht 
geeft in subtiele individuele verschillen in bijvoorbeeld ernst van klachten. 
Continue maten voor depressie en angst (zoals ernstmaten of 
symptoomdimensies) geven waarschijnlijk een nauwkeuriger en 
genuanceerder beeld. Een andere hieraan gerelateerde reden voor 
tegenstrijdige resultaten van voorgaand onderzoek kan zijn dat een deel 
van de studies alleen onderzocht of mensen met depressie of angst vaker 
voldeden aan de algemene criteria voor het metabool syndroom. Omdat er 
bij deze methode weinig rekening wordt gehouden met individuele 
verschillen in samenstelling en ernst van metabole risicofactoren, kan dat 
onduidelijke resultaten hebben opgeleverd.  
  Omdat er relatief weinig onderzoek is gedaan naar de relatie van 
continue depressie- en angstmaten met losse continue waarden van 
metabole risicofactoren, willen we aan de hand van dit proefschrift de 
kennis hierover vergroten.  
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Antidepressiva en metabole risicofactoren 
Antidepressiva worden aan circa zes procent van de Nederlanders 
voorgeschreven ter verlichting van zowel depressieve als angstklachten. 
Twee van de meest gebruikte soorten antidepressiva zijn selectieve 
serotonine-heropnameremmers (SSRIs) en tricyclische antidepressiva 
(TCAs). Er zijn aanwijzingen dat TCAs maar ook SSRIs metabole 
verstoringen zoals dyslipidemie en overgewicht kunnen veroorzaken. 
Omdat antidepressiva veel worden gebruikt en waarschijnlijk metabole 
bijwerkingen hebben, zouden zij een deel van het verhoogde metabole 
risico bij mensen met depressie of angststoornissen kunnen verklaren. 
Deze mogelijkheid is nog niet grondig onderzocht. Daarom wordt daar in 
dit proefschrift uitgebreid bij stilgestaan. 
 
Mogelijke oorzaken van metabool risico bij depressie en angst 
Behalve dat we wilden onderzoeken of depressie, angst of 
antidepressivagebruik samenhangen met metabole ontregelingen, wilden 
we ook weten waarom. Hier is nog maar heel weinig over bekend. Meer 
kennis over mogelijke verklaringen geeft ons aanknopingspunten over hoe 
we metabole ontregelingen bij depressie en angststoornissen kunnen 
voorkomen en genezen. In dit proefschrift werd de rol van biologische 
stresssystemen en van leefstijl onderzocht. 
 
Biologische stresssystemen  
Ons lichaam wordt automatisch actief bij zowel lichamelijk als mentaal 
stressvolle gebeurtenissen, bijvoorbeeld door het mobiliseren van brandstof 
zoals cholesterol en glucose, en door het verhogen van bloeddruk en 
hartslag. Dit zorgt ervoor dat we adequaat op stressvolle situaties kunnen 
reageren door te ‘vechten of vluchten’. Ons lichaam heeft daarnaast ook 
regelmechanismen die zorgen voor ontspanning en herstel zo gauw de 
stressvolle situatie voorbij is. Drie belangrijke biologische stresssystemen 
zijn de hypothalamus-hypofyse-bijnierschors as (HPA as, wat staat voor 
het Engelse ‘hypothalamic-pituitary-adrenal’), het autonome zenuwstelsel 
(AZS) en de ontstekingsreacties van het immuunsysteem.  
  De HPA as zorgt ervoor dat in stressvolle situaties de hypothalamus 
in de hersenen corticotrofine releasing hormoon (CRH) afgeeft in het bloed, 
wat de afgifte van adrenocorticotroop hormoon (ACTH) door de 
hypofyseklier stimuleert en vervolgens productie van het stresshormoon 
cortisol door de bijnierschors in gang zet. Het stresshormoon cortisol zorgt 
voor het vrijmaken van onder andere glucose en cholesterol om actief te 
kunnen zijn in tijden van stress. Doordat cortisol als een soort thermostaat 
de aanmaak van CRH en ACTH remt, komt de stressreactie van de HPA as 
vanzelf weer tot rust.  
  Het AZS bestaat uit een sympatisch deel dat het lichaam klaar 
maakt voor actie door bijvoorbeeld het verhogen van de hartslag en 
bloeddruk, en een parasympatisch deel dat zorgt voor ontspanning en 
herstel door het verlagen van hartslag en bloeddruk. Als het sympatische 
AZS actief is, onderdrukt dit het parasympatische AZS en andersom.  
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Elke stresssituatie (zowel fysiek als mentaal) activeert ook het 
immuunsysteem en kan daardoor ontstekingsreacties oproepen. Dit is 
nodig om voorbereid te zijn op verwondingen die kunnen ontstaan tijdens 
het vechten of vluchten, en heeft als doel het verwijderen van eventuele 
infecties en het herstel van schade.  
  Als een van deze drie biologische stresssystemen langdurig actief is, 
veroorzaakt dit metabole ontregelingen doordat het lichaam aanhoudend 
in de actieve stand staat. Zodoende kunnen chronisch verhoogde 
cholesterolspiegels, glucosewaardes en bloeddruk ontstaan. 
  Onderzoek laat zien dat ontregelde biologische stresssystemen 
samenhangen met depressie en angststoornissen. Dat bij mensen met 
depressie of angst de normale reacties op stress verstoord zijn, kan dus 
bijdragen aan het verhoogde metabole risico bij depressie en 
angststoornissen. Of het inderdaad zo is dat overactieve stresssystemen 
kunnen verklaren dat depressieve en angstige mensen een groter metabool 
risico lopen is nog niet bekend. Daarom wordt er in dit proefschrift 
aandacht aan deze mogelijkheid besteed. 
 
Leefstijl 
Iets anders wat het metabole risico onder mensen met depressie of angst 
kan verhogen is leefstijl. Mensen met een depressie of angststoornis 
hebben de neiging om te gaan roken, meer alcohol te drinken en minder te 
bewegen. Een dergelijke leefstijl vergroot de kans op metabole 
ontregelingen zoals een hoge bloeddruk en overgewicht. De rol van een 
leefstijl is in het verleden nog niet zo grondig onderzocht. 
 
Metabole risicofactoren in relatie tot persoonlijkheid en jeugdtrauma  
Hoewel we ons in dit proefschrift vooral richten op depressie en 
angststoornissen, zijn er ook andere factoren denkbaar die metabole 
risicofactoren kunnen beïnvloeden. Wij bestudeerden daarom ook de 
relatie van persoonlijkheid en jeugdtrauma met metabole risicofactoren 
voor HVZ. Onderzoeksresultaten hierover zijn schaars en tegenstrijdig, en 
daarom is verder onderzoek hiernaar van belang.  
Een gangbare manier om persoonlijkheid in te delen is aan de hand 
van het Big Five model. Dit model gaat ervan uit dat persoonlijkheid 
bestaat uit vijf dimensies, namelijk de mate van extraversie (versus 
introversie), openheid (voor bijvoorbeeld nieuwe ervaringen en ideeën), 
meegaandheid (tegenover competitiviteit), neuroticisme (versus emotionele 
stabiliteit) en zorgvuldigheid (tegenover onverschilligheid). Iedereen heeft 
elk van deze vijf persoonlijkheidstrekken in een bepaalde mate, en de 
combinatie van deze vijf trekken bepaalt iemands karakter. Deze 
persoonlijkheidstrekken beïnvloeden onder andere de mate waarin we een 
gezonde levensstijl belangrijk vinden en naleven, en onze behoefte aan 
middelengebruik zoals roken of alcoholgebruik. Dit heeft op zijn beurt weer 
invloed op metabole risicofactoren.  
Jeugdtrauma zoals emotionele verwaarlozing, en psychologisch, 
fysiek of seksueel misbruik hangt samen met een lagere welvaart. Ook 
vergroot het meemaken van jeugdtrauma de kans op psychische klachten 
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zoals depressie en angststoornissen. Zowel een lagere welvaart als 
psychische klachten faciliteren een ongunstige leefstijl, wat het risico op 
metabole verstoringen kan verhogen.  
 
Doel van dit proefschrift 
Samenvattend was het doel van de studies opgenomen in dit proefschrift 
om te onderzoeken welke kenmerken van depressie en angst (namelijk 
stoornissen, ernst of symptoomdimensies) mensen kwetsbaar maken voor 
metabole ontregelingen. De relatie van antidepressivagebruik met metabole 
risicofactoren werd ook onderzocht. Bovendien namen we de rol die 
biologische stresssystemen en leefstijl hierin spelen onder de loep. 
Daarnaast werd gekeken of persoonlijkheidstrekken en jeugdtrauma 
bijdragen aan metabool risico.  
  Om dit alles te kunnen onderzoeken, hebben wij dankbaar gebruik 
gemaakt van gegevens van de Nederlandse Studie naar Depressie en Angst 
(NESDA). Binnen NESDA worden 2329 volwassenen met een depressie of 
angststoornis gedurende het leven en 652 gezonde controles (mensen die 
nooit een dergelijke stoornis hebben gehad) jarenlang gevolgd om het 
ontstaan, het beloop en de consequenties van depressie en 
angststoornissen in kaart te brengen.  
 
RESULTATEN 
In hoofdstuk 2 lieten we allereerst zien dat mensen met een huidige 
depressieve en/of angststoornis niet meer kans hadden op metabole 
risicofactoren dan mensen die nooit een dergelijke stoornis hadden gehad. 
Wel bleek dat ernstige depressieve klachten een groter risico gaven op 
overgewicht en dyslipidemie. Ernstige angstklachten gaven in mindere 
mate ook een groter risico op overgewicht en dyslipidemie. Deze 
bevindingen laten zien dat vooral ernstige depressieve en angstklachten, en 
niet zozeer depressieve of angststoornissen, samenhangen met een 
verhoogd metabool risico, en met overgewicht en dyslipidemie in het 
bijzonder.  
  Ten tweede lieten we zien dat gebruikers van TCAs vatbaar waren 
voor dyslipidemie, overgewicht en hoge bloeddruk. Mogelijk weerspiegelt 
dit bijwerkingen van TCAs. Bij behandeling met TCAs kan het belangrijk 
zijn om deze metabole bijwerkingen in ogenschouw te nemen.  
  In hoofdstuk 3 werd beschreven dat mensen met een huidige 
depressieve stoornis meer kans op dyslipidemie hadden dan mensen met 
een depressie in het verleden of mensen die nog nooit een dergelijke 
stoornis gehad hadden. Het lijkt er dus op dat remissie van depressie 
uiteindelijk leidt tot genormaliseerd gewicht en cholesterol. 
 Hoe symptoomdimensies van depressie en angst samenhingen met 
metabool risico werd besproken in hoofdstuk 4. Symptomen van 
lichamelijke prikkeling die bij angst horen (zoals hartkloppingen en 
zweten) hingen onafhankelijk van leefstijl samen met overgewicht, 
dyslipidemie en hoge bloeddruk. Dit wijst erop dat vooral lichamelijke 
symptomen gerelateerd zijn aan metabole ontregelingen. 
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In hoofdstuk 5 beschreven we dat ernstige symptomen van depressie of 
angst bij aanvang van het onderzoek een verergering van dyslipidemie en 
overgewicht voorspelden over de volgende twee jaar. Over het algemeen 
namen symptomen van depressie en angst af tijdens die twee jaar. 
Desalniettemin ging deze algehele verbetering in stemming niet samen met 
een afname van dyslipidemie of overgewicht. Dit suggereert dat mensen die 
kwetsbaar zijn voor ernstige symptomen van depressie of angst een 
verergering van dyslipidemie en overgewicht laten zien over de tijd, zelfs 
wanneer hun stemming verbetert. Als depressie of angst direct leidt tot 
dyslipidemie en overgewicht zou je verwachten dat een verbeterde 
stemming juist samen zou gaan met een verbetering van dyslipidemie en 
overgewicht. Dat we dat juist niet vonden suggereert dat depressie en 
angststoornissen op een indirecte manier met dyslipidemie en overgewicht 
samenhangen. Relatief stabiele factoren onder mensen die kwetsbaar zijn 
voor depressie of angststoornissen - zoals roken, ongezonde voeding, 
inflammatie of een genetische kwetsbaarheid – zouden dan dyslipidemie en 
overgewicht in de hand kunnen werken. Hoe dan ook lijken mensen met 
ernstige symptomen van depressie en angst langdurig en in toenemende 
mate kwetsbaar te zijn voor dyslipidemie en overgewicht, en dus voor HVZ. 
 In hoofdstuk 6 bestudeerden we de relatie van het AZS en de HPA 
as met metabool risico. We concludeerden dat een toegenomen activiteit 
van het sympatische en een afgenomen activiteit van het parasympatische 
AZS samenhingen met het metabool syndroom en al diens componenten. 
We vonden geen relatie van de HPA as met metabole risicofactoren.  
  In hoofdstuk 7 rapporteerden we dat ontsteking en roken in 
belangrijke mate bijdroegen aan dyslipidemie en overgewicht bij mensen 
met ernstiger symptomen van depressie of angst. Daarnaast verklaarden 
ontregelingen van het AZS (namelijk een verhoogde sympathische AZS en 
een verminderde parasympatische AZS activiteit) voor een deel de 
dyslipidemie en het overgewicht bij TCA gebruikers. Zulke AZS 
ontregelingen zouden een bijwerking van TCAs kunnen zijn. Hoewel 
ontsteking, roken en het AZS een rol speelden, verklaarden zij niet alles. 
De rol van andere mogelijke mechanismen – zoals voeding – moet in de 
toekomst nog bepaald worden. Als toekomstig onderzoek onze resultaten 
bevestigt, zouden interventies die inflammatie verminderen (zoals stoppen 
met roken) en AZS activiteit normaliseren (zoals TCA-gebruik staken en 
vervangen door andere behandeling) dyslipidemie en overgewicht kunnen 
terugdringen. 
   In hoofdstuk 8 bestudeerden we of er een verband is van 
persoonlijkheidstrekken en jeugdtrauma met metabole risicofactoren voor 
HVZ. Seksueel misbruik in de jeugd bleek samen te hangen met 
dyslipidemie en overgewicht. Een verklaring hiervoor kan zijn dat seksueel 
misbruik een chronisch verhoogde activiteit van het stresssysteem kan 
veroorzaken. Openheid als persoonlijkheidskenmerk bleek juist 
beschermend te zijn voor dyslipidemie en overgewicht, en ook voor hoge 
bloeddruk. Misschien zijn open persoonlijkheden ontvankelijker voor 
gezondheidsaanbevelingen. Eventueel is deze kennis nuttig bij het 
ontwikkelen van richtlijnen om metabool risico te verlagen. 
NEDERLANDSE SAMENVATTING 187 
 
 
SAMENVATTING EN DISCUSSIE 
In hoofdstuk 9 werden alle bevindingen samengevat en bediscussieerd. In 
het kort laten de resultaten van dit proefschrift zien dat mensen met 
ernstige depressieve of angstklachten meer kans hebben op dyslipidemie 
en overgewicht, ook op de langere termijn. Het feit dat deze mensen vaker 
roken en meer ontstekingsreacties hebben verklaart deze relaties deels, en 
het aanpakken van deze factoren kan dus een belangrijke methode zijn 
voor preventie en behandeling van dyslipidemie en overgewicht bij deze 
groep. Onze resultaten laten ook zien dat het gebruik van TCAs een grotere 
kans geeft op dyslipidemie, overgewicht en hoge bloeddruk. Dit wordt deels 
verklaard door ontregelingen van het AZS, wat mogelijk een bijwerking is 
van TCAs. Dit geeft aan dat behandelaren zich bewust moeten zijn van 
deze metabole bijwerkingen bij het voorschrijven van TCAs. 
 Onderzoek richt zich in toenemende mate op het samenspel tussen 
psychische en lichamelijke gezondheid. Hieruit komt steeds meer naar 
voren dat psychische problemen zoals depressieve en angststoornissen 
samengaan met lichamelijke aandoeningen zoals metabole ontregelingen 
en HVZ.  
 In de gezondheidszorg bestaat er ondanks de signalen uit 
onderzoek nog steeds een duidelijke tweedeling tussen geestelijke en 
lichamelijke gezondheid. Zo is er binnen de zorg voor depressieve en 
angststoornissen nog geen systematische aanpak van het verhoogde risico 
op HVZ. Meer bewustzijn in de praktijk van de samenhang die hiertussen 
bestaat is van grote waarde om dit risico terug te kunnen dringen. 
    Toekomstig onderzoek moet uitwijzen of preventie, opsporing en 
behandeling van dyslipidemie en overgewicht onder mensen met ernstige 
symptomen van depressie of angst effectief is. Zo ja, dan kan dit als 
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